Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors

Abstract
Compounds of Formula I:
Description

The present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds, to processes for making the compounds and to the use of the compounds in therapy. More particularly, it relates to certain substituted pyrazolo[1,5-a]pyrimidine compounds which exhibit Trk family protein tyrosine kinase inhibition, and which are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.


The current treatment regimes for pain conditions utilize several classes of compounds. The opioids (such as morphine) have several drawbacks including emetic, constipatory and negative respiratory effects, as well as the potential for addictions. Non-steroidal anti-inflammatory analgesics (NSAIDs, such as COX-1 or COX-2 types) also have drawbacks including insufficient efficacy in treating severe pain. In addition, COX-1 inhibitors can cause ulcers of the mucosa. Accordingly, there is a continuing need for new and more effective treatments for the relief of pain, especially chronic pain.


Trk's are the high affinity receptor tyrosine kinases activated by a group of soluble growth factors called neurotrophins (NT). The Trk receptor family has three members: TrkA, TrkB and TrkC. Among the neurotrophins are (i) nerve growth factor (NGF) which activates TrkA, (ii) brain-derived neurotrophic factor (BDNF) and NT-4/5 which activate TrkB and (iii) NT3 which activates TrkC. Trk's are widely expressed in neuronal tissue and are implicated in the maintenance, signaling and survival of neuronal cells (Patapoutian, A. et al., Current Opinion in Neurobiology, 2001, 11, 272-280).


Inhibitors of the Trk/neurotrophin pathway have been demonstrated to be effective in numerous pre-clinical animal models of pain. For example, antagonistic NGF and TrkA antibodies such as RN-624 have been shown to be efficacious in inflammatory and neuropathic pain animal models (Woolf, C. J. et al. (1994) Neuroscience 62, 327-331; Zahn, P. K. et al. (2004) J. Pain 5, 157-163; McMahon, S. B. et al., (1995) Nat. Med. 1, 774-780; Ma, Q. P. and Woolf, C. J. (1997) Neuroreport 8, 807-810; Shelton, D. L. et al. (2005) Pain 116, 8-16; Delafoy, L. et al. (2003) Pain 105, 489-497; Lamb, K. et al. (2003) Neurogastroenterol. Motil. 15, 355-361; Jaggar, S. I. et al. (1999) Br. J. Anaesth. 83, 442-448) and neuropathic pain animal models (Ramer, M. S. and Bisby, M. A. (1999) Eur. J. Neurosci. 11, 837-846; Ro, L. S. et al. (1999); Pain 79, 265-274 Herzberg, U. et al. (1997) Neuroreport 8, 1613-1618; Theodosiou, M. et al. (1999) Pain 81, 245-255; Li, L. et al. (2003) Mol. Cell. Neurosci. 23, 232-250; Gwak, Y. S. et al. (2003) Neurosci. Lett. 336, 117-120). Additionally, recent literature indicates after inflammation, BDNF levels and TrkB signaling is increased in the dorsal root ganglion (Cho, L. et al. Brain Research 1997, 749, 358) and several studies have show antibodies that decrease signaling through the BDNF/TrkB pathway inhibit neuronal hypersensitization and the associated pain (Chang-Qi, L et al. Molecular Pain 2008, 4:27).


It has also been shown that NGF secreted by tumor cells and tumor invading macrophages directly stimulates TrkA located on peripheral pain fibers. Using various tumor models in both mice and rats, it was demonstrated that neutralizing NGF with a monoclonal antibody inhibits cancer related pain to a degree similar or superior to the highest tolerated dose of morphine. In addition, activation of the BDNF/TrkB pathway has been implicated in numerous studies as a modulator of various types of pain including inflammatory pain (Matayoshi, S., J. Physiol. 2005, 569:685-95), neuropathic pain (Thompson, S. W., Proc. Natl. Acad. Sci. USA 1999, 96:7714-18) and surgical pain (Li, C.-Q. et al., Molecular Pain, 2008, 4(28), 1-11). Because TrkA and TrkB kinases may serve as a mediator of NGF driven biological responses, inhibitors of TrkA and/or other Trk kinases may provide an effective treatment for chronic pain states.


Recent literature has also shown that overexpression, activation, amplification and/or mutation of Trk kinases are associated with many cancers including neuroblastoma (Brodeur, G. M., Nat. Rev. Cancer 2003, 3, 203-216), ovarian (Davidson. B., et al., Clin. Cancer Res. 2003, 9, 2248-2259) and colorectal cancer (Bardelli, A., Science 2003, 300, 949). In preclinical models of cancer, non-selective small molecule inhibitors of Trk A, B and C were efficacious in both inhibiting tumor growth and stopping tumor metastasis (Nakagawara, A. (2001) Cancer Letters 169:107-114; Meyer, J. et al. (2007) Leukemia, 1-10; Pierottia, M. A. and Greco A., (2006) Cancer Letters 232:90-98; Eric Adriaenssens, E. et al. Cancer Res (2008) 68:(2) 346-351).


In addition, inhibition of the neurotrophin/Trk pathway has been shown to be effective in treatment of pre-clinical models of inflammatory diseases with NGF antibodies or non-selective small molecule inhibitors of Trk A, B and C. For example, inhibition of the neurotrophin/Trk pathway has been implicated in preclinical models of inflammatory lung diseases including asthma (Freund-Michel, V; Frossard, N.; Pharmacology & Therapeutics (2008), 117(1), 52-76), interstitial cystitis (Hu Vivian Y; et. al. The Journal of Urology (2005), 173(3), 1016-21), inflammatory bowel diseases including ulcerative colitis and Crohn's disease (Di Mola, F. F, et. al., Gut (2000), 46(5), 670-678) and inflammatory skin diseases such as atopic dermatitis (Dou, Y.-C.; et. al. Archives of Dermatological Research (2006), 298(1), 31-37), eczema and psoriasis (Raychaudhuri, S. P., et al., J. Investigative Dermatology (2004), 122(3), 812-819).


The neurotrophin/Trk pathway, particularly BDNF/TrkB, has also been implicated in the etiology of neurodegenerative diseases including multiple sclerosis, Parkinson's disease and Alzheimer's Disease (Sohrabji, Farida; Lewis, Danielle K., Frontiers in Neuroendocrinology (2006), 27(4), 404-414).


The TrkA receptor is also thought to be critical to the disease process in the infection of the parasitic infection of Trypanosoma cruzi (Chagas disease) in human hosts (de Melo-Jorge, M. et al. Cell Host & Microbe (2007), 1(4), 251-261).


Trk inhibitors may also find use in treating disease related to an imbalance of the regulation of bone remodeling, such as osteoporosis, rheumatoid arthritis, and bone metastases. Bone metastases are a frequent complication of cancer, occurring in up to 70 percent of patients with advanced breast or prostate cancer and in approximately 15 to 30 percent of patients with carcinoma of the lung, colon, stomach, bladder, uterus, rectum, thyroid, or kidney. Osteolytic metastases can cause severe pain, pathologic fractures, life-threatening hypercalcemia, spinal cord compression, and other nerve-compression syndromes. For these reasons, bone metastasis is a serious and costly complication of cancer. Therefore, agents that can induce apoptosis of proliferating osteoblasts would be highly advantageous. Expression of TrkA and TrkC receptors has been observed in the bone forming area in mouse models of bone fracture (K. Asaumi, et al., Bone (2000) 26(6) 625-633). In addition, localization of NGF was observed in almost all bone forming cells (K. Asaumi, et al.). Recently, it was demonstrated that a pan-Trk inhibitor inhibits the tyrosine signaling activated by neurotrophins binding to all three of the Trk receptors in human hFOB osteoblasts (J. Pinski, et al., (2002) 62, 986-989). These data support the rationale for the use of Trk inhibitors for the treatment of bone remodeling diseases, such as bone metastases in cancer patients.


Several classes of small molecule inhibitors of Trk kinases said to be useful for treating pain or cancer are known (Expert Opin. Ther. Patents (2009) 19(3), 305-319).


Pyrazolo[1,5-a]pyrimidine compounds are known. For example, International patent application publication WO 2004/089415 discloses certain pyrazolo[1,5-a]pyrimidine-3-carboxamide compounds having a phenyl, thienyl or furyl group in the 5-position which are said to be 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors useful in combination therapies.


European patent application publication No. EP 1948633A2 describes 5-phenyl-7-hydroxy-substituted pyrazolo[1,5-a]pyrimidine-3-carboxamide compounds as casein kinase II modulators for treating cancer.


PCT publication WO 2010/051549 describes pyrazolopyrimidine compounds having the general structure:




embedded image


said to be inhibitors of Jak kinases.


It has now been found that certain pyrazolo[1,5-a]pyrimidine compounds bearing an aryl-substituted or heteroaryl-substituted heterocyclic group at the 5-position and a group having the formula C(═O)NR1R2 at the 3-position, wherein R1 and R2 are as defined herein, are inhibitors of Trk kinases, in particular inhibitors of TrkA and/or TrkB and/or TrkC, and are useful for treating disorders and diseases such as cancer and pain, including chronic and acute pain. Certain compounds which are inhibitors of TrkA and/or TrkB may be useful in the treatment of multiple types of pain including inflammatory pain, neuropathic pain, and pain associated with cancer, surgery, and bone fracture. In addition, compounds of the invention may be useful for treating cancer, inflammation, neurodegenerative diseases and certain infectious diseases.


In addition, compounds of the invention have been shown to be selective for the Trk family of kinases over closely related kinases. In particular, compounds of the invention are more selective for inhibiting TrkA kinase activity over inhibiting the activity of one or more members of the Jak kinase family (Jak1, Jak2, Jak3 and Tyk2). Inhibition of the Jak family of kinases has been postulated or demonstrated to result in several unwanted side effects including CD8 T and NK cell depletion (which can result in loss of tumor surveillance and increased infections), elevated cholesterol, neutropenia, thrombocytopenia, decreased reticulocytes (resulting in anemia) and bone marrow suppression (Igaz P. et al., Inflamm. Res., 2001, 50:435-441; O'Shea J. J., Immunity, 1997, 7:1-11; Ihle J. N. et al., Canc. J. Sci. Am., 1998, 4 suppl 1 S84-91; Gupta P. et al., J. Clin. Pharm. 2009; Kremer J. M. et al., Arth. & Rheum., 2009, 60:1895-1905 and van Gurp E., et al., Am. J. Transpl, 2008, 8:1711-18). Accordingly, compounds of the invention may be more suitable as therapeutic treatments owing to their ability to inhibit the Trk family of kinases in preference over closely related kinases such as the Jak family of kinases, and therefore may avoid unwanted side effects in a mammal being treated with a compound of the invention.


Accordingly, one embodiment of this invention provides a compound of the general Formula I:




embedded image


or a salt thereof, wherein:


R1 is H or (1-6C alkyl);


R2 is H, (1-6C)alkyl, -(1-6C)fluoroalkyl, -(1-6C)difluoroalkyl, -(1-6C)trifluoroalkyl, -(1-6C)chloroalkyl, -(2-6C)chlorofluoroalkyl, -(2-6C)difluorochloroalkyl, -(2-6C)chlorohydroxyalkyl, -(1-6C)hydroxyalkyl, -(2-6C)dihydroxyalkyl, -(1-6C alkyl)CN, -(1-6C alkyl)SO2NH2, -(1-6C alkyl)NHSO2(1-3C alkyl), -(1-6C alkyl)NH2, -(1-6C alkyl)NH(1-4C alkyl), -(1-6C alkyl)N(1-4C alkyl)2, -(1-6C alkyl)NHC(═O)O(1-4C alkyl), -(1-6C alkyl)hetCyc1, -(1-6C alkyl)hetAr1, hetAr2, hetCyc2, —O(1-6C alkyl) which is optionally substituted with halogen, OH or (1-4C)alkoxy, —O(3-6C cycloalkyl), Cyc1, -(1-6C alkyl)(3-6C cycloalkyl), -(1-6Calkyl)(1-4C alkoxy), -(1-6C hydroxyalkyl)(1-4C alkoxy), a bridged 7-membered cycloalkyl ring optionally substituted with (1-6C)hydroxyalkyl, or a bridged 7-8 membered heterocyclic ring having 1-2 ring nitrogen atoms;


or NR1R2 forms a 4-6 membered azacyclic ring optionally substituted with one or more substituents independently selected from (1-6C)alkyl, OH, CO2H, (1-3C alkyl)CO2H, —O(1-6C alkyl) and (1-6C)hydroxyalkyl;


hetCyc1 is a 5-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein hetCyc1 is optionally substituted with oxo, OH, halogen or (1-6C)alkyl;


hetCyc2 is a 6 membered carbon-linked heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein hetCyc2 is optionally substituted with F, SO2NH2, SO2(1-3C alkyl) or halogen;


hetAr1 is a 5-membered heteroaryl ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with (1-4C)alkyl;


hetAr2 is a 5-6 membered heteroaryl ring having 1-2 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from (1-4C)alkyl, (3-6C)cycloalkyl, halogen and OH;


Cyc1 is a 3-6 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, —OMe, —CO2H, -(1-4C alkyl)OH, halogen and CF3;


Y is (i) phenyl optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkoxy, —CF3—CHF2, —O(1-4C alkyl)hetCyc3, -(1-4C alkyl)hetCyc3, —O(1-4C alkyl)O(1-3C alkyl) and —O(3-6C dihydroxyalkyl), or (ii) a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from halogen, —O(1-4C alkyl), (1-4C)alkyl and NH2, or (iii) a pyrid-2-on-3-yl ring optionally substituted with one or more substituents independently selected from halogen and (1-4C)alkyl;


hetCyc3 is a 5-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with (1-6C)alkyl;


X is null, —CH2—, —CH2CH2—, —CH2O— or —CH2NRd—;


Rd is H or -(1-4C alkyl);


R3 is H or -(1-4C alkyl);


each R4 is independently selected from halogen, -(1-4C)alkyl, —OH, -(1-4C)alkoxy, —NH2, —NH(1-4C alkyl) and —CH2OH; and


n is 0, 1, 2, 3, 4, 5 or 6.


In one embodiment of Formula I, X is selected from any of the values described above, other than null.


In one embodiment of Formula I, X is CH2.


Compounds of Formula I include compounds of the general Formula Ia:




embedded image


or a salt thereof, wherein:


R1 is H or (1-6C alkyl);


R2 is H, (1-6C)alkyl, -(1-6C)fluoroalkyl, -(1-6C)hydroxyalkyl, -(2-6C)dihydroxyalkyl, -(1-6C alkyl)CN, -(1-6C alkyl)SO2NH2, -(1-6C alkyl)NHSO2(1-3C alkyl), -(1-6C alkyl)NH2, -(1-6C alkyl)NH(1-4C alkyl), -(1-6C alkyl)N(1-4C alkyl)2, -(1-6C alkyl)hetCyc1, -(1-6C alkyl)hetAr1, hetAr2, hetCyc2, —O(1-6C alkyl), —O(3-6C cycloalkyl), Cyc1, or a bridged 7-membered cycloalkyl ring,


or NR1R2 forms a 4-6 membered azacyclic ring optionally substituted with one or more substituents independently selected from (1-6C)alkyl, OH, CO2H and (1-3C alkyl)CO2H;


hetCyc1 is a 5-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein hetCyc1 is optionally substituted with oxo;


hetCyc2 is a 6 membered carbon-linked heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein hetCyc2 is optionally substituted with F, SO2NH2, or SO2(1-3C alkyl);


hetAr1 is a 5-membered heteroaryl ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with (1-4C)alkyl;


hetAr2 is a 5-6 membered heteroaryl ring having 1-2 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from (1-4C)alkyl;


Cyc1 is a 3-6 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, —OMe, —CO2H and -(1-4C alkyl)OH;


Y is (i) phenyl optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkoxy, —CF3—CHF2, —O(1-4C alkyl)hetCyc3 and —O(1-4C alkyl)O(1-3C alkyl), or (ii) a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from halogen, —O(1-4C alkyl) and (1-4C)alkyl;


hetCyc3 is a 5-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O;


X is null, —CH2—, —CH2CH2—, —CH2O— or —CH2NRd—;


Rd is H or -(1-4C alkyl);


R3 is H or -(1-4C alkyl);


each R4 is independently selected from halogen, -(1-4C)alkyl, —OH, -(1-4C)alkoxy, —NH2, —NH(1-4C alkyl) and —CH2OH; and


n is 0, 1, 2, 3, 4, 5 or 6.


In one embodiment of Formula Ia, X is selected from any of the values described above, other than null.


In one embodiment of Formula Ia, X is CH2.


In certain embodiments of Formula I, R1 is hydrogen.


In certain embodiments of Formula I, R1 is -(1-6C)alkyl. Examples include methyl, ethyl, propyl and isopropyl. A particular example is methyl.


In certain embodiments of Formula I, R2 is H or -(1-6C)alkyl.


In certain embodiments, R2 is hydrogen. In one embodiment, R2 and R1 are both hydrogen. In one embodiment, R2 is hydrogen and R1 is -(1-6C alkyl).


In certain embodiments, R2 is selected from -(1-6C)alkyl, -(1-6C)fluoroalkyl, -(1-6C)difluoroalkyl, -(1-6C)trifluoroalkyl, -(1-6C)chloroalkyl, -(2-6C)chlorofluoroalkyl, -(2-6C)chlorohydroxyalkyl, -(1-6C alkyl)CN, -(1-6C alkyl)SO2NH2, and -(1-6C alkyl)NHSO2(1-3C alkyl).


In certain embodiments, R2 is -(1-6C)alkyl. In certain embodiments R2 is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl. Particular examples include methyl, ethyl, isopropyl and tert-butyl. In one embodiment, R2 is -(1-6C)alkyl and R1 is hydrogen. In one embodiment, R2 is -(1-6C)alkyl and R1 is (1-6C alkyl).


In certain embodiments, R2 is selected from -(1-6C)fluoroalkyl, -(1-6C)difluoroalkyl, -(1-6C)trifluoroalkyl, -(1-6C)chloroalkyl, -(2-6C)chlorofluoroalkyl, -(2-6C)chlorohydroxyalkyl, -(1-6C alkyl)CN, -(1-6C alkyl)SO2NH2, and -(1-6C alkyl)NHSO2(1-3C alkyl).


In certain embodiments, R2 is selected from -(1-6C)fluoroalkyl, -(1-6C alkyl)CN, -(1-6C alkyl)SO2NH2, and -(1-6C alkyl)NHSO2(1-3C alkyl).


In certain embodiments, R2 is -(1-6C)fluoroalkyl. A particular example is —C(CH3)2CH2F. In one embodiment, R2 is -(1-6C)fluoroalkyl and R1 is hydrogen. In one embodiment, R2 is -(1-6C)fluoroalkyl and R1 is (1-6C alkyl).


In certain embodiments, R2 is -(1-6C)difluoroalkyl. Examples include —CHF2 and —CH2CHF2. In one embodiment, R2 is -(1-6C)difluoroalkyl and R1 is hydrogen. In one embodiment, R2 is -(1-6C)difluoroalkyl and R1 is (1-6C alkyl).


In certain embodiments, R2 is -(1-6C)trifluoroalkyl. Examples include CF3, CH2CF3 and CH(CH3)CF3. In one embodiment, R2 is -(1-6C)trifluoroalkyl and R1 is hydrogen. In one embodiment, R2 is -(1-6C)trifluoroalkyl and R1 is (1-6C alkyl).


In certain embodiments, R2 is -(1-6C)chloroalkyl. An example includes CH2CH2Cl. In one embodiment, R2 is -(1-6C)chloroalkyl and R1 is hydrogen. In one embodiment, R2 is -(1-6C)chloroalkyl and R1 is (1-6C alkyl).


In certain embodiments, R2 is -(1-6C)chlorofluoroalkyl. An example includes CH2CHFCH2Cl. In one embodiment, R2 is -(1-6C)chlorofluoroalkyl and R1 is hydrogen. In one embodiment, R2 is -(1-6C)chlorofluoroalkyl and R1 is (1-6C alkyl).


In certain embodiments, R2 is -(1-6C)difluorochloroalkyl. An example includes —CH2CF2CH2Cl. In one embodiment, R2 is -(1-6C)difluorochloroalkyl and R1 is H. In one embodiment, R2 is -(1-6C)difluorochloroalkyl and R1 is (1-6C alkyl).


In certain embodiments, R2 is -(2-6C)chlorohydroxyalkyl. An example includes —CH2CH(OH)CH2Cl. In one embodiment, R2 is -(2-6C)chlorohydroxyalkyl and R1 is hydrogen. In one embodiment, R2 is -(2-6C)chlorohydroxyalkyl and R1 is (1-6C alkyl).


In certain embodiments, R2 is selected from methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, —C(CH3)2CH2F, —CHF2, —CH2CHF2, CF3, CH2CF3, CH(CH3)CF3, CH2CH2Cl, CH2CHFCH2Cl, and —CH2CF2CH2Cl.


In certain embodiments, R2 is selected from methyl, ethyl, propyl, isopropyl, —CF3 and —CH2CF3.


In certain embodiments, R2 is -(1-6C)hydroxyalkyl or -(2-6C)dihydroxyalkyl.


In certain embodiments, R2 is -(1-6C)hydroxyalkyl. Examples include —CH2CH2OH, —CH2CH2CH2OH, —CH2CH2CH2CH2OH, —CH2CH(OH)CH3, —C(CH3)2CH2OH, —CH2C(CH3)2OH, —CH(CH3)CH2OH, —CH2C(CH3)2CH2OH, —CH(CH2OH)CH(CH3)2, —CH(CH2CH3)CH2OH, and —CH(CH2OH)C(CH3)3. A particular example is —CH2CH2OH. In one embodiment, R2 is -(1-6C)hydroxyalkyl and R1 is hydrogen. In one embodiment, R2 is -(1-6C)hydroxyalkyl and R1 is -(1-6C alkyl).


In certain embodiments, R2 is -(2-6C)dihydroxyalkyl. Examples include —CH2CH(OH)CH2OH, —C(CH3)(CH2OH)2, —CH(CH2OH)2 and —CH(CH2OH)(CHOHCH3). Particular examples include —CH2CH(OH)CH2OH and —C(CH3)(CH2OH)2. In one embodiment, R2 is -(2-6C)dihydroxyalkyl and R1 is hydrogen. In one embodiment, R2 is -(2-6C)dihydroxyalkyl and R1 is -(1-6C alkyl).


In certain embodiments, R2 is -(1-6C alkyl)CN. Particular examples include —CH2CN and —C(CH3)2CN. In one embodiment, R2 is -(1-6C alkyl)CN and R1 is hydrogen. In one embodiment, R2 is -(1-6C alkyl)CN and R1 is (1-6C alkyl).


In certain embodiments, R2 is -(1-6C alkyl)SO2NH2. A particular example is —CH2CH2SO2NH2. In one embodiment, R2 is -(1-6C alkyl)SO2NH2 and R1 is hydrogen. In one embodiment, R2 is -(1-6C alkyl)SO2NH2 and R1 is (1-6C alkyl).


In certain embodiments, R2 is -(1-6C alkyl)NHSO2(1-3C alkyl). Particular examples include —CH2CH2NHSO2CH3 and —C(CH3)2CH2NHSO2CH3. In one embodiment, R2 is -(1-6C alkyl)NHSO2(1-3C alkyl) and R1 is hydrogen. In one embodiment, R2 is -(1-6C alkyl)NHSO2(1-3C alkyl) and R1 is (1-6C alkyl).


In certain embodiments, R2 is selected from -(1-6C alkyl)NH2, -(1-6C alkyl)NH(1-4C alkyl) and -(1-6C alkyl)N(1-4C alkyl)2.


In certain embodiments, R2 is -(1-6C alkyl)NH2. Examples include —CH2C(CH3)2NH2 and —CH2CH2CH2NH2. A particular example is —CH2C(CH3)2NH2. In one embodiment, R2 is -(1-6C alkyl)NH2 and R1 is hydrogen. In one embodiment, R2 is -(1-6C alkyl)NH2 and R1 is (1-6C alkyl).


In certain embodiments, R2 is -(1-6C alkyl)NH(1-4C alkyl). Examples include groups having the formula -(1-4C alkyl)NHCH3. A particular value is —C(CH3)2NHCH3. In one embodiment, R2 is -(1-6C alkyl)NH(1-4C alkyl) and R1 is hydrogen. In one embodiment, R2 is -(1-6C alkyl)NH(1-4C alkyl) and R1 is (1-6C alkyl).


In certain embodiments, R2 is -(1-6C alkyl)N(1-4C alkyl)2. Examples include groups having the formula -(1-4C alkyl)N(CH3)2. A particular value is -(1-6C alkyl)NMe2. In one embodiment, R2 is -(1-6C alkyl)N(1-4C alkyl)2 and R1 is hydrogen. In one embodiment, R2 is -(1-6C alkyl)N(1-4C alkyl)2 and R1 is (1-6C alkyl).


In certain embodiments, R2 is -(1-6C alkyl)NHC(═O)O(1-4C alkyl). An example includes CH2CH2CH2NHC(═O)OC(CH3)3. In one embodiment, R2 is -(1-6C alkyl)NHC(═O)O(1-4C alkyl) and R1 is hydrogen. In one embodiment, R2 is -(1-6C alkyl)NHC(═O)O(1-4C alkyl) and R1 is (1-6C alkyl).


In certain embodiments, R2 is selected from -(1-6C alkyl)hetCyc1 and -(1-6C alkyl)hetAr1.


In certain embodiments, R2 is -(1-6C alkyl)hetCyc1. Examples of hetCyc1 rings include morpholinyl, piperidinyl, piperazinyl and imidazolidinyl, each of which is optionally substituted with a substituent selected from oxo, OH, halogen, and (1-6C)alkyl. In certain embodiments hetCyc1 is morpholinyl, piperidinyl, piperazinyl or imidazolidin-2-one optionally substituted with OH, halogen or (1-6C)alkyl. Examples of the -(1-6C)alkyl portion include methylene, ethylene, dimethylethylene, and the like.


Examples of R2 when represented by -(1-6C alkyl)hetCyc1 include the structures:




embedded image


In certain embodiments, R2 when represented by -(1-6C alkyl)hetCyc1 includes the structures:




embedded image


In certain embodiments hetCyc1 is morpholinyl or imidazolidin-2-one.


In one embodiment, R2 is -(1-6C alkyl)hetCyc1 and R1 is hydrogen. In one embodiment, R2 is-(1-6C alkyl)hetCyc1 and R1 is (1-6C alkyl).


In certain embodiments, R2 is -(1-6C alkyl)hetAr1. Examples of hetAr1 include furanyl, pyrazolyl, and imidazolyl rings which are optionally substituted with -(1-4C alkyl), for example methyl. Examples of the -(1-6C)alkyl portion include methylene, ethylene, dimethylmethylene, and the like. Examples of R2 when represented by -(1-6C alkyl)hetAr1 include the structures:




embedded image


Particular values for R2 when represented by -(1-6C alkyl)hetAr1 include the structures:




embedded image


In one embodiment, R2 is -(1-6C alkyl)hetAr1 and R1 is hydrogen. In one embodiment, R2 is -(1-6C alkyl)hetAr1 and R1 is (1-6C alkyl).


In certain embodiments, R2 is hetAr2. Examples of hetAr2 include pyridyl, pyrazolyl and imidazolyl rings optionally substituted with one or more substituents independently selected from (1-4C)alkyl, (3-6C)cycloalkyl, halogen and OH. Particular examples of hetAr2 substituents include methyl, ethyl, isopropyl, cyclopropyl, fluoro and hydroxy. Particular examples of hetAr2 include the structures:




embedded image


In certain embodiments hetAr2 is a pyridyl or pyrazolyl ring optionally substituted with one or more substituents independently selected from -(1-4C)alkyl, for example one or more methyl groups, for example 1 or 2 methyl groups. Particular examples of hetAr2 include the structures:




embedded image


In one embodiment, R2 is hetAr2 and R1 is hydrogen. In one embodiment, R2 is hetAr2 and R1 is (1-6C alkyl).


In certain embodiments, R2 is hetCyc2. Examples of hetCyc2 include piperidinyl and tetrahydropyranyl rings optionally substituted with F, SO2NH2 or SO2(1-3C alkyl). Particular examples of R2 when represented by hetCyc2 include the structures:




embedded image


In one embodiment, R2 is hetCyc2 and R1 is hydrogen. In one embodiment, R2 is hetCyc2 and R1 is (1-6C alkyl).


In certain embodiments, R2 is —O(1-6C alkyl) which is optionally substituted with halogen, OH or (1-4C)alkoxy. Examples include —OMe, —OEt, —OCH2CH2OC(CH3)3, —OCH2CH2Br, —OCH2CH2Cl and —OCH2CH2OH. In one embodiment, R2 is —O(1-6C alkyl) which is optionally substituted with halogen, OH or (1-4C)alkoxy, and R1 is hydrogen. In one embodiment, R2 is —O(1-6C alkyl) which is optionally substituted with halogen, OH or (1-4C)alkoxy, and R1 is (1-6C alkyl).


In certain embodiments, R2 is —O(1-6C alkyl). Particular examples include OMe and OEt.


In certain embodiments, R2 is —O(3-6C cycloalkyl). A particular example is cyclopropoxy. In one embodiment, R2 is —O(3-6C cycloalkyl) and R′ is hydrogen. In one embodiment, R2 is —O(3-6C cycloalkyl) and R1 is (1-6C alkyl).


In certain embodiments, R2 is —O(1-6C alkyl) or —O(3-6C cycloalkyl)


In certain embodiments, R2 is Cyc1 or a bridged 7-membered cycloalkyl ring.


In certain embodiments, R2 is Cyc1, wherein Cyc1 is a 3-6 membered cycloalkyl ring optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, —OMe, —CO2H, -(1-4C alkyl)OH, halogen and CF3. In one embodiment, Cyc1 is optionally substituted with one or more substituents independently selected from methyl, —OH, —OMe, —CO2H, CH2OH, CH2CH2OH and CF3. In certain embodiments, R2 is Cyc1, wherein the cycloalkyl ring is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, —OMe, —CO2H and -(1-4C alkyl)OH, such as one or more substituents independently selected from methyl, —OH, —CH2OH and —CO2H. In one embodiment, Cyc1 is optionally substituted with one or more substituents independently selected from methyl, —OH, —CH2OH and —CO2H. In one embodiment, Cyc1 is optionally substituted with one or two of said substituents.


Examples of R2 when represented by Cyc1 include the structures:




embedded image


Particular examples of R2 when represented by Cyc1 include the structures:




embedded image


In one embodiment of Formula I, Cyc1 is a 3, 4 or 5 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, —OMe, —CO2H, -(1-4C alkyl)OH, halogen and CF3.


In one embodiment of Formula I, Cyc1 is a 3, 4 or 5 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, OMe, —CO2H and -(1-4C alkyl)OH.


In one embodiment, R2 is cyclopropyl.


In one embodiment R2 is selected from the structures:




embedded image


In one embodiment, R2 is Cyc1 and R1 is hydrogen. In one embodiment, R2 is Cyc1 and R1 is (1-6C alkyl).


In one embodiment, R2 is a 3, 4 or 5 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, —OMe, —CO2H, -(1-4C alkyl)OH, halogen and CF3.


In one embodiment, R2 is a 3, 4 or 5 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, OMe, —CO2H and -(1-4C alkyl)OH.


In one embodiment, R2 is a 3, 4 or 5 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from methyl, —CO2H, and CH2OH.


In certain embodiments, R2 is cyclopropyl optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, —OMe, —CO2H, -(1-4C alkyl)OH, halogen and CF3.


In certain embodiments, R2 is cyclopropyl optionally substituted with one or more substituents independently selected from methyl, —CO2H, and CH2OH.


In certain embodiments, R2 is cyclobutyl optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, —OMe, —CO2H, -(1-4C alkyl)OH, halogen and CF3. In certain embodiments, R2 is cyclobutyl optionally substituted with one or more substituents independently selected from methyl, —OH, —OMe, —CO2H, CH2OH, CH2CH2OH and CF3.


In certain embodiments, R2 is cyclopentyl optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, —OMe, —CO2H, -(1-4C alkyl)OH, halogen and CF3. In certain embodiments, R2 is cyclopentyl optionally substituted with one or more substituents independently selected from methyl, —OH, —OMe, —CO2H, CH2OH, CH2CH2OH and CF3.


In certain embodiments, R2 is cyclohexyl optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, —OMe, —CO2H, -(1-4C alkyl)OH, halogen and CF3. In certain embodiments, R2 is cyclohexyl optionally substituted with one or more substituents independently selected from methyl, —OH, —OMe, —CO2H, CH2OH, CH2CH2OH and CF3.


In certain embodiments, R2 is -(1-6C alkyl)(3-6C cycloalkyl). Examples of the (1-6C alkyl) portion include methyl, ethyl, propyl and butyl. Examples of the cycloalkyl portion include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. In one embodiment, the cycloalkyl portion is cyclopropyl. Particular examples include the structures:




embedded image


In one embodiment, R2 is -(1-6C alkyl)(3-6C cycloalkyl) and R1 is hydrogen. In one embodiment, R2 is -(1-6C alkyl)(3-6C cycloalkyl) and R1 is (1-6C alkyl).


In certain embodiments, R2 is -(1-6Calkyl)(1-4C alkoxy). Examples include CH2CH2OCH3 and CH(CH3)CH2OCH3. In one embodiment, R2 is -(1-6Calkyl)(1-4C alkoxy) and R1 is hydrogen. In one embodiment, R2 is -(1-6Calkyl)(1-4C alkoxy) and R1 is (1-6C alkyl).


In certain embodiments, R2 is -(1-6C hydroxyalkyl)(1-4C alkoxy). An example includes —CH2CH(OH)CH2OCH3. In one embodiment, R2 is -(1-6C hydroxyalkyl)(1-4C alkoxy) and R1 is hydrogen. In one embodiment, R2 is -(1-6C hydroxyalkyl)(1-4C alkoxy) and R1 is (1-6C alkyl).


In certain embodiments, R2 is a bridged 7-membered cycloalkyl ring. In certain embodiments, R2 is a bridged 7-membered cycloalkyl ring optionally substituted with (1-6C)hydroxyalkyl. In certain embodiments, R2 is a bridged 7-membered cycloalkyl ring optionally substituted with hydroxymethyl. Examples of R2 include the structures:




embedded image


A particular example or R2 is the structure:




embedded image


In one embodiment, R2 is a bridged 7-membered cycloalkyl ring optionally substituted with (1-6C)hydroxyalkyl and R1 is hydrogen. In one embodiment, R2 is a bridged 7-membered cycloalkyl ring and R1 is (1-6C alkyl).


In certain embodiments, R2 is a bridged 7-8 membered heterocyclic ring having 1-2 ring nitrogen atoms. A particular example is the structure:




embedded image


In one embodiment, R2 is a bridged 7-8 membered heterocyclic ring having 1-2 ring nitrogen atoms and R1 is hydrogen. In one embodiment, R2 is a bridged 7-8 membered heterocyclic ring having 1-2 ring nitrogen atoms and R1 is (1-6C alkyl).


In certain embodiments, NR1R2 forms a 4-6 membered azacyclic ring optionally substituted with one or more substituents independently selected from (1-6C)alkyl, OH, CO2H, (1-3C alkyl)CO2H, —O(1-6C alkyl) and (1-6C)hydroxyalkyl. Examples include 4-6 membered azacyclic rings optionally substituted with one or more groups independently selected from methyl, OH, —C(═O)OH, —CH2COOH, OMe, and —CH2OH. In certain embodiments, the azacyclic ring is optionally substituted with one or two of said substituents. Particular examples include the structures:




embedded image


In certain embodiments, NR1R2 forms a 4-6 membered azacyclic ring optionally substituted with one or more substituents independently selected from -(1-6C)alkyl, —OH, —CO2H and -(1-3C alkyl)CO2H. Examples include 4-6 membered azacyclic rings optionally substituted with one or two groups independently selected from methyl, OH, —C(═O)OH and —CH2COOH. Particular examples include the structures:




embedded image


Compounds of Formula I also include compounds wherein:


R1 is H or -(1-6C alkyl);


R2 is H, -(1-6C)alkyl, -(1-6C)fluoroalkyl, -(1-6C)hydroxyalkyl, -(2-6C)dihydroxyalkyl, -(1-6C alkyl)CN, -(1-6C alkyl)SO2NH2, -(1-6C alkyl)NHSO2(1-3C alkyl), -(1-6C alkyl)NH2, -(1-6C alkyl)NH(1-4C alkyl), -(1-6C alkyl)N(1-4C alkyl)2, -(1-6C alkyl)hetCyc1, -(1-6C alkyl)hetAr1, hetAr2, —O(1-6C alkyl), —O(3-6C cycloalkyl), or a 3, 4 or 5 membered cycloalkyl ring optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, OMe, —CO2H and -(1-4C alkyl)OH;


or NR1R2 forms a 4-6 membered azacyclic ring optionally substituted with one or more substituents independently selected from -(1-6C)alkyl, —OH, —CO2H and -(1-3C alkyl)CO2H;


and X, Y, R3, R4 and n are as defined for Formula I.


Compounds of Formula I also include compounds wherein:


R1 is H or -(1-6C alkyl);


R2 is H, -(1-6C)alkyl, -(1-6C)fluoroalkyl, -(1-6C)hydroxyalkyl, -(2-6C)dihydroxyalkyl, -(1-6C alkyl)CN, -(1-6C alkyl)SO2NH2, -(1-6C alkyl)NHSO2(1-3C alkyl), -(1-6C alkyl)NH2, -(1-6C alkyl)NH(1-4C alkyl), -(1-6C alkyl)N(1-4C alkyl)2, -(1-6C alkyl)hetCyc1, -(1-6C alkyl)hetAr1, hetAr2, hetCyc2, —O(1-6C alkyl), —O(3-6C cycloalkyl), or a bridged 7-membered cycloalkyl ring,


or NR1R2 forms a 4-6 membered azacyclic ring optionally substituted with one or more substituents independently selected from -(1-6C)alkyl, —OH, —CO2H and -(1-3C alkyl)CO2H; and


and X, Y, R3, R4 and n are as defined for Formula I.


Referring now to the substituents on the ring at the 5-position of Formula I, wherein the 5-position is identified in the following structure:




embedded image


in one embodiment Y is phenyl optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkoxy, —CF3—CHF2, —O(1-4C alkyl)hetCyc3, -(1-4C alkyl)hetCyc3, —O(1-4C alkyl)O(1-3C alkyl) and —O(3-6C dihydroxyalkyl).


In one embodiment, Y is phenyl optionally substituted with one or two of said substituents. In one embodiment Y is phenyl optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkoxy, —O(1-4C alkyl)hetCyc3, -(1-4C alkyl)hetCyc3, —O(1-4C alkyl)O(1-3C alkyl) and —O(3-6C dihydroxyalkyl). In one embodiment, Y is phenyl optionally substituted with one or two of said substituents.


In one embodiment, Y is phenyl optionally substituted with one or more substituents independently selected from —F, —Cl, —OMe, —CF3, —CHF2, morpholinylethoxy, morpholinylethyl, —OCH2CH2OMe, 2,3-dihydroxypropoxy and 2,2-dimethyl-1,3-dioxolanyl. In one embodiment, Y is phenyl optionally substituted with one or two of said substituents.


The term “morpholinylethoxy” as used herein refers to a morpholinyl ring substituted at the nitrogen ring atom with an ethoxy group and can be represented by the structure:




embedded image


The term “morpholinylethyl” as used herein refers to a morpholinyl ring substituted at the nitrogen ring atom with an ethyl group and can be represented by the structure:




embedded image


Example of Y include phenyl, 3-fluorophenyl, 2,5-difluorophenyl, 2-chloro-5-fluorophenyl, 2-methoxyphenyl, 2-methoxy-5-fluorophenyl, 2-trifluoromethyl-5-fluorophenyl, 2-difluoromethyl-5-fluorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-(2-morpholinylethoxy)phenyl, 3-fluoro-5-(2-morpholinylethyl)phenyl, 5-fluoro-2-(2-morpholinyl-ethyl)phenyl, 3-fluoro-5-methoxyethoxyphenyl, 5-fluoro-2-methoxyethoxyphenyl, 3-fluoro-5-(2,3-dihydroxypropoxy)phenyl, 2-(2,3-dihydroxypropoxy)-5-fluorophenyl,




embedded image


The terms “3-fluoro-5-(2-morpholinylethoxy)phenyl”, “3-fluoro-5-(2-morpholinylethyl)phenyl” and “5-fluoro-2-(2-morpholinylethyl)phenyl” can be represented by the structures:




embedded image



respectively.


In one embodiment, Y is fluorophenyl optionally substituted with a substituent selected from —O(1-4C alkyl)hetCyc3, -(1-4C alkyl)hetCyc3, —O(1-4C alkyl)O(1-3C alkyl) and —O(3-6C dihydroxyalkyl).


In one embodiment, Y is fluorophenyl substituted with a substituent selected from morpholinylethoxy, morpholinylethyl, —OCH2CH2OMe, 2,3-dihydroxypropoxy and 2,2-dimethyl-1,3-dioxolanyl.


In one embodiment, Y is selected from 3-fluoro-5-(2-morpholinylethoxy)phenyl, 5-fluoro-2-(2-morpholinoethoxy)phenyl, 3-fluoro-5-methoxyethoxyphenyl, 3-fluoro-5-(2-morpholinylethyl)phenyl, 5-fluoro-2-(2-morpholinylethyl)phenyl, 3-fluoro-5-(2,3-dihydroxypropoxy)phenyl, 2-(2,3-dihydroxypropoxy)-5-fluorophenyl,




embedded image


In one embodiment Y is phenyl optionally substituted with one or more substituents independently selected from halogen, -(1-4C)alkoxy, —CF3, —CHF2, —O(1-4C alkyl)hetCyc3 and —O(1-4C alkyl)O(1-3C alkyl).


In one embodiment, Y is phenyl optionally substituted with one or more substituents independently selected from —F, —Cl, —OMe, —CF3, —CHF2, morpholinylethoxy and —OCH2CH2OMe. In certain embodiments, Y is phenyl optionally substituted with one or two of said substituents. Particular values for Y include phenyl, 3-fluorophenyl, 2,5-difluorophenyl, 2-chloro-5-fluorophenyl, 2-methoxyphenyl, 2-methoxy-5-fluorophenyl, 2-trifluoromethyl-5-fluorophenyl, 2-difluoromethyl-5-fluorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-(2-morpholinylethoxy)phenyl, 5-fluoro-2-(2-morpholinoethoxy)phenyl, 3-fluoro-5-methoxyethoxyphenyl and 5-fluoro-2-methoxyethoxyphenyl.


In one embodiment, Y is a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from halogen, —O(1-4C alkyl), (1-4C)alkyl and NH2. Examples include pyridyl and thienyl groups optionally substituted with one or more substituents independently selected from halogen, —O(1-4C alkyl), (1-4C)alkyl and NH2.


In certain embodiments, Y is pyridyl optionally substituted with one or more substituents independently selected from fluoro, chloro, methoxy, methyl, ethyl, and amino.


In certain embodiments Y is pyrid-2-yl, pyrid-3-yl, 5-fluoropyrid-3-yl, 2-methoxy-5-fluoropyridy-3-yl, 2-chloro-5-fluoropyridy-3-yl, 2-methyl-5-fluoropyrid-3-yl, 2-ethyl-5-fluoropyrid-3-yl or 2-amino-5-fluoropyrid-3-yl.


In certain embodiments, Y is pyridyl substituted with one or more substituents independently selected from halogen, (1-4C)alkyl and amino.


In certain embodiments, Y is pyridyl substituted with one or more substituents independently selected from halogen and (1-4C)alkyl.


In certain embodiments, Y is pyridyl substituted with one or more substituents independently selected from fluoro, chloro, methyl and ethyl.


In certain embodiments, Y is pyridyl substituted with one or more substituents independently selected from F, methyl and ethyl.


In certain embodiments, Y is 5-fluoropyrid-3-yl, 2-methyl-5-fluoropyrid-3-yl or 2-ethyl-5-fluoropyrid-3-yl.


In certain embodiments, Y is 5-fluoropyrid-3-yl.


In one embodiment, Y is a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from halogen, —O(1-4C alkyl) and (1-4C)alkyl. Examples include pyridyl and thienyl groups optionally substituted with one or more substituents independently selected from halogen, —O(1-4C alkyl) and (1-4C)alkyl, for example one or more substituents independently selected from fluoro, methoxy and methyl. Particular values for Y include pyrid-2-yl, pyrid-3-yl, 5-fluoropyrid-3-yl, 2-methoxy-5-fluoropyridy-3-yl and 2-methyl-5-fluoropyridy-3-yl.


In one embodiment, Y is a pyrid-2-on-3-yl ring optionally substituted with one or more substituents independently selected from halogen and (1-4C)alkyl. Examples include pyrid-2-on-3-yl rings optionally substituted with one or more substituents independently selected from fluoro and methyl. In certain embodiments the pyrid-2-on-3-yl ring is optionally substituted with one or two of said substituents. In one embodiment, Y is 5-fluoropyridin-2(1H)-one optionally substituted with (1-4C)alkyl, for example methyl. Particular values for Y include the structures:




embedded image


In one embodiment, the Y group has the absolute configuration shown in Figure Ia:




embedded image


wherein R1, R2, R3, R4, X, Y and n are as defined herein.


With reference to the R3 substituent, in one embodiment R3 is H.


In one embodiment, R3 is -(1-4C)alkyl, for example, methyl, ethyl, propyl, isopropyl or butyl. In one embodiment, R3 is methyl.


With reference to the R4 substituent, in one embodiment R4 is halogen. Particular examples are fluoro and chloro.


In one embodiment, R4 is -(1-4C)alkyl, such as methyl, ethyl, propyl, isopropyl, or butyl. A particular example is methyl.


In one embodiment, R4 is —OH.


In one embodiment, R4 is (1-4C)alkoxy, for example —OMe and —OEt.


In one embodiment, R4 is —NH2.


In one embodiment, R4 is —NH(1-4C alkyl), for example —NHMe, —NHEt, —NHPr, —NHiPr or —NHBu. A particular example is —NHMe.


In one embodiment, R4 is CH2OH.


In one embodiment, each R4 is independently selected from —F, —Cl, —OH, —OMe, —NH2, -Me, —CH2OH and —NHMe.


In one embodiment, n is 0, 1, 2, 3 or 4. In one embodiment, n is 0, 1, 2 or 3. In one embodiment, n is 0, 1 or 2.


In one embodiment, n is 0.


In one embodiment, n is 1.


In one embodiment, n is 2.


With reference to the heterocyclic ring directly attached to the 5-position of Formula I, in certain embodiments, X is null, —CH2— or —CH2CH2—.


In one embodiment X is null, such that the heterocyclic ring at the 5-position of Formula I has the structure:




embedded image


where R3, R4, Y and n are as defined herein. In one embodiment, Y is phenyl optionally substituted with one or more substituents independently selected from halogen, -(1-4C)alkoxy, —CF3 and —CHF2. In one embodiment, Y is phenyl, 3-fluorophenyl and 2,5-difluorophenyl. In one embodiment, Y is 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from halogen, —O(1-4C alkyl) and (1-4C)alkyl, for example one or more halogen atoms. In one embodiment, Y is pyridyl. In one embodiment, R3 is hydrogen. In another embodiment, R3 is methyl. In one embodiment, n is 0. A particular example of the ring at the 5-position of Formula I when X is null includes the structures:




embedded image


In one embodiment, X is CH2, such that the heterocyclic ring at the 5-position of Formula I has the structure:




embedded image


where R3, R4, Y and n are as defined herein. In one embodiment, X is CH2, R3, R4 and n are as defined herein, and Y is phenyl optionally substituted with one or more substituents independently selected from —F, —Cl, —OMe, —CF3, —CHF2, morpholinylethoxy, morpholinylethyl, —OCH2CH2OMe, 2,3-dihydroxypropoxy and 2,2-dimethyl-1,3-dioxolanyl.


In one embodiment, X is CH2, R3, R4 and n are as defined herein, and Y is phenyl, 3-fluorophenyl, 2,5-difluorophenyl, 2-chloro-5-fluorophenyl, 2-methoxyphenyl, 2-methoxy-5-fluorophenyl, 2-trifluoromethyl-5-fluorophenyl, 2-difluoromethyl-5-fluorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-(2-morpholinylethoxy)phenyl, 3-fluoro-5-(2-morpholinylethyl)phenyl, 5-fluoro-2-(2-morpholinylethyl)phenyl, 3-fluoro-5-methoxyethoxyphenyl, 5-fluoro-2-methoxyethoxyphenyl, 3-fluoro-5-(2,3-dihydroxypropoxy)phenyl, 2-(2,3-dihydroxypropoxy)-5-fluorophenyl,




embedded image


In one embodiment, X is CH2, R3, R4 and n are as defined herein, and Y is fluorophenyl substituted with a substituent selected from morpholinylethoxy, —OCH2CH2OMe, 2,3-dihydroxypropoxy and 2,2-dimethyl-1,3-dioxolanyl.


In one embodiment, X is CH2, Y and R4 are as defined herein, and R3 is hydrogen. In another embodiment, X is CH2, Y and R4 are as defined herein, and R3 is methyl. In one embodiment, each R4 is independently selected from F, Cl, Me, OH, OMe, NH2, NHMe, CH2OH, CHF2 and CF3. In one embodiment, n is 0. In one embodiment, n is 1. In one embodiment, n is 2.


In one embodiment X is CH2, R3, R4 and n are as defined herein, and Y is a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from halogen, —O(1-4C alkyl), (1-4C)alkyl and NH2.


In one embodiment, X is CH2, R3, R4 and n are as defined herein, and Y is pyrid-2-yl, pyrid-3-yl, 5-fluoropyrid-3-yl, 2-chloro-5-fluoropyridy-3-yl, 2-methyl-5-fluoropyrid-3-yl, or 2-ethyl-5-fluoropyrid-3-yl. In one embodiment, R3 is hydrogen. In another embodiment, R3 is methyl. In one embodiment, each R4 is independently selected from F, Cl, Me, OH, OMe, NH2, NHMe, CH2OH, CHF2 and CF3. In one embodiment, n is 0. In one embodiment, n is 1. In one embodiment, n is 2.


In one embodiment, X is CH2, R3, R4 and n are as defined herein, and Y is pyridyl optionally substituted with one or more substituents independently selected from halogen and (1-4C)alkyl.


In one embodiment, X is CH2, R3, R4 and n are as defined herein, and Y is pyridyl optionally substituted with one or more substituents independently selected from fluoro, methyl and ethyl.


In one embodiment, X is CH2, R3, R4 and n are as defined herein, and Y is 5-fluoropyrid-3-yl, 2-methyl-5-fluoropyrid-3-yl, or 2-ethyl-5-fluoropyrid-3-yl. In one embodiment, R3 is hydrogen.


In one embodiment, X is CH2, R3, R4 and n are as defined herein, and Y is a pyrid-2-on-3-yl ring optionally substituted with one or more substituents independently selected from halogen and (1-4C)alkyl.


In one embodiment, X is CH2, R3, R4 and n are as defined herein, and Y is a pyrid-2-on-3-yl ring optionally substituted with one or more groups selected from methyl and fluoro. In one embodiment, Y is 5-fluoropyridin-2(1H)-one optionally substituted with methyl. In one embodiment, R3 is hydrogen. In another embodiment, R3 is methyl. In one embodiment, each R4 is independently selected from F, Cl, Me, OH, OMe, NH2, NHMe, CH2OH, CHF2 and CF3. In one embodiment, n is 0. In one embodiment, n is 1. In one embodiment, n is 2.


In one embodiment the ring at the 5-position of Formula I when X is CH2 include the structures:




embedded image


embedded image


embedded image


In one embodiment, X is CH2, such that the heterocyclic ring at the 5-position of Formula I has the structure:




embedded image


where R3, R4, Y and n are as defined herein. In one embodiment Y is phenyl optionally substituted with one or more substituents independently selected from halogen, -(1-4C)alkoxy, —CF3—CHF2, —O(1-4C alkyl)hetCyc3 or —O(1-4C alkyl)O(1-3C alkyl). In one embodiment, Y is phenyl, 3-fluorophenyl, 2,5-difluorophenyl, 2-difluoromethyl-5-fluorophenyl, 2-trifluoromethyl-5-fluorophenyl, 2-chloro-5-fluorophenyl, 3-chloro-5-fluorophenyl, 2-methoxy-5-fluorophenyl, 3-fluoro-5-methoxyethoxyphenyl, 3-fluoro-5-(2-morpholinylethoxy)phenyl, 5-fluoro-2-(2-morpholinoethoxy)phenyl, or 5-fluoro-2-methoxyethoxyphenyl. In one embodiment, Y is a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from halogen, —O(1-4C alkyl) and (1-4C)alkyl. In one embodiment, R3 is hydrogen. In another embodiment, R3 is methyl. In one embodiment, each R4 is independently selected from F, Cl, Me, OH, OMe, NH2, NHMe, CH2OH, CHF2 and CF3. In one embodiment, Y is pyrid-2-yl, 5-fluoropyrid-3-yl or 2-methoxy-5-fluoropyridy-3-yl. In one embodiment, n is 0, 1 or 2.


Particular examples of the ring at the 5-position of Formula I when X is CH2 include the structures:




embedded image


embedded image


embedded image


In one embodiment, X is —CH2CH2—, such that the heterocyclic ring at the 5-position of Formula I has the structure:




embedded image


where R3, R4, Y and n are as defined herein. In one embodiment, Y is phenyl optionally substituted with one or more substituents independently selected from halogen, -(1-4C)alkoxy, —CF3 and —CHF2. In one embodiment, Y is phenyl or 3-fluorophenyl. In one embodiment, Y is a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from halogen, —O(1-4C alkyl) and (1-4C)alkyl. In one embodiment, Y is pyridyl optionally substituted with one or more F atoms. In one embodiment, R3 is hydrogen. In another embodiment, R3 is methyl. In one embodiment, n is 0, 1 or 2. In one embodiment, n is 0. Particular examples of the ring at the 5-position of Formula I when X is —CH2CH2— include the structures:




embedded image


In one embodiment, X is —CH2O—. In one embodiment, the heterocyclic ring at the 5-position of Formula I has the structure:




embedded image


where R3, R4, Y and n are as defined herein. In one embodiment, Y is phenyl optionally substituted with one or more substituents independently selected from halogen, -(1-4C)alkoxy, —CF3 and —CHF2. In one embodiment, Y is phenyl optionally substituted with one or more substituents independently selected from —F and -(1-4C)alkoxy. In one embodiment, Y is phenyl, 3-fluorophenyl, 2,5-difluorophenyl, or 2-methoxyphenyl. In one embodiment, Y is a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from halogen, —O(1-4C alkyl) and (1-4C)alkyl, for example one or more halogen atoms. In one embodiment, Y is pyrid-3-yl. In one embodiment, R3 is hydrogen. In another embodiment, R3 is methyl. In one embodiment, n is 0, 1 or 2. Particular examples of the ring at the 5-position of Formula I when X is —CH2O— include the structures:




embedded image


In one embodiment, X is —CH2NRd—. In one embodiment, the heterocyclic ring at the 5-position of Formula I has the structure:




embedded image


where R3, R4, Y, Rd and n are as defined herein. In one embodiment, Rd is H. In one embodiment, Rd is -(1-4C alkyl), for example methyl, ethyl, propyl, isopropyl, or butyl. A particular example is methyl. In one embodiment, Y is phenyl optionally substituted with one or more substituents independently selected from halogen, -(1-4C)alkoxy, —CF3 and —CHF2. In one embodiment, Y is a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from halogen, —O(1-4C alkyl) and (1-4C)alkyl. In one embodiment, Y is pyridyl optionally substituted with one or more F atoms. In one embodiment, n is 0. Particular examples of the ring at the 5-position of Formula I when X is —CH2NRd— include the structures:




embedded image


It will be appreciated that certain compounds according to the invention may contain one or more centers of asymmetry and may therefore be prepared and isolated as a mixture of isomers such as a racemic or diastereomeric mixture, or in an enantiomerically or diastereomerically pure form.


The compounds of Formula I also include compounds of Formula Ib




embedded image


and salts thereof, wherein:


R1 is H;


R2 is H, (1-6C)alkyl, (1-6C)fluoroalkyl, -(1-6C)hydroxyalkyl or -(2-6C)dihydroxyalkyl;


Y is (i) phenyl optionally substituted with one or more substituents independently selected from halogen, -(1-4C)alkoxy, —CF3—CHF2, —O(1-4C alkyl)hetCyc3 and —O(1-4C alkyl)O(1-3C alkyl) or (ii) a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from halogen, —O(1-4C alkyl) and (1-4C)alkyl;


hetCyc3 is a 5-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O;


X is CH2 or CH2CH2;


R3 is H;


each R4 is independently selected from halogen, -(1-4C)alkyl, —OH, -(1-4C)alkoxy, —NH2, —NH(1-4C alkyl) and —CH2OH; and


n is 0, 1, or 2.


In certain embodiments of Formula Ib, R2 is H, (1-6C)alkyl, -(1-6C)hydroxyalkyl or -(2-6C)dihydroxyalkyl; Y is phenyl optionally substituted with one or more substituents independently selected from —F, —Cl, —OMe, —CF3, —CHF2, morpholinylethoxy and —OCH2CH2OMe; X is CH2 and n is 0.


In certain embodiments of Formula Ib, R2 is H, methyl, ethyl, isopropyl, tert-butyl, CH2CH2OH, or CH2CH(OH)CH2OH; Y is phenyl, 3-fluorophenyl, 2,5-difluorophenyl, 2-chloro-5-fluorophenyl, 2-methoxyphenyl, 2-methoxy-5-fluorophenyl, 2-trifluoromethyl-5-fluorophenyl, 2-difluoromethyl-5-fluorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-(2-morpholinylethoxy) phenyl, 5-fluoro-2-(2-morpholinoethoxy)phenyl, 3-fluoro-5-methoxyethoxyphenyl or 5-fluoro-2-methoxyethoxyphenyl; X is CH2; and n is 0.


In certain embodiments of Formula Ib, R2 is H, (1-6C)alkyl, -(1-6C)hydroxyalkyl or -(2-6C)dihydroxyalkyl; Y is pyridyl optionally substituted with one or more substituents independently selected from F, OMe and Me; X is CH2; and n is 0.


In certain embodiments of Formula Ib, R2 is H, methyl, ethyl, isopropyl, tert-butyl, CH2CH2OH, or CH2CH(OH)CH2OH; Y is pyrid-2-yl, pyrid-3-yl, 5-fluoropyrid-3-yl, 2-methoxy-5-fluoropyridy-3-yl or 2-methyl-5-fluoropyridy-3-yl; X is CH2; and n is 0.


Compounds of Formula I also include compounds of Formula Ic,




embedded image


and salts thereof, wherein:


NR1R2 forms a 4-6 membered azacyclic ring optionally substituted with one or more substituents independently selected from (1-6C)alkyl, OH, CO2H and (1-3C alkyl)CO2H;


X is CH2 or CH2CH2;


Y is (i) phenyl optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkoxy, —CF3—CHF2, —O(1-4C alkyl)hetCyc3 and —O(1-4C alkyl)O(1-3C alkyl) or (ii) a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from halogen, —O(1-4C alkyl) and (1-4C)alkyl;


hetCyc3 is a 5-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O;


R3 is H;


each R4 is independently selected from halogen, -(1-4C)alkyl, —OH, -(1-4C)alkoxy, —NH2, —NH(1-4C alkyl) and —CH2OH; and


n is 0, 1, or 2.


In certain embodiments of Formula Ic, NR1R2 forms 4-6 membered azacyclic ring optionally substituted with one or two groups independently selected from methyl, OH, C(═O)OH or CH2COOH; Y is phenyl optionally substituted with one or more substituents independently selected from —F, —Cl, —OMe, —CF3, —CHF2, morpholinylethoxy and —OCH2CH2OMe; X is CH2; and n is 0.


In certain embodiments of Formula Ic, Y is phenyl, 3-fluorophenyl, 2,5-difluorophenyl, 2-chloro-5-fluorophenyl, 2-methoxyphenyl, 2-methoxy-5-fluorophenyl, 2-trifluoromethyl-5-fluorophenyl, 2-difluoromethyl-5-fluorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-(2-morpholinylethoxy) phenyl, 5-fluoro-2-(2-morpholinoethoxy)phenyl, 3-fluoro-5-methoxyethoxyphenyl or 5-fluoro-2-methoxyethoxyphenyl; X is CH2; n is 0; and NR1R2 forms 4-6 membered azacyclic ring selected from one of the following structures:




embedded image


In certain embodiments of Formula Ic, NR1R2 forms 4-6 membered azacyclic ring optionally substituted with one or two groups independently selected from methyl, OH, C(═O)OH or CH2COOH; Y is pyridyl optionally substituted with one or more substituents independently selected from F, OMe and Me; X is CH2; and n is 0.


In certain embodiments of Formula Ic, Y is pyrid-2-yl, pyrid-3-yl, 5-fluoropyrid-3-yl, 2-methoxy-5-fluoropyridy-3-yl or 2-methyl-5-fluoropyridy-3-yl; X is CH2; n is 0; and NR1R2 forms 4-6 membered azacyclic ring selected from one of the following structures:




embedded image


Compounds of Formula I also include compounds of Formula Id:




embedded image


and salts thereof, wherein:


R1 is H;


R2 is Cyc1 or a bridged 7-membered cycloalkyl ring, wherein Cyc1 is a 3-6 membered cycloalkyl ring optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, —OMe, —CO2H and -(1-4C alkyl)OH;


Y is (i) phenyl optionally substituted with one or more substituents independently selected from halogen, -(1-4C)alkoxy, —CF3—CHF2, —O(1-4C alkyl)hetCyc3 and —O(1-4C alkyl)O(1-3C alkyl) or (ii) a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from halogen, —O(1-4C alkyl) and (1-4C)alkyl;


hetCyc3 is a 5-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O;


X is CH2 or CH2CH2;


R3 is H;


each R4 is independently selected from halogen, -(1-4C)alkyl, —OH, -(1-4C)alkoxy, —NH2, —NH(1-4C alkyl) and —CH2OH; and


n is 0, 1, or 2.


In certain embodiments of Formula Id, R2 is Cyc1 which is optionally substituted with one or more substituents independently selected from methyl, —OH, —CH2OH and —CO2H; Y is phenyl optionally substituted with one or more substituents independently selected from —F, —Cl, —OMe, —CF3, —CHF2, morpholinylethoxy and —OCH2CH2OMe; X is CH2; and n is 0.


In certain embodiments of Formula Id, Y is phenyl, 3-fluorophenyl, 2,5-difluorophenyl, 2-chloro-5-fluorophenyl, 2-methoxyphenyl, 2-methoxy-5-fluorophenyl, 2-trifluoromethyl-5-fluorophenyl, 2-difluoromethyl-5-fluorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-(2-morpholinylethoxy)phenyl, 5-fluoro-2-(2-morpholinoethoxy)phenyl, 3-fluoro-5-methoxyethoxyphenyl or 5-fluoro-2-methoxyethoxyphenyl; X is CH2, n is 0; and R2 is selected from the structures:




embedded image


In certain embodiments of Formula Id, R2 is cyclopropyl optionally substituted with one or two substituents independently selected from methyl, —OH, —CH2OH and —CO2H; Y is phenyl optionally substituted with one or more substituents independently selected from —F, —Cl, —OMe, —CF3, —CHF2, morpholinylethoxy and —OCH2CH2OMe; X is CH2; and n is 0.


In certain embodiments of Formula Id, R2 is Cyc1 which is optionally substituted with one or more substituents independently selected from methyl, —OH, —CH2OH and —CO2H; Y is pyridyl optionally substituted with one or more substituents independently selected from F, OMe and Me; X is CH2; and n is 0.


In certain embodiments of Formula Id, Y is pyrid-2-yl, pyrid-3-yl, 5-fluoropyrid-3-yl, 2-methoxy-5-fluoropyridy-3-yl or 2-methyl-5-fluoropyridy-3-yl; X is CH2; n is 0; and R2 is selected from the structures:




embedded image


Compounds of Formula I also include compounds of Formula Ie




embedded image


and salts thereof, wherein:


R1 is H;


R2 is -(1-6C alkyl)CN, -(1-6C alkyl)SO2NH2, -(1-6C alkyl)NHSO2(1-3C alkyl), -(1-6C alkyl)NH2, -(1-6C alkyl)NH(1-4C alkyl), or -(1-6C alkyl)N(1-4C alkyl)2;


Y is (i) phenyl optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkoxy, —CF3—CHF2, —O(1-4C alkyl)hetCyc3 and —O(1-4C alkyl)O(1-3C alkyl), or (ii) a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from halogen and —O(1-4C alkyl);


hetCyc3 is a 5-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O;


X is CH2 or CH2CH2;


R3 is H;


each R4 is independently selected from halogen, -(1-4C)alkyl, —OH, -(1-4C)alkoxy, —NH2, —NH(1-4C alkyl) and —CH2OH; and


n is 0, 1, or 2.


In certain embodiments of Formula Ie, Y is phenyl optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkoxy, —CF3—CHF2, —O(1-4C alkyl)hetCyc3 and —O(1-4C alkyl)O(1-3C alkyl); X is CH2; and n is 0.


In certain embodiments of Formula Ie, Y is phenyl, 3-fluorophenyl, 2,5-difluorophenyl, 2-chloro-5-fluorophenyl, 2-methoxyphenyl, 2-methoxy-5-fluorophenyl, 2-trifluoromethyl-5-fluorophenyl, 2-difluoromethyl-5-fluorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-(2-morpholinylethoxy) phenyl, 5-fluoro-2-(2-morpholinoethoxy)phenyl, 3-fluoro-5-methoxyethoxyphenyl or 5-fluoro-2-methoxyethoxyphenyl; X is CH2; and n is 0.


In certain embodiments of Formula Ie, Y is a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from halogen and —O(1-4C alkyl); X is CH2; and n is 0.


In certain embodiments of Formula Ie, Y is pyrid-2-yl, pyrid-3-yl, 5-fluoropyrid-3-yl, 2-methoxy-5-fluoropyridy-3-yl or 2-methyl-5-fluoropyridy-3-yl; X is CH2 and n is 0.


Compounds of Formula I also include compounds of Formula If




embedded image


and salts thereof, wherein:


R1 is H;


R2 is -(1-6C alkyl)hetCyc1, -(1-6C alkyl)hetAr1, hetAr2 or hetCyc2;


hetCyc1 is a 5-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein hetCyc1 is optionally substituted with oxo;


hetCyc2 is a 6 membered carbon-linked heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein hetCyc2 is optionally substituted with F, SO2NH2, or SO2(1-3C alkyl);


hetAr1 is a 5-membered heteroaryl ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with (1-4C)alkyl;


hetAr2 is a 5-6 membered heteroaryl ring having 1-2 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from (1-4C)alkyl;


Y is (i) phenyl optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkoxy, —CF3—CHF2, —O(1-4C alkyl)hetCyc3 and —O(1-4C alkyl)O(1-3C alkyl), or (ii) a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from halogen and —O(1-4C alkyl);


X is CH2 or CH2CH2;


R3 is H;


each R4 is independently selected from halogen, -(1-4C)alkyl, —OH, -(1-4C)alkoxy, —NH2, —NH(1-4C alkyl) and —CH2OH; and


n is 0, 1, or 2.


In certain embodiments of Formula If, R2 is -(1-6C alkyl)hetAr1 or hetAr2; Y is (i) phenyl optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkoxy, —CF3—CHF2, —O(1-4C alkyl)hetCyc3 and —O(1-4C alkyl)O(1-3C alkyl); X is CH2; and n is 0.


In certain embodiments of Formula If, R2 is -(1-6C alkyl)hetAr1 or hetAr2; hetAr1 is a furanyl, pyrazolyl, or imidazolyl ring optionally substituted with -(1-4C alkyl); hetAr2 is a pyridyl or pyrazolo ring optionally substituted with one or more methyl groups; Y is phenyl, 3-fluorophenyl, 2,5-difluorophenyl, 2-methoxyphenyl, 2-chloro-5-fluorophenyl, 2-methoxy-5-fluorophenyl, 2-trifluoromethyl-5-fluorophenyl, 2-difluoromethyl-5-fluorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-(2-morpholinylethoxy)phenyl, 5-fluoro-2-(2-morpholinoethoxy)phenyl, 3-fluoro-5-methoxyethoxyphenyl or 5-fluoro-2-methoxyethoxyphenyl; X is CH2 and n is 0.


In certain embodiments of Formula If, R2 is -(1-6C alkyl)hetAr1 or hetAr2; Y is a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from halogen and —O(1-4C alkyl); X is CH2; and n is 0.


In certain embodiments of Formula If, R2 is -(1-6C alkyl)hetAr1 or hetAr2; hetAr1 is a furanyl, pyrazolyl, or imidazolyl ring optionally substituted with -(1-4C alkyl); hetAr2 is a pyridyl or pyrazolo ring optionally substituted with one or more methyl groups; Y is pyrid-2-yl, pyrid-3-yl, 5-fluoropyrid-3-yl, 2-methoxy-5-fluoropyridy-3-yl or 2-methyl-5-fluoropyridy-3-yl; X is CH2; and n is 0.


In certain embodiments of Formula If, R2 is -(1-6C alkyl)hetCyc1 or hetCyc2; Y is (i) phenyl optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkoxy, —CF3—CHF2, —O(1-4C alkyl)hetCyc3 and —O(1-4C alkyl)O(1-3C alkyl); X is CH2; and n is 0.


In certain embodiments of Formula If, R2 is -(1-6C alkyl)hetCyc1 or hetCyc2; hetCyc1 is a morpholinyl or imidazolidin-2-one ring; hetCyc2 is a piperidinyl or tetrahydropyranyl ring optionally substituted with F, SO2NH2, or SO2(1-3C alkyl); Y is phenyl, 3-fluorophenyl, 2,5-difluorophenyl, 2-chloro-5-fluorophenyl, 2-methoxyphenyl, 2-methoxy-5-fluorophenyl, 2-trifluoromethyl-5-fluorophenyl, 2-difluoromethyl-5-fluorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-(2-morpholinylethoxy)phenyl, 5-fluoro-2-(2-morpholinoethoxy)phenyl, 3-fluoro-5-methoxyethoxyphenyl or 5-fluoro-2-methoxyethoxyphenyl; X is CH2; and n is 0.


In certain embodiments of Formula If, R2 is hetCyc2; hetCyc2 is a piperidinyl or tetrahydropyranyl ring optionally substituted with F, SO2NH2, or SO2(1-3C alkyl); Y is pyrid-2-yl, pyrid-3-yl, 5-fluoropyrid-3-yl, 2-methoxy-5-fluoropyridy-3-yl or 2-methyl-5-fluoropyridy-3-yl; X is CH2; and n is 0.


The compounds of Formula I also include compounds of Formula Ig




embedded image


and salts thereof, wherein:


R1 is H;


R2 is —O(1-6C alkyl), —O(3-6C cycloalkyl);


Y is (i) phenyl optionally substituted with one or more substituents independently selected from halogen, -(1-4C)alkoxy, —CF3—CHF2, —O(1-4C alkyl)hetCyc3 and —O(1-4C alkyl)O(1-3C alkyl) or (ii) a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from halogen, —O(1-4C alkyl) and (1-4C)alkyl;


hetCyc3 is a 5-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O;


X is CH2 or CH2CH2;


R3 is H;


each R4 is independently selected from halogen, -(1-4C)alkyl, —OH, -(1-4C)alkoxy, —NH2, —NH(1-4C alkyl) and —CH2OH; and


n is 0, 1, or 2.


In certain embodiments of Formula Ig, R2 is —O(1-6C alkyl), —O(3-6C cycloalkyl); Y is phenyl optionally substituted with one or more substituents independently selected from —F, —Cl, —OMe, —CF3, —CHF2, morpholinylethoxy and —OCH2CH2OMe; X is CH2 and n is 0.


In certain embodiments of Formula Ig, R2 is OMe, OEt or cyclopropoxy; Y is phenyl, 3-fluorophenyl, 2,5-difluorophenyl, 2-chloro-5-fluorophenyl, 2-methoxyphenyl, 2-methoxy-5-fluorophenyl, 2-trifluoromethyl-5-fluorophenyl, 2-difluoromethyl-5-fluorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-(2-morpholinylethoxy)phenyl, 5-fluoro-2-(2-morpholinoethoxy)phenyl, 3-fluoro-5-methoxyethoxyphenyl or 5-fluoro-2-methoxyethoxyphenyl; X is CH2; and n is 0.


In certain embodiments of Formula Ig, R2 is —O(1-6C alkyl), —O(3-6C cycloalkyl); Y is pyridyl optionally substituted with one or more substituents independently selected from F, OMe and Me; X is CH2; and n is 0.


In certain embodiments of Formula Ig, R2 is OMe, OEt or cyclopropoxy; Y is pyrid-2-yl, pyrid-3-yl, 5-fluoropyrid-3-yl, 2-methoxy-5-fluoropyridy-3-yl or 2-methyl-5-fluoropyridy-3-yl; X is CH2; and n is 0.


The compounds of Formula I also include compounds of Formula Ih




embedded image


and salts thereof, wherein:


R1 is H or -(1-6C alkyl);


R2 is H, -(1-6C)alkyl, -(1-6C)fluoroalkyl, -(1-6C)hydroxyalkyl, -(2-6C)dihydroxyalkyl, -(1-6C alkyl)CN, -(1-6C alkyl)SO2NH2, -(1-6C alkyl)NHSO2(1-3C alkyl), -(1-6C alkyl)NH2, -(1-6C alkyl)NH(1-4C alkyl), -(1-6C alkyl)N(1-4C alkyl)2, -(1-6C alkyl)hetCyc1, -(1-6C alkyl)hetAr1, hetAr2, hetCyc2, —O(1-6C alkyl), —O(3-6C cycloalkyl), or Cyc1;


or NR1R2 forms a 4-6 membered azacyclic ring optionally substituted with one or more substituents independently selected from -(1-6C)alkyl, —OH, —CO2H and -(1-3C alkyl)CO2H;


Cyc1 is a 3, 4 or 5 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, OMe, —CO2H and -(1-4C alkyl)OH;


hetCyc1 is a 5-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein hetCyc1 is optionally substituted with oxo;


hetCyc2 is a 6 membered carbon-linked heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein hetCyc2 is optionally substituted with F, SO2NH2, or SO2(1-3C alkyl);


hetAr1 is a 5-membered heteroaryl ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with (1-4C)alkyl;


hetAr2 is a 5-6 membered heteroaryl ring having 1-2 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from (1-4C)alkyl;


X is CH2;


Y is (i) fluorophenyl optionally substituted with a substituent selected from —O(1-4C alkyl)hetCyc3, -(1-4C alkyl)hetCyc3, —O(1-4C alkyl)O(1-3C alkyl) and —O(3-6C dihydroxyalkyl), (ii) pyridyl substituted with one or more substituents independently selected from F, methyl and ethyl, or (iii) 5-fluoropyridin-2(1H)-one optionally substituted with (1-4C)alkyl;


R3 is H or -(1-4C alkyl);


each R4 is independently selected from halogen, -(1-4C)alkyl, —OH, -(1-4C)alkoxy, —NH2, —NH(1-4C alkyl) and —CH2OH; and


n is 0, 1, 2, 3, 4, 5 or 6.


In one embodiment of Formula Ih, Y is fluorophenyl optionally substituted with a substituent selected from —O(1-4C alkyl)hetCyc3, -(1-4C alkyl)hetCyc3, —O(1-4C alkyl)O(1-3C alkyl) and —O(3-6C dihydroxyalkyl).


In one embodiment of Formula Ih, Y is pyridyl substituted with one or more substituents independently selected from F, methyl and ethyl.


In one embodiment of Formula Ih, Y is 5-fluoropyridin-2(1H)-one optionally substituted with (1-4C)alkyl.


In one embodiment of Formula Ih, R2 is a 3, 4 or 5 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, OMe, —CO2H and -(1-4C alkyl)OH.


In one embodiment of Formula Ih, R2 is cyclopropyl optionally substituted with methyl, —CO2H or —CH2OH.


In one embodiment of Formula Ih, R4 is OH, F, methyl, or CH2OH.


In one embodiment of Formula Ih, n is 0, 1 or 2.


In one embodiment of Formula Ih, R3 is hydrogen.


In one embodiment of Formula Ih, R1 is H; R2 is a 3, 4 or 5 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, OMe, —CO2H and -(1-4C alkyl)OH; X is CH2; Y is (i) fluorophenyl optionally substituted with a substituent selected from —O(1-4C alkyl)hetCyc3, —O(1-4C alkyl)O(1-3C alkyl) and —O(3-6C dihydroxyalkyl), (ii) pyridyl substituted with one or more substituents independently selected from F, methyl and ethyl, or (iii) 5-fluoropyridin-2(1H)-one optionally substituted with (1-4C)alkyl; R3 is H, and n is 0.


It will be appreciated that certain compounds of the invention may contain asymmetric or chiral centers, and therefore exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the invention, including but not limited to, diastereomers, enantiomers and atropisomers, as well as mixtures thereof such as racemic mixtures, form part of the present invention.


In the structures shown herein, where the stereochemistry of any particular chiral atom is not specified, then all stereoisomers are contemplated and included as the compounds of the invention. Where stereochemistry is specified by a solid wedge or dashed line representing a particular configuration, then that stereoisomer is so specified and defined.


It will also be appreciated that certain compounds of Formula I may be used as intermediates for further compounds of Formula I.


The compounds of Formula I include salts thereof. In certain embodiments, the salts are pharmaceutically acceptable salts. In addition, the compounds of Formula I include other salts of such compounds which are not necessarily pharmaceutically acceptable salts, and which may be useful as intermediates for preparing and/or purifying compounds of Formula I and/or for separating enantiomers of compounds of Formula I.


It will further be appreciated that the compounds of Formula I and their salts may be isolated in the form of solvates, and accordingly that any such solvate is included within the scope of the present invention.


Compounds of the invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. That is, an atom, in particular when mentioned in relation to a compound according to Formula I, comprises all isotopes and isotopic mixtures of that atom, either naturally occurring or synthetically produced, either with natural abundance or in an isotopically enriched form. For example, when hydrogen is mentioned, it is understood to refer to 1H, 2H, 3H or mixtures thereof; when carbon is mentioned, it is understood to refer to 11C, 12C, 13C, 14C or mixtures thereof; when nitrogen is mentioned, it is understood to refer to 13N, 14, 15N or mixtures thereof; when oxygen is mentioned, it is understood to refer to 14O, 15O, 16O, 17O, 18O or mixtures thereof; and when fluoro is mentioned, it is understood to refer to 18F, 19F or mixtures thereof. The compounds according to the invention therefore also comprise compounds with one or more isotopes of one or more atom, and mixtures thereof, including radioactive compounds, wherein one or more non-radioactive atoms has been replaced by one of its radioactive enriched isotopes. Radiolabeled compounds are useful as therapeutics, research reagents, e.g., assay reagents, and diagnostic agents, e.g., in vivo imaging agents. All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.


The term “(1-6C) alkyl” as used herein refers to saturated linear or branched-chain monovalent hydrocarbon radicals of one to six carbon atoms, respectively. Examples include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-methyl-1-propyl, 2-butyl, 2-methyl-2-propyl, pentyl, and hexyl. The definition of “(1-6C) alkyl” likewise applies to the term “O-(1-6C alkyl)”.


The terms “(1-6C)fluoroalkyl”, “(1-6C alkyl)CN”, “(1-6C alkyl)SO2NH2”, “(1-6C alkyl)NHSO2(1-3C alkyl)”, “(1-6C alkyl)NH2”, “(1-6C alkyl)NH(1-4C alkyl)”, “(1-6C alkyl)N(1-4C alkyl)2”, “(1-6C alkyl)hetCyc1” and “(1-6C alkyl)hetAr1” as used herein refer to saturated linear or branched-chain monovalent hydrocarbon radicals of one to six carbon atoms, respectively, wherein one of the hydrogen atoms is replaced with a fluoro atom, or a CN, SO2NH2, NHSO2(1-3C alkyl), NH2, NH(1-4C alkyl), N(1-4C alkyl)2, hetCyc1 or hetAr1 group, respectively.


The term “(1-6C)chloroalkyl” as used herein refers to saturated linear or branched-chain monovalent hydrocarbon radicals of one to six carbon atoms, respectively, wherein one of the hydrogen atoms is replaced with a chloro atom.


The term “(1-6C)hydroxyalkyl” as used herein refers to saturated linear or branched-chain monovalent hydrocarbon radicals of one to six carbon atoms, respectively, wherein one of the hydrogen atoms are replaced with a OH group.


The term “(2-6C)dihydroxyalkyl” as used herein refers to saturated linear or branched-chain monovalent hydrocarbon radicals of two to six carbon atoms, respectively, wherein two of the hydrogen atoms are replaced with a OH group, provided that two OH groups are not on the same carbon.


The term “(1-6C)difluoroalkyl” as used herein refers to saturated linear or branched-chain monovalent hydrocarbon radicals of one to six carbon atoms, respectively, wherein two of the hydrogen atoms are replaced with a fluoro atom.


The term “(1-6C)trifluoroalkyl” as used herein refers to saturated linear or branched-chain monovalent hydrocarbon radicals of one to six carbon atoms, respectively, wherein three of the hydrogen atoms are replaced with a fluoro atom.


The term “(2-6C)chlorofluoroalkyl” as used herein refers to saturated linear or branched-chain monovalent hydrocarbon radicals of two to six carbon atoms, respectively, wherein one of the hydrogen atoms is replaced with a chloro atom and one of the hydrogen atoms is replaced with a fluoro atom.


The term “(2-6C)difluorochloroalkyl” as used herein refers to saturated linear or branched-chain monovalent hydrocarbon radicals of two to six carbon atoms, respectively, wherein one of the hydrogen atoms is replaced with a chloro and two of the hydrogen atoms are replaced with a fluoro atom.


The term “(2-6C)chlorohydroxyalkyl” as used herein refers to a saturated linear or branched-chain monovalent hydrocarbon radicals of two to six carbon atoms, respectively, wherein one of the hydrogen atoms is replaced with a chloro and one of the hydrogen atoms is replaced with OH.


The term “(1-6C alkyl)NHC(═O)O(1-4C alkyl)” as used herein refers to saturated linear or branched-chain monovalent hydrocarbon radicals of one to six carbon atoms, respectively, wherein one of the hydrogen atoms is replaced with a —NHC(═O)O(1-4C alkyl) group.


The phrase “O(1-6C alkyl) which is optionally substituted with halogen, OH or (1-4C)alkoxy” as used herein refers to a saturated linear or branched-chain monovalent alkyl ether radical of one to six carbon atoms wherein the term “alkyl” is as defined herein and the radical is on the oxygen atom, and one of the hydrogen atoms on the carbon chain is optionally replaced with halogen, OH or (1-4C)alkoxy. Examples include methoxy, ethoxy, propoxy, isopropoxy, and butoxy radicals optionally substituted with halogen, OH or (1-4C)alkoxy.


The term “O(3-6C cycloalkyl)” as used herein refers to a cycloalkyl ether radical wherein the term “cycloalkyl” is a 3-6 membered carbocyclic ring and the radical is on the oxygen atom.


The term “-(1-6C alkyl)(3-6C cycloalkyl)” as used herein refers to a saturated linear or branched-chain monovalent hydrocarbon radical of one to six carbon atoms, respectively, wherein one of the hydrogen atoms is replaced with a 3-6 membered carbocyclic ring.


The term “-(1-6Calkyl)(1-4C alkoxy)” as used herein refers to a saturated linear or branched-chain monovalent hydrocarbon radical of one to six carbon atoms, respectively, wherein one of the hydrogen atoms is replaced with an (1-4C)alkoxy group.


The term “-(1-6C hydroxyalkyl)(1-4C alkoxy)” as used herein refers to a saturated linear or branched-chain monovalent hydrocarbon radical of one to six carbon atoms, respectively, wherein one of the hydrogen atoms is replaced with hydroxy (OH) group and one of the hydrogen atoms is replaced with an (1-4C)alkoxy group.


The term “halogen” includes fluoro, chloro, bromo and iodo.


The term “pharmaceutically acceptable” indicates that the substance or composition is compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.


The present invention also provides a process for the preparation of a compound of Formula I or a salt thereof as defined herein, which comprises:


(a) reacting a corresponding compound of Formula II




embedded image


or a reactive derivative thereof with an amine having the formula HNR1R2; or


(b) for compounds of Formula I where R1 and R2 are each hydrogen, reacting a compound of Formula III




embedded image


with an inorganic acid; or


(c) for a compound of Formula I where R2 is (alkyl)NHSO2((1-3C alkyl), reacting a compound having the formula IV




embedded image


with -(1-3C alkyl)SO2Cl; or


(d) for compounds of Formula I wherein Y is 5-fluoropyridin-2(1H)-one, treating a corresponding compound having the formula VIII




embedded image


with an acid at elevated temperatures; or


(e) for a compound of Formula I wherein R2 is CH2CH(OH)CH2OH, treating a corresponding compound having the formula IX




embedded image


with an acid; or


(f) for a compound of Formula I wherein Y is fluorophenyl substituted with —OCH2CH(OH)CH2OH, treating a corresponding compound having the formula X




embedded image


with an acid; and


removing or adding any protecting groups if desired, and forming a salt if desired.


Referring to method (a), the coupling of the compound of formula II with an amine having the formula HNR1R2 may be performed using conventional amide bond formation conditions, for example by reacting an amine with a reactive derivative of a carboxylic acid, for example an acid halide, such as an acid chloride. When reacting the acid form of a compound of Formula II, the reaction may be performed in the presence of a suitable coupling agent such as 2-(1H-7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate methanaminium (HATU), O-Benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluoro-phosphate (HBTU), O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyl-uronium tetrafluoroborate (TBTU), N,N′-dicyclohexylcarbodiimide (DCC), 1-(3-dimethylaminopropyl)-3-ethylcarboiimide (DIEC) and any other amide coupling reagents well known to persons skilled in the art. Suitable bases include tertiary amine bases such as diisopropylethylamine (DIEA) and triethylamine. Suitable solvents include DMF and CH3CN.


Referring to method (b), suitable acids include strong inorganic acids such as sulfuric acid.


Referring to methods (d), (e) and (f), suitable acids include inorganic acids such as hydrogen halides, for example HCl.


Compounds of formula II may be prepared by coupling a corresponding compound having formula IV




embedded image


with a corresponding compound having formula V




embedded image


where Z1 is OH or a leaving group or atom and P1 is H or a carboxyl protecting group. The leaving atom represented by Z1 may be, for example, a halogen atom such as a chlorine atom. In this instance, the reaction is performed in the presence of a base, such as an amine base, for example diisopropylethylamine. The reaction is conveniently performed at elevated temperatures, for example at 100° C. Convenient solvents include alcohols such as butanol. When Z1 is OH the reaction is performed in the presence of a coupling reagent. Suitable coupling reagents when Z1 is OH include benzotriazolyloxy tris [dimethyl-amino] phosphonium hexafluorophosphate (BOP), HATU, HBTU or TBTU. The carboxyl protecting group may be any convenient carboxyl protecting group, for example as described in Greene & Wuts, eds., “Protecting Groups in Organic Synthesis”, John Wiley & Sons, Inc. Examples of carboxyl protecting groups include (1-6C)alkyl groups, such as methyl, ethyl and t-butyl.


A compound of Formula V can be prepared by cyclizing a corresponding compound of Formula VI




embedded image


with (E)-ethyl 3-ethoxyacrylate to provide the compound of Formula V where Z1 is OH as shown




embedded image


or when Z1 is a leaving group or atom, converting the hydroxy group into a leaving atom or group, for example by treating the compound of Formula V where Z1 is OH with POCl3.


Compounds of Formula I where the Y group has the absolute configuration shown in Figure Ia:




embedded image


are prepared by coupling a compound of Formula V with a corresponding compound having the formula IV-A




embedded image


The compound of Formula IV-A can be prepared by treating a compound of Formula VII




embedded image


where P2 is an amine protecting group, with an alkyl lithium base (for example sec-butyl lithium) in the presence of a chiral complexing agent (for example (−)-sparteine), followed by coupling with a compound having Y—Z2 where Z2 is a leaving group or atom, such as a halogen atom (for example bromine) in the presence of a palladium (II) catalyst and a ligand. Such enantioselective palladium-catalyzed reactions are described in Campos, et al., J. Am. Chem. Soc., 2006, 128:3538-3539. Suitable catalysts include Pd(OAc)2. Suitable ligands include phosphine ligands such as t-Bu3P—HBF4. The amine protecting group may be any convenient amine protecting group, for example as described in Greene & Wuts, eds., “Protecting Groups in Organic Synthesis”, John Wiley & Sons, Inc. Examples of amine protecting groups include acyl and alkoxycarbonyl groups, such as t-butoxycarbonyl (BOC).


The compounds of the formulas II, III, and IV are also believed to be novel and are provided as further aspects of the invention.


The ability of compounds of the invention to act as TrkA inhibitors may be demonstrated by the assays described in Examples A and B. The ability of compounds of the invention to act as TrkB inhibitors may be demonstrated by the assay described in Example B.


The selectivity of compounds of Formula I for TrkA versus one or more JAK kinases was determined using the assays describes in Examples C, D, E and F.


It was unexpectedly discovered that compounds of Formula I wherein X is CH2 are particularly selective for inhibiting TrkA activity over inhibiting the activity of one or more JAK kinases, for example JAK2, as shown in Table 1. In one embodiment, compounds of Formula I are 10-30 fold more potent in inhibiting TrkA kinase activity over inhibiting Jak2 kinase activity. In one embodiment, compounds of Formula I are 30-100 fold more potent in inhibiting TrkA kinase activity over inhibiting Jak2 kinase activity. In one embodiment, compounds of Formula I are greater than 100 fold more potent in inhibiting TrkA kinase activity over inhibiting Jak2 kinase activity.


Additionally, it was unexpectedly discovered that compounds of Formula I wherein R2 is a 3, 4 or 5 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, OMe, —CO2H and -(1-4C alkyl)OH are particularly selective for inhibiting TrkA activity over inhibiting the activity of one or more JAK kinases, for example JAK2, as shown in Table 1.


Additionally, it was unexpectedly discovered that compounds of Formula I wherein Y is (i) fluorophenyl optionally substituted with a substituent selected from —O(1-4C alkyl)hetCyc3, —O(1-4C alkyl)O(1-3C alkyl) and —O(3-6C dihydroxyalkyl), (ii) pyridyl substituted with one or more substituents independently selected from F, methyl and ethyl, or (iii) 5-fluoropyridin-2(1H)-one optionally substituted with (1-4C)alkyl, are particularly selective for inhibiting TrkA activity over inhibiting the activity of one or more JAK kinases, for example JAK2, as shown in Table 1.


Compounds of Formula I are useful for treating pain, including chronic and acute pain. Certain compounds which are inhibitors of TrkA and/or TrkB may be useful in the treatment of multiple types of pain including inflammatory pain, neuropathic pain, and pain associated with cancer, surgery, and bone fracture.


In one embodiment, compounds of Formula I are useful for treating acute pain. Acute pain, as defined by the International Association for the Study of Pain, results from disease, inflammation, or injury to tissues. This type of pain generally comes on suddenly, for example, after trauma or surgery, and may be accompanied by anxiety or stress. The cause can usually be diagnosed and treated, and the pain is confined to a given period of time and severity. In some instances, it can become chronic.


In one embodiment, compounds of Formula I are useful for treating chronic pain. Chronic pain, as defined by the International Association for the Study of Pain, is widely believed to represent disease itself. It can be made much worse by environmental and psychological factors. Chronic pain persists over a longer period than acute pain and is resistant to most medical treatments, generally over 3 months or more. It can and often does cause severe problems for patients.


Compounds of Formula I are also useful for treating cancer. Particular examples include neuroblastoma, ovarian, pancreatic, colorectal and prostate cancer.


Compounds of Formula I are also useful for treating inflammation and certain infectious diseases.


In addition, compounds of Formula I may also be used to treat interstitial cystitis (IC), painful bladder syndrome (PBS), urinary incontinence, asthma, anorexia, atopic dermatitis, and psoriasis.


Compounds of Formula I are also useful for treating a neurodegenerative disease in a mammal, comprising administering to said mammal one or more compounds of Formula I or a pharmaceutically acceptable salt thereof in an amount effective to treat or prevent said neurodegenerative disease. In one embodiment, compounds of Formula I may also be used to treat demyelination and dysmyelination by promoting myelination, neuronal survival, and oligodendrocyte differentiation via blocking Sp35-TrkA interaction. In one embodiment, the neurodegenerative disease is multiple sclerosis. In one embodiment, the neurodegenerative disease is Parkinson's disease. In one embodiment, the neurodegenerative disease is Alzheimer's disease.


As used herein, the term treatment includes prophylaxis as well as treatment of a preexisting condition. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder, as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.


Accordingly, another embodiment of this invention provides a method of treating pain in a mammal, comprising administering to said mammal one or more compounds of Formula I or a pharmaceutically acceptable salt thereof in an amount effective to treat or prevent said pain.


Another embodiment of this invention provides a method of treating inflammation in a mammal, comprising administering to said mammal one or more compounds of Formula I or a pharmaceutically acceptable salt thereof in an amount effective to treat or prevent said inflammation.


Another embodiment of this invention provides a method of treating a neurodegenerative disease in a mammal, comprising administering to said mammal one or more compounds of Formula I or a pharmaceutically acceptable salt thereof in an amount effective to treat or prevent said neurodegenerative disease.


Another embodiment of this invention provides a method of treating Trypanosoma cruzi infection in a mammal, comprising administering to said mammal one or more compounds of Formula I or a pharmaceutically acceptable salt thereof in an amount effective to treat or prevent said Trypanosoma cruzi infection.


The phrase “effective amount” means an amount of compound that, when administered to a mammal in need of such treatment, is sufficient to (i) treat or prevent a particular disease, condition, or disorder which can be treated with an inhibitor of TrkA and/or TrkB, (ii) attenuate, ameliorate, or eliminate one or more symptoms of the particular disease, condition, or disorder, or (iii) prevent or delay the onset of one or more symptoms of the particular disease, condition, or disorder described herein.


The amount of a compound of Formula I that will correspond to such an amount will vary depending upon factors such as the particular compound, disease condition and its severity, the identity (e.g., weight) of the mammal in need of treatment, but can nevertheless be routinely determined by one skilled in the art.


As used herein, the term “mammal” refers to a warm-blooded animal that has or is at risk of developing a disease described herein and includes, but is not limited to, guinea pigs, dogs, cats, rats, mice, hamsters, and primates, including humans.


The compounds of the present invention can be used in combination with one or more additional drugs that work by the same or a different mechanism of action. Examples include anti-inflammatory compounds, steroids (e.g., dexamethasone, cortisone and fluticasone), analgesics such as NSAIDs (e.g., aspirin, ibuprofen, indomethacin, and ketoprofen), and opioids (such as morphine), and chemotherapeutic agents.


Compounds of the invention may be administered by any convenient route, e.g. into the gastrointestinal tract (e.g. rectally or orally), the nose, lungs, musculature or vasculature, or transdermally or dermally. Compounds may be administered in any convenient administrative form, e.g. tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches etc. Such compositions may contain components conventional in pharmaceutical preparations, e.g. diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents. If parenteral administration is desired, the compositions will be sterile and in a solution or suspension form suitable for injection or infusion. Such compositions form a further aspect of the invention.


According to another aspect, the present invention provides a pharmaceutical composition, which comprises a compound of Formula I or a pharmaceutically acceptable salt thereof, as defined hereinabove, together with a pharmaceutically acceptable diluent or carrier.


According to another embodiment, the present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, for use in the treatment of pain in a mammal.


In another embodiment, the present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, for use in the treatment of inflammation in a mammal.


In another embodiment, the present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, for use in the treatment of infectious diseases, for example Trypanosoma cruzi infection, in a mammal.


In another embodiment, the present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, for use in the treatment of a neurodegenerative disease in a mammal.


According to a further aspect, the present invention provides the use of a compound of Formula I or a pharmaceutically acceptable salt thereof, in the treatment of a condition selected from pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection. In one embodiment, the condition is pain. In one embodiment, the condition is cancer. In one embodiment, the condition is inflammation. In one embodiment, the condition is a neurodegenerative disease. In one embodiment, the condition is Trypanosoma cruzi infection.







EXAMPLES

The following examples illustrate the invention. In the examples described below, unless otherwise indicated all temperatures are set forth in degrees Celsius. Reagents were purchased from commercial suppliers such as Aldrich Chemical Company, Lancaster, TCI or Maybridge, and were used without further purification unless otherwise indicated. Tetrahydrofuran (THF), dichloromethane (DCM, methylene chloride), toluene, dimethyl formamide (DMF) and dioxane were purchased from Aldrich in Sure/Seal™ bottles and used as received.


The reactions set forth below were done generally under a positive pressure of nitrogen or argon or with a drying tube (unless otherwise stated) in anhydrous solvents, and the reaction flasks were typically fitted with rubber septa for the introduction of substrates and reagents via syringe. Glassware was oven dried and/or heat dried.


Column chromatography was done on a Biotage system (Manufacturer: Dyax Corporation) having a silica gel or C-18 reverse phase column, or on a silica SepPak cartridge (Waters).


Biological Assays

The ability of compounds of the invention to act as TrkA inhibitors may be demonstrated by the assays described in Examples A and B. The ability of compounds of the invention to act as TrkB inhibitors may be demonstrated by the assay described in Example B.


The selectivity of compounds of Formula I for inhibiting TrkA kinase activity over inhibiting one or more JAK kinases was determined using the assays describes in Examples C, D, E and F.


Example A
TrkA ELISA Assay

An enzyme-linked immunosorbant assay (ELISA) was used to assess TrkA kinase activity in the presence of inhibitors. Immulon 4HBX 384-well microtiter plates (Thermo part #8755) were coated with a 0.025 mg/mL solution of poly (Glu, Ala, Tyr; 6:3:1; Sigma P3899). Various concentrations of test compound, 2.5 nM TrkA (Invitrogen Corp., histidine-tagged recombinant human TrkA, cytoplasmic domain), and 500 μM ATP were incubated for 25 minutes at ambient temperature in the coated plates while shaking. The assay buffer consisted of 25 mM MOPS pH 7.5, 0.005% (v/v) Triton X-100 and 5 mM MgCl2. The reaction mixture was removed from the plate by washing with PBS containing 0.1% (v/v) Tween 20. The phosphorylated reaction product was detected using 0.2 μg/mL of a phosphotyrosine specific monoclonal antibody (clone PY20) conjugated to horseradish peroxidase in conjunction with the TMB Peroxidase Substrate System (KPL). After the addition of 1M phosphoric acid, the chromogenic substrate color intensity was quantitated via absorbance at 450 nm. IC50 values were calculated using either a 4 or 5-parameter logistic curve fit and are provided in Table 1.


Example B
TrkA and TrkB Omnia Assay

Trk enzymatic selectivity was assessed using Omnia™ Kinase Assay reagents from Invitrogen Corp. Enzyme (either TrkA or TrkB from Invitrogen Corp.) and test compound (various concentrations) were incubated for 10 minutes at ambient temperature in a 384-well white polypropylene plate (Nunc catalog#267462). Omnia Tyr Peptide #4 (for TrkA) or #5 (for TrkB), as well as ATP, were then added to the plate. Final concentrations were as follows: 20 nM enzyme, 500 μM of ATP for TrkA assay or 1 mM ATP for TrkB assay, 10 μM peptide substrate. The assay buffer consisted of 25 mM MOPS pH 7.5, 0.005% (v/v) Triton X-100 and 5 mM MgCl2. The production of phosphorylated peptide was monitored continuously for 70 minutes using a Molecular Devices FlexStation II384 microplate reader (excitation=360 nm; emission=485 nm). Initial rates were calculated from the progress curves. IC50 values were calculated from these rates using either a 4 or 5-parameter logistic curve fit.


In each of TrkA and TrkB Omnia assays, compounds of the invention had an average IC50 value below 1000 nM. Certain compounds had an average IC50 value below 100 nM.


General JAK Kinase Enzyme Inhibition Assay Method

The assays described in Examples C, D, E and F for the determination of JAK1, JAK2, JAK3 and Tyk2 kinase activity, respectively, utilized the Omnia® Kinase fluorescence peptide substrate-based technology (Invitrogen). The specific components of the assay mixture are described in Examples C, D and E. In each of the assays described in Examples C, D and E, Mg2+ is chelated upon phosphorylation of the Omnia peptide by the kinase to form a bridge between the chelation-enhanced fluorophore Sox and the phosphate, resulting in an increase in fluorescence emission at 485 nM when excited at 360 nM. The reactions were therefore read at excitation 360 nm and emission was measured at 485 nm every 50 seconds for 45 minutes using a PerkinElmer EnVision Multilabel Plate Reader.


The final buffer conditions for each of the JAK1, JAK2, JAK3 and Tyk2 assays were as follows: 25 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% Triton X-100 and 1 mM DTT.


IC50 Determinations

Compounds were prepared at 50× the final concentration in DMSO by conducting 3-fold serial dilutions from a 500-μM or 1000-μM intermediate dilution to give a 10-point dosing curve having a high dose of 10 or 20 μM. Two-μL aliquots of these were transferred to a fresh plate for a ten-fold intermediate dilution with assay buffer. Five-μL aliquots of the diluted compounds were then transferred to 20-μL of assay mixtures described in Examples C, D, E and F for a final concentration of DMSO of 2%. A standard or reference compound was typically included on each assay plate to validate that plate. For each plate, percent of control (POC) values were calculated for each well according to the following equation:







POC
=



Sample
-


X
_


m





i





n






X
_


ma





x


-


X
_


m





i





n




×
100


,




where Xmax=Average Uninhibited Controls

    • Xmin=Average Background


      IC50's were estimated from the POC's using a standard 4-parameter logistic model:







Y
=

A
+


B
-
A


1
+


(

C
X

)

D





,




where A=Minimum Y (Bottom Asymptote)

    • B=Maximum Y (Top Asymptote)
    • C=EC50
    • D=Slope Factor
    • X=Compound Concentration (nM)
    • Y=POC


The IC50 is defined as the concentration of inhibitor at which the POC equals 50 for the fitted curve.


Example C
Jak1 Inhibition Assay

Compounds of Formula I were screened for their ability to inhibit Jak1 using the general enzyme inhibition assay method, in which the assay mixture contained 500 μM ATP, 8 μM Omnia® Y12 peptide (Catalog # IVGN KPZ3121C; Invitrogen Corporation, Carlsbad, Calif.) and 5 nM Jak1 in a total volume of 20 μL. GST-tagged human Jak1 kinase domain comprising amino acids 866-1154 was purchased from Invitrogen Corporation, Carlsbad, Calif. (catalog # IVGN PV4774). Results are shown in Table 2.


Example D
Jak2 Inhibition Assay

Compounds of Formula I were screened for their ability to inhibit Jak2 using the general enzyme inhibition assay method, in which the assay mixture contained 500 μM ATP, 10 μM Omnia® Y7 peptide (Catalog # IVGN KNZ3071C, Invitrogen Corporation, Carlsbad, Calif.) and 4 nM Jak2 in a total volume of 20 μL. Human Jak2 kinase domain comprising amino acids 808-1132 was purchased from Invitrogen Corporation, Carlsbad, Calif. (catalog # IVGN PV4210). Results are shown in Tables 1 and 2.


Example E
Jak3 Inhibition Assay

Compounds of Formula I were screened for their ability to inhibit Jak3 using the general enzyme inhibition assay method, in which the assay mixture contained 500 μM ATP, 10 μM Omnia® Y7 peptide (Catalog # IVGN KNZ3071C, Invitrogen Corporation, Carlsbad, Calif.) and 1.5 nM Jak3 in a total volume of 20 μL. GST-tagged human Jak3 kinase domain comprising amino acids 781-1124 was purchased from Invitrogen Corporation, Carlsbad, Calif. (catalog # IVGN PV3855). Results are shown in Table 2.


Example F
Tyk2 Inhibition Assay

Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture contained 500 μM ATP, 8 μM Omnia® Y12 peptide (Catalog # IVGN KPZ3121C; Invitrogen Corporation, Carlsbad, Calif.) and 1 nM Tyk2 in a total volume of 20 μL. Human Tyk2 kinase domain, comprising amino acids 886 to 1187 with 10 additional histidine residues (histidine tag) on the carboxy terminus, was expressed and purified from baculovirus in-house at Array BioPharma Inc. (Boulder, Colo.). The histidine tag was cleaved after purification using standard conditions. Results are shown in Table 2.


Table 1 provides IC50 values for compounds of the invention when tested in the assays of Examples A and D. The Jak2 enzyme IC50 was designated as >1000 nM when >50% inhibition was not observed at a 1000 nM concentration of test compound.











TABLE 1







Jak2 Enzyme



TrkA Enzyme
IC50 (nM)


Example #
IC50 (nM)
(% inhibition at 1000 nM)


















1
0.7
>1000
(39.5)


2
0.7
>1000
(19.1)


3
2.3
>1000
(10.1)


4
0.95
>1000
(18.8)


5
0.95
>1000
(14.2)


6
1.55
>1000
(12.9)


7
0.45
106.8
(90.0)


8
1.1
>1000
(25.7)


9
3.45
>1000
(4.6)


10
1.05
>1000
(47.5)


11
777.1
>1000
(10.1)


12
238.25
>1000
(4.5)


13
0.5
>1000
(41.4)


14
0.55
470
(66.7)


15
0.6
156
(83.1)


16
0.9
>1000
(31.7)


17
2.15
>1000
(5.6)


18
38.3
>1000
(2.8)


19
74.25
>1000
(3.4)


20
0.6
257
(78.9)


21
2.95
>1000
(5.8)


22
2.1
>1000
(9.8)


23
1.1
>1000
(10.1)


24
3.6
>1000
(11.5)


25
0.4
>1000
(19.4)


26
1.3
>1000
(9.9)


27
214.5
>1000
(1.3)


28
2.8
>1000
(5.0)


29
1.3
>1000
(13.2)


30
1.95
>1000
(25.7)


31
10.6
>1000
(5.1)


32
5.3
>1000
(8.6)


33
1.5
23.4
(99.9)


34
1.1
42.3
(96.9)


35
1.2
278
(77.4)


36
2.1
>1000
(22.2)


37
1.65
>1000
(25.0)


38
1.3
>1000
(18.2)


39
0.7
>1000
(30.4)


40
0.8
>1000
(41.4)


41
28.9
>1000
(6.0)


42
48.3
>1000
(7.7)


43
139
>1000
(4.2)


44
1.5
388
(71.5)


45
1.4
195
(84.0)


46
3.3
>1000
(13.8)


47
1.5
>1000
(37.3)


48
0.6
429
(72.7)


49
4.2
>1000
(17.2)


50
1.23
418
(73.7)


51
1.18
186
(82.5)


52
7.4
>1000
(9.4)


53
10.4
>1000
(8.7)


54
2.25
>1000
(23.0)


55
1
>1000
(24.1)


56
2.4
>1000
(28.0)


57
3.93
>1000
(9.7)


58
9.4
>1000
(4.7)


59
16.95
>1000
(14.5)


60
2.25
>1000
(21.1)


61
1.95
699
(54.4)


62
2.53
>1000
(35.2)


63
4.55
>1000
(33.1)


64
1.6
575
(60.3)


65
0.6
>1000
(34.1)


66
0.57
>1000
(24.7)


67
5.1
>1000
(22.3)


68
6.6
>1000
(23.0)


69
60.3
>1000
(6.0)


70
23.95
>1000
(9.0)


71
8.65
>1000
(6.2)


72
44.35
>1000
(11.7)


73
48.55
>1000
(4.9)


74
12.6
>1000
(12.2)


75
6.95
>1000
(15.1)


76
90.05
>1000
(4.8)


77
5.37
>1000
(15.3)


78
34.85
>1000
(5.8)


79
1.3
698
(54.8)


80
1.8
869
(50.7)


81
1.15
666
(54.4)


82
2.55
>1000
(10.7)


83
1.77
>1000
(26.3)


84
21.05
>1000
(2.7)


85
9.38
>1000
(6.0)


86
26.7
>1000
(17.3)


87
16.1
>1000
(37.2)


88
6.13
>1000
(15.1)


89
3.6
>1000
(33.1)


90
0.95
472
(67.3)


91
3.2
>1000
(34.9)


92
1013.3
>1000
(0.5)


93
5.1
>1000
(34.7)


94
568.2
>1000
(4.4)


95
5.4
>1000
(19.2)


96
342.5
>1000
(4.8)


97
6.2
>1000
(6.8)


98
9.0
>1000
(23.7)


99
7.0
>1000
(45.8)


100
4.7
>1000
(13.8)


101
11.7
>1000
(26.2)


102
5.2
>1000
(17.3)


103
87.8
>1000
(4.5)


104
83.1
>1000
(6.1)


105
25.4
>1000
(18.7)


106
7.7
>1000
(8)


107
16.4
>1000
(7.1)


108
1191.6
>1000
(2.8)


109
36.7
>1000
(−0.3)


110
37.2
>1000
(−0.5)


111
37.8
>1000
(0.1)


112
30.9
>1000
(3.2)


113
3.2
>1000
(44.6)


114
29.9
>1000
(5)


115
15.3
>1000
(12.6)


116
26.2
>1000
(4.7)


117
45.0
>1000
(−1.4)


118
22.5
>1000
(−4.5)


119
131.2
>1000
(1.7)


120
22.8
>1000
(2.3)


121
182.5
>1000
(3.7)


122
33.2
>1000
(7.4)


123
6.4
>1000
(38.8)


124
2.9
759
(53.3)


125
12.8
>1000
(6.1)


126
218.5
>1000
(−1)


127
469.8
>1000
(0.2)


128
2595.0
>1000
(1.2)


129
8.0
>1000
(25.2)


130
1.7
>1000
(27.9)


131
5.0
>1000
(14.6)


132
44.4
>1000
(3.7)


133
16.0
>1000
(14.4)


134
7.4
>1000
(3.3)


135
142.2
>1000
(−1)


136
26.3
>1000
(4.8)


137
793.7
>1000
(3.6)


138
34.8
>1000
(10)


139
32.7
>1000
(−0.4)


140
0.9
76.7
(90.1)


141
9.4
>1000
(9.4)


142
12.7
>1000
(−0.9)


143
8.0
>1000
(7)









144
not tested
not tested


145
not tested
not tested


146
not tested
not tested










147
30.8
>1000
(0.9)


148
1.1
>1000
(44.3)


149
6.1
>1000
(10.2)


150
5.7
>1000
(8.9)


151
1.4
>1000
(35.6)


152
18.1
>1000
(7.6)


153
2.1
>1000
(33.8)


154
1.3
524
(64.4)


155
0.2
>1000
(33.3)


156
2.1
>1000
(16.1)


157
2.8
>1000
(9.6)


158
9.9
>1000
(14.4)


159
4.3
>1000
(28.9)


160
25.6
>1000
(8.5)


161
3.0
>1000
(27.4)


162
2.2
444
(66.2)









163
not tested
not tested


164
not tested
not tested










165
1.1
>1000
(26.8)


166
2.4
>1000
(13.8)


167
2.2
>1000
(9.8)


168
1.2
>1000
(23.2)


169
0.9
759
(51.9)


170
11.6
>1000
(0.7)


171
4.7
>1000
(7.8)


172
2.5
>1000
(11)


173
1.5
>1000
(5.4)


174
16.3
>1000
(6.4)


175
12.2
>1000
(3.8)


176
27.2
>1000
(6.3)


177
1.8
>1000
(26.2)


178
2.5
>1000
(16.9)


179
8.5
>1000
(−0.2)


180
12.3
>1000
(−0.8)


181
17.1
>1000
(5.2)


182
11.3
>1000
(21.2)


183
6.9
>1000
(−0.8)


184
7.4
>1000
(11.8)


185
8.6
>1000
(11.7)


186
57.1
>1000
(10.5)


187
61.6
>1000
(9.1)


188
83.0
>1000
(9.3)


189
76.4
>1000
(4.6)


190
2.4
>1000
(28.4)


191
69.5
>1000
(4.8)


192
437.8
>1000
(0.3)


193
15.6
>1000
(8.4)


194
4.7
>1000
(31.2)


195
7.7
>1000
(16.2)


196
6.8
>1000
(10.6)


197
4.8
>1000
(3.6)


198
242.8
>1000
(1.6)


199
3.6
>1000
(38.8)


200
12.7
>1000
(12.5)


201
71.8
>1000
(3.8)


202
19.3
>1000
(11.5)









203
not tested
not tested










204
16.6
>1000
(37)


205
14.3
>1000
(7.2)


206
3.9
>1000
(12.6)


207
33.3
>1000
(0.9)


208
1.7
>1000
(21.2)


209
17.1
>1000
(5.4)


210
3.3
>1000
(32.3)


211
4.2
>1000
(19.5)


212
38.0
>1000
(14.2)


213
6.8
>1000
(21.9)


214
8.6
>1000
(29.7)


215
15.3
>1000
(28.3)


216
3.1
670
(54)


217
5.8
551
(61.7)


218
33.9
>1000
(24.6)


219
187.7
>1000
(25.5)


220
109.9
>1000
(15.2)


221
49.3
>1000
(−1.2)









222
not tested
not tested


223
not tested
not tested


224
not tested
not tested










225
52.4
>1000
(2.7)


226
10.5
>1000
(100)


227
12.3
445.8
(62.8)


228
13.0
>1000
(31.9)


229
15.9
>1000
(34.9)


230
3.0
665.6
(53.3)


231
8.7
>1000
(26.6)


232
4.5
>1000
(31.9)


233
75.9
>1000
(6.7)


234
10.7
>1000
(5.3)


235
2.8
311
(73.1)


236
2.2
419
(69.1)


237
2.1
616
(51.9)


238
1.9
499
(58.9)


239
10.1
>1000
(15.5)









240
11.3
not tested


241
21.8
not tested


242
8.9
not tested


243
9
not tested


244
38.2
not tested









Representative compounds of the invention were tested in the four Jak Kinase enzyme assays described in Examples C, D, E and F. The IC50 values are shown in Table 2. These compounds were found to be even more selective for inhibiting TrkA kinase activity over inhibiting kinase activity of Jak1, Jak3 and Tyk2 than over inhibiting Jak2.














TABLE 2







Jak1
Jak2
Jak3
Tyk2



TrkA
IC50 (nM)
IC50 (nM)
IC50 (nM)
IC50 (nM)



IC50
(% inhibition
(% inhibition
(% inhibition
(% inhibition


Ex #
(nM)
at 1000 nM)
at 1000 nM)
at 1000 nM)
at 1000 nM)
























30
1.9
>1000
(13.4)
>1000
(30.4)
>1000
(2.9)
>1000
(11.3)


52
7.4
>1000
(8.6)
>1000
(13.0)
>1000
(0.8)
>1000
(13.8)


140
0.9
546
(64.2)
76.7
(98.5)
>1000
(20.2)
>1000
(34.8)


93
5.1
>1000
(19.7)
>1000
(42.2)
>1000
(10.6)
>1000
(17.2)


106
7.6
>1000
(8.2)
>1000
(21.0)
>1000
(9.7)
>1000
(14.8)


114
17.1
>1000
(10.9)
>1000
(15.6)
>1000
(8.5)
>1000
(11.4)


181
29.8
>1000
(12.8)
>1000
(18.1)
>1000
(8.9)
>1000
(10.7)


91
3.2
>1000
(20.3)
>1000
(42.1)
>1000
(8.3)
>1000
(14.8)


123
6.3
>1000
(22.0)
>1000
(49.1)
>1000
(8.9)
>1000
(14.4)


124
2.9
>1000
(36.4)
759
(72.3)
>1000
(7.2)
>1000
(16.2)


190
2.4
>1000
(14.3)
>1000
(33.9)
>1000
(7.2)
>1000
(13.4)


98
9.0
>1000
(8.8)
>1000
(27.8)
>1000
(5.5)
>1000
(9.2)


194
4.6
>1000
(7.4)
>1000
(37.6)
>1000
(2.6)
>1000
(8.1)









Preparation A



embedded image


(R)-2-(2,5-difluorophenyl)pyrrolidine
Step A: Preparation of (R)-tert-butyl 2-(2,5-difluorophenyl)pyrrolidine-1-carboxylate

A solution of tert-butyl pyrrolidine-1-carboxylate (20 g, 116.8 mmol) and (−)-sparteine (32.9, 140 mmol) in MTBE (360 mL) was cooled to −78° C. and sec-BuLi (100 mL, 140 mmol, 1.4 M in cyclohexane) was introduced drop-wise via cannula, keeping the internal temperature under −70° C. The resulting solution was stirred for 3 hours at −78° C., followed by addition of a solution of ZnCl2 (93.4 mL, 93.4 mmol, 1M in Et2O) drop-wise with rapid stirring, keeping the internal temperature below −65° C. The resulting light suspension was stirred at −78° C. for 30 minutes and then warmed to ambient temperature. The resulting mixture was sequentially charged with 2-bromo-1,4-difluorobenzene (14.5 mL, 128 mmol), Pd(OAc)2 (1.31 g, 5.8 mmol) and t-Bu3P—HBF4 (2.03 g, 7.0 mmol) in one portion. After stirring overnight at ambient temperature, concentrated NH4OH (10.5 mL) was added and the reaction was stirred for 1 hour. The resulting slurry was filtered through Celite and the filter cake washed with Et2O (1 L). The filtrate was washed with a 1M aqueous HCl solution (0.5 L) and brine. The organic layer was filtered and concentrated, and the crude product was purified by silica column chromatography, eluting with 5-10% EtOAc/hexanes to give product (R)-tert-butyl 2-(2,5-difluorophenyl)pyrrolidine-1-carboxylate as yellow oil (23.9 g, 72% yield).


Step B: Preparation of (R)-2-(2,5-difluorophenyl)pyrrolidine

To (R)-tert-butyl 2-(2,5-difluorophenyl)pyrrolidine-1-carboxylate (23.9 g, 84.4 mmol) was added 4N HCl in dioxane (56.2 mL). After stirring at ambient temperature for 2 hours, ether (200 mL) was added and the mixture was stirred for 10 minutes. The resulting slurry was filtered, yielding the title compound hydrochloride salt as a white solid (17.2 g). To obtain the free base, the HCl salt product was dispersed in a mixture of EtOAc (200 mL) and NaOH solution (100 mL, 2 N aq.) The layers were separated and the aqueous layer was extracted with EtOAc. The combined organic extracts were filtered and concentrated to give the desired product as a liquid (13.2 g, 85% yield).


The enantiomeric excess (% ee) of (R)-2-(2,5-difluorophenyl)pyrrolidine was determined as follows: To an ethanol solution of (R)-2-(2,5-difluorophenyl)pyrrolidine was added excess N-(2,4-dinitro-5-fluorophenyl)-L-alanine amide (FDAA, Marfey's reagent). The mixture was heated to reflux for approximately two minutes. After cooling to ambient temperature, the reaction mixture was diluted with acetonitrile and analyzed by HPLC (YMC ODS-AQ 4.6×50 mm 3 μm 120 Å column; mobile phase: 5-95% solvent B in A; solvent A: H2O/1% iPrOH/10 mM ammonium acetate, and solvent B: ACN/1% iPrOH/10 mM ammonium acetate; flow rate: 2 mL/min). The enantiomeric excess (ee %) was determined from the peak areas of the two diastereomeric derivatives formed. A 1:1 racemic standard was prepared according the same procedure described herein, replacing (R)-2-(2,5-difluorophenyl)pyrrolidine with (rac)-2-(2,5-difluorophenyl)pyrrolidine. The ee % of the title compound obtained as described above was determined to be >93%.


Preparation B



embedded image


Ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate
Step A: Preparation of ethyl 5-hydroxypyrazolo[1,5-a]pyrimidine-3-carboxylate

Ethyl 3-amino-1H-pyrazole-4-carboxylate (25.0 g, 161 mmol) and (E)-ethyl 3-ethoxyacrylate (35.8 ml, 242 mmol) were mixed in DMF (537 mL). Cesium carbonate (78.7 g, 242 mmol) was added and the mixture heated to 110° C. for 15 hours. The reaction mixture was cooled to ambient temperature and acidified with HOAc to pH 4. The resultant precipitate was filtered and washed with water and EtOAc, yielding the title compound as a fluffy white solid. Additional material was obtained by an aqueous workup. The filtrate was concentrated to remove the DMF, was diluted in EtOAc (500 mL) and washed with H2O. The resultant precipitate in the EtOAc layer was filtered and washed with water and EtOAc to obtain additional product. The solids were pooled and dried in vacuum to afford ethyl 5-hydroxypyrazolo[1,5-a]pyrimidine-3-carboxylate (33.3 g, 100% yield) as a fluffy white solid. MS (apci) m/z=206.2 (M−H).


Step B: Preparation of ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate

Ethyl 5-hydroxypyrazolo[1,5-a]pyrimidine-3-carboxylate (22.7 g, 110 mmol) was suspended in phosphoryl trichloride (100 mL) and heated to reflux. After heating for 2 hours, the reaction mixture was cooled and concentrated to remove the excess POCl3. The residue was diluted in DCM (100 mL) and slowly added to a flask containing ice water. The mixture was separated and the aqueous layer extracted with DCM. The combined organics were dried with MgSO4, filtered and concentrated to afford ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (24.2 g, 97.6% yield) as a pale yellow solid. MS (apci) m/z=225.9 (M+H).


Preparation C



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
Step A: Preparation of (R)-ethyl 5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate

A mixture of ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (Preparation B, 2.00 g, 8.86 mmol), (R)-2-(2,5-difluorophenyl)pyrrolidine (Preparation A, 1.62 g, 8.86 mmol), diisopropylethylamine (3.09 mL, 17.7 mmol) and butan-1-ol (2.95 ml, 8.86 mmol) was heated at 100° C. for 15 hours. The reaction mixture was cooled to ambient temperature and was diluted with EtOAc (30 mL) and water (10 mL). Undissolved solid was filtered and washed with Et2O to afford the title compound as a light orange solid (2.13 g). The organic layer was separated from the filtrate, washed with brine (10 mL) and dried over MgSO4. The solution was filtered and concentrated to provide additional solid that was purified by silica chromatography using gradient elution with 50-100% EtOAc/hexanes. This afforded the title compound (0.50 g) as a light yellow solid. The combined yield was 2.63 g, 79.7%. MS (apci) m/z=373.1 (M+H).


Step B: Preparation of (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid

(R)-ethyl 5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (2.13 g, 5.72 mmol) was suspended in EtOH (28.6 mL) and heated at 90° C. for 20 min (homogeneous). 1M aq. LiOH (11.4 mL, 11.4 mmol) was added and the reaction mixture was heated for 15 hours at 90° C. After cooling, the reaction mixture was concentrated, diluted with water and washed with EtOAc to remove any unreacted starting material. The aqueous layer was then acidified to pH 1 using 2N HCl. After extracting with DCM and EtOAc, the combined organic fractions were dried with MgSO4, filtered and concentrated to afford (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (1.82 g, 92.4%) as a light yellow solid. MS (apci) m/z=345.0 (M+H).


Preparation D



embedded image


(R)-2-(3-fluorophenyl)pyrrolidine

Prepared by the method of Preparation A, substituting 2-bromo-1,4-difluorobenzene with 1-bromo-3-fluorobenzene in Step A. MS (apci) m/z=166.0 (M+H). The ee % of the title compound was determined to be 94%.


Preparation E



embedded image


(R)-5-(2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid
Step A: Preparation of (R)-ethyl 5-(2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate

Prepared according to the method of Preparation C, substituting (R)-2-(2,5-difluorophenyl)pyrrolidine in Step A with (R)-2-(3-fluorophenyl)pyrrolidine. MS (apci) m/z=355.0 (M+H).


Step B: Preparation of (R)-5-(2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid

(R)-ethyl 5-(2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (0.76 g, 2.14 mmol) was suspended in EtOH (10.7 mL) and the mixture was heated at 90° C. for 20 minutes (homogeneous). 1M aqueous LiOH (4.29 ml, 4.29 mmol) was added and the reaction mixture was heated for 15 hours at 90° C. After cooling, the reaction mixture was concentrated, diluted with water and washed with EtOAc to remove any unreacted starting material. The aqueous layer was then acidified to pH 4 using 2N HCl. After extracting with DCM and EtOAc, the combined organic layers were dried with MgSO4, filtered and concentrated to afford (R)-5-(2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (0.60 g, 85.7% yield) as a glassy yellow solid. MS (apci) m/z=327.0 (M+H).


Preparation F



embedded image


(R)-2-(5-fluoro-2-methoxyphenyl)pyrrolidine

Prepared by the method of Preparation A, substituting 2-bromo-1,4-difluorobenzene with 2-bromo-4-fluoro-1-methoxybenzene in Step A. MS (apci) m/z=196.1 (M+H). The ee % of the title compound was determined to be >99%.


Preparation G



embedded image


(R)-5-(2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid

In a sealed tube, ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (Preparation B, 500 mg, 2.22 mmol), (R)-2-(5-fluoro-2-methoxyphenyl)pyrrolidine hydrochloride salt (513 mg, 2.22 mmol), and diisopropylethylamine (0.774 mL, 4.43 mmol) were combined in isopropanol (2 mL) and heated at 160° C. for 3 days. 2N NaOH (6 mL) and MeOH (5 mL) were added and the reaction mixture stirred at ambient temperature for 24 hours, followed by heating to 40° C. for 3 hours. The reaction was partially concentrated, treated with saturated aqueous NH4Cl (10 mL) and the mixture extracted with EtOAc. The combined organic extracts were filtered, concentrated and the residue purified by reverse phase chromatography eluting with 0-60% acetonitrile/water to yield the title compound as a pink solid (254 mg, 32.2% yield). MS (apci) m/z=357.0 (M+H).


Preparation H



embedded image


(R)-3-fluoro-5-(pyrrolidin-2-yl)pyridine

Prepared by the method of Preparation A, substituting 2-bromo-1,4-difluorobenzene with 3-bromo-5-fluoropyridine in Step A. MS (apci) m/z=167.1 (M+H). The ee % of the title compound was determined to be 92%.


Preparation I



embedded image


(R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid
Step A: Preparation of ethyl 5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate

Ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (Preparation B; 0.50 g, 2.22 mmol), (R)-3-fluoro-5-(pyrrolidin-2-yl)pyridine dihydrochloride (0.53 g, 2.22 mmol) and diisopropylethylamine (1.46 mL, 8.86 mmol) were combined in isopropanol (2 mL) and heated at 95° C. for 70 hours. The crude product was purified by reverse phase chromatography, eluting with 0-50% acetonitrile/water to yield the title compound (540 mg, 68.6% yield). MS (apci) m/z=356.0 (M+H).


Step B: Preparation of 5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid

Ethyl 5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (0.540 g, 1.52 mmol) was dissolved in MeOH (20 mL) and treated with 1N NaOH (13 mL). After stirring for 5 days, citric acid (solid) was added to acidify the mixture to pH 4-5. Saturated aqueous NaCl (10 mL) was added and the reaction mixture extracted with DCM and EtOAc. The combined organic layers were combined to afford 5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (0.49 g, 99% yield). MS (apci) m/z=328.0 (M+H).


Preparation J



embedded image


(R)-5-fluoro-2-methoxy-3-(pyrrolidin-2-yl)pyridine
Step A: Preparation of 3-bromo-5-fluoro-2-methoxypyridine

3-Bromo-5-fluoropyridin-2(1H)-one (10.0 g, 52.1 mmol) and Ag2CO3 (10.0 g, 36.5 mmol) were combined in toluene (100 mL) and iodomethane (3.89 mL, 62.5 mmol) was added drop-wise. The reaction was stirred at ambient temperature overnight, filtered through Celite and the solids were washed with toluene. The filtrate was concentrated and the residue was purified on a silica gel column (5-25% EtOAc/hexanes) to afford 3-bromo-5-fluoro-2-methoxypyridine (4.70 g, 43.8%) as a clear oil.


Step B: Preparation of (R)-5-fluoro-2-methoxy-3-(pyrrolidin-2-yl)pyridine

Prepared by the method of Preparation A, substituting 2-bromo-1,4-difluorobenzene with 3-bromo-5-fluoro-2-methoxypyridine in Step A. MS (apci) m/z=197.1 (M+H). The ee % of the title compound was determined to be 98%.


Preparation K



embedded image


(R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid
Step A: Preparation of (R)-ethyl 5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate

Ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (Preparation B, 0.75 g, 3.32 mmol), (R)-5-fluoro-2-methoxy-3-(pyrrolidin-2-yl)pyridine dihydrochloride (0.984 g, 3.66 mmol), diisopropylethylamine (2.32 mL, 13.3 mmol) and n-butanol (1.11 mL) were heated at 90° C. for 48 hours. The reaction mixture was diluted with EtOAc and the mixture was washed with water, brine and saturated NaHCO3. The organic layer was dried with MgSO4, filtered and concentrated afford a dark orange oil. The oil was purified by silica chromatography, eluting with a 50-80% EtOAc/Hexane gradient, to afford (R)-ethyl 5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (0.72 g, 56.2%) as a yellow foam. MS (apci) m/z=386.0 (M+H).


Step B: (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid

To a suspension of (R)-ethyl 5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (0.72 g, 1.868 mmol) in MeOH (9.34 mL) was added 1N LiOH (3.74 ml, 3.74 mmol) and the reaction mixture heated to 70° C. for 15 hours. After cooling, the reaction mixture was concentrated and the resulting residue diluted in water. After acidifying with citric acid (solid), the aqueous layer was extracted with DCM. The combined organics were dried with MgSO4, filtered and concentrated to afforded (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (0.67 g, 100%) as a yellow solid. MS (apci) m/z=357.9 (M+H).


Preparation L



embedded image


(R)-2-(5-fluoro-2-(trifluoromethyl)phenyl)pyrrolidine

Prepared by the method of Preparation A, substituting 2-bromo-1,4-difluorobenzene with 2-bromo-4-fluoro-1-(trifluoromethyl)benzene in Step A. MS (apci) m/z=234.1 (M+H). The ee % of the title compound was determined to be 90%.


Preparation M



embedded image


(R)-5-(2-(5-fluoro-2-(trifluoromethyl)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid
Step A: Preparation of (R)-ethyl 5-(2-(5-fluoro-2-(trifluoromethyl)phenyl) pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate

Ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (Preparation B, 0.51 g, 2.26 mmol), (R)-2-(5-fluoro-2-(trifluoromethyl)phenyl)pyrrolidine hydrochloride (0.610 g, 2.26 mmol) and diisopropylethylamine (1.12 mL, 6.78 mmol) were suspended in isopropanol (2.5 mL) and heated to 120° C. for 24 hours. The reaction mixture was purified by reverse phase chromatography eluting with 0-75% acetonitrile/water to yield the title compound (0.92 g, 96.4% yield). MS (apci) m/z=423.0.0 (M+H).


Step B: Preparation of 5-(2-(5-fluoro-2-(trifluoromethyl)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid

(R)-ethyl 5-(2-(5-fluoro-2-(trifluoromethyl) phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (0.92 g, 2.2 mmol) was combined with 1N NaOH (25 mL) and MeOH (40 mL). The reaction mixture was stirred at ambient temperature for 20 hours, followed by heating to 40° C. until complete. Citric acid (solid) was added until the mixture was pH 4-5. Brine (10 mL) was added and this was extracted with DCM and EtOAc. The combined organic layers were concentrated and the crude product was purified by reverse phase silica gel column chromatography eluting with 0-60% acetonitrile/water to yield 5-(2-(5-fluoro-2-(trifluoromethyl)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (0.45 g, 52%). MS (apci) m/z=395.0 (M+H).


Preparation N



embedded image


(R)-5-fluoro-2-methyl-3-(pyrrolidin-2-yl)pyridine
Step A: Preparation of 3-bromo-5-fluoro-2-methylpyridine

2,3-Dibromo-5-fluoropyridine (5.0 g, 19.6 mmol), Pd(PPh3)4 (1.13 g, 0.98 mmol) and methyl boronic acid (3.52 g, 58.9 mmol) were combined in dioxane (50 mL) then treated with K2CO3 (8.13, 58.9 mmol) and water (10 mL). The mixture was purged with N2 then heated to 110° C. in a sealed vessel for 16 hours. The cooled mixture was partitioned between water (100 mL) and EtOAc (50 mL) and the layers separated. The aqueous layer was extracted with EtOAc (2×50 mL) and the combined organic phases were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography eluting with 1-3% EtOAc/hexanes to afford the product as a white solid (1.20 g, 32% yield). MS (apci) m/z=190.2 (M+).


Step B: Preparation of (R)-5-fluoro-2-methyl-3-(pyrrolidin-2-yl)pyridine

Prepared by the method of Preparation A, substituting 2-bromo-1,4-difluorobenzene with 3-bromo-5-fluoro-2-methylpyridine in Step A. MS (apci) m/z=181.1 (M+H).


Preparation O



embedded image


(R)-5-(2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid
Step A: Preparation of (R)-ethyl 5-(2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate

To a solution of ethyl 5-hydroxypyrazolo[1,5-a]pyrimidine-3-carboxylate (Preparation B, Step A, 372 mg, 1.8 mmol) in DMF (10 mL) was added (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (874 mg, 1.98 mmol). The mixture was stirred at ambient temperature for 10 minutes then treated with DIEA (1.57 mL, 8.99 mmol) and (R)-5-fluoro-2-methyl-3-(pyrrolidin-2-yl)pyridine dihydrochloride (455 mg, 1.80 mmol). After stirring at ambient temperature for 4 hours the mixture was partitioned between 10% citric acid (50 mL) and EtOAc (50 mL). The layers were separated and the aqueous layer was extracted with EtOAc (2×30 mL). The combined organic phases were washed successively with water (30 mL), saturated NaHCO3 (30 mL), water (30 mL) and brine (2×30 mL), then dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography eluting with 1% MeOH/DCM to afford the product as white foam (480 mg, 72% yield). MS (apci) m/z=370.0 (M+H).


Step B: Preparation of (R)-5-(2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid

To a solution of (R)-ethyl 5-(2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (480 mg, 1.3 mmol) in a 1:1:1 mixture of THF:MeOH:water (30 mL) was added lithium hydroxide monohydrate (164 mg, 3.9 mmol). The mixture was stirred at ambient temperature for 16 hours then concentrated to ⅓ volume, acidified to pH 3 with 1N HCl and extracted with EtOAc (3×30 mL). The combined organic phases were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated to afford the title product as a white solid (381 mg, 86% yield). MS (apci) m/z=342.0 (M+H).


Preparation P



embedded image


(R)-2-ethyl-5-fluoro-3-(pyrrolidin-2-yl)pyridine

Prepared by the method of Preparation N, substituting methyl boronic acid with ethyl boronic acid in Step A. MS (apci) m/z=195.1 (M+H).


Preparation Q



embedded image


(R)-5-(2-(2-ethyl-5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid

Prepared by the method of Preparation O, substituting (R)-5-fluoro-2-methyl-3-(pyrrolidin-2-yl)pyridine dihydrochloride with (R)-2-ethyl-5-fluoro-3-(pyrrolidin-2-yl)pyridine dihydrochloride in Step A. MS (apci) m/z=356.0 (M+H).


Preparation R



embedded image


(R)-5-(2-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid

Step A: Preparation of (R)-ethyl 5-(2-(5-fluoro-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate. To a mixture of (R)-ethyl 5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (1.0 g, 2.60 mmol, Preparation K, Step A) and AcOH (7.44 mL, 130 mmol) was added HBr (4.76 mL, 33 wt % in acetic acid, 26 mmol) at ambient temperature. The reaction mixture was heated at 90° C. for 2 hours. After cooling, the reaction mixture was diluted with EtOAc, washed with water, saturated NaHCO3, and brine, dried with MgSO4, filtered and concentrated. The crude material was purified by silica column chromatography, eluting with 2-3% MeOH/DCM to yield the title product (0.73 g, 76%). MS (apci) m/z=372.0 (M+H).


Step B: Preparation of (R)-ethyl 5-(2-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate. To a suspension of (R)-ethyl 5-(2-(5-fluoro-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (0.73 g, 1.97 mmol) in DMF (10 mL) at 0° C. was added LiH (20 mg, 2.36 mmol). After stirring for 30 minutes, a solution of MeI (0.56 g, 3.93 mmol) in DMF (2 mL) was added and the reaction was stirred at ambient temperature for 17 hours. The reaction mixture was cooled to 0° C. and quenched with ice-water (30 mL). The mixture was extracted with EtOAc (3×), washed with water and brine, dried with MgSO4, filtered and concentrated. The crude material was purified by silica column chromatography, eluting with 2.5% MeOH/DCM to yield the title product (0.64 g, 85%). MS (apci) m/z=386.0 (M+H).


Step C: Preparation of (R)-5-(2-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid. Prepared by the method described in Preparation K, Step B using (R)-ethyl 5-(2-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate to yield the title compound (0.571 g, 96% yield). MS (apci) m/z=358.0 (M+H).


Example 1



embedded image


(R)—N-tert-butyl-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

To a solution of (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation C, 20.0 mg, 0.058 mmol) and HATU (24.3 mg, 0.064 mmol) in dry DMF (0.4 mL) was added tert-butyl amine (12.7 mg, 0.174 mmol) followed by diisopropylethylamine (22.5 mg, 0.174 mmol). The mixture was stirred under an atmosphere of N2 for 18 hours and was added to H2O (3 mL) and mixed. The mixture was extracted with EtOAc and combined extracts were washed with 1M HCl, H2O, saturated NaHCO3 and dried over MgSO4. The solution was eluted through a SPE SiOH column eluting first with 50% EtOAc-hexanes then with EtOAc. The EtOAc pool was concentrated and the residual colorless glass was treated with hexanes give a white suspension. The hexanes were removed, and the solid was washed with hexanes and dried in vacuum to afford the title compound as a white solid (20 mg, 90%). MS (apci) m/z=400.1 (M+H).


Example 2



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(pyridin-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

The title compound was prepared according to the procedure outlined for Example 1, using 2-aminopyridine (2 equivalents) heating at 90° C. for 7 hours. The crude material was purified out by SiO2 column chromatography (50% EtOAc-hexanes) to give the title compound as a white solid (45% yield). MS (apci) m/z=421.1 (M+H).


Example 3



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(3-methylpyridin-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

To a suspension of (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation C, 25.0 mg, 0.072 mmol) in CCl4 (1.0 mL) was added thionyl chloride (0.10 mL) and the mixture heated at reflux for 4 hours. The mixture was cooled to ambient temperature and was concentrated to a brittle foam. The foam was dissolved in pyridine (2 mL), 2-amino-3-methyl-pyridine (9.3 mg, 0.086 mmol) was added and the mixture was heated at 90° C. for 20 hours. The reaction was cooled to ambient temperature and the pyridine evaporated. The residue was partitioned into 1M NaOH and EtOAc, mixed and the EtOAc layer removed. The aqueous layer was extracted with EtOAc and combined EtOAc fractions were washed with H2O, saturated NaCl and dried over MgSO4. The solution was filtered and concentrated, and the resulting solid was washed with dry Et2O to afford the title compound as a white solid (7 mg, 29%). MS (apci) m/z=435.1 (M+H).


Example 4



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(2-morpholinoethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

The title compound was prepared according to the procedure outlined for Example 1 using 2-morpholinoethanamine (1.5 equiv). The combined EtOAc extracts were washed with 1M Na2CO3, H2O, saturated NaCl and dried over MgSO4. The solution was filtered through a SPE SiOH column eluting first with EtOAc and then with 10% MeOH/EtOAc. The MeOH/EtOAc pool was concentrated and the residual colorless glass was triturated with hexanes to give fine white precipitate. The solvent was decanted and the solid was washed with hexanes and dried in vacuum. This afforded the title compound as a white solid (79%). MS (apci) m/z=457.1 (M+H).


Example 5



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((5-methyl furan-2-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

The title compound was prepared according to the procedure outlined for Example 1 using (5-methylfuran-2-yl)methanamine (1.5 equiv.) The dried EtOAc solution was filtered through a packed Celite plug and concentrated. The residual colorless glass was treated with Et2O until dissolved then diluted with hexanes to give a white suspension. Solvents were decanted, the solid washed with hexanes and dried in vacuum. This provided the title compound as a white solid (43% yield). MS (apci) m/z=438.1 (M+H).


Example 6



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

The title compound was prepared according to the procedure outlined for Example 3 using 1-methyl-1H-pyrazol-3-amine (1.5 equiv.) at ambient temperature for 64 hours. The crude EtOAc solution was eluted through a SPE SiOH column (EtOAc elution) and concentrated. The residual white solid was washed with 10% Et2O-hexanes and dried in vacuum to afford the title compound (47% yield). MS (apci) m/z=424.1 (M+H).


Example 7



embedded image


5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((trans)-4-hydroxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

The title compound was prepared according to the procedure outlined for Example 1 using trans-4-aminocyclohexanol (1.5 equiv). The combined EtOAc extracts were washed with 1M Na2CO3, H2O, saturated NaCl and dried over MgSO4. The solution was filtered through a Celite plug, concentrated and the residual colorless glass was treated with hexanes to give a white suspension. The hexanes were decanted and the solid washed with hexanes and dried in vacuum. This afforded the title compound as a white solid (86% yield). MS (apci) m/z=442.1 (M+H).


Example 8



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(1-hydroxy-2-methyl propan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

The compound was prepared according to Example 3 using 2-amino-2-methylpropan-1-ol (4 equiv.). In this instance, the amine was added to the crude acid chloride in THF at 0° C. and the mixture was stirred for 15 hours during which time the temperature reached ambient temperature after 1-2 hours. The reaction mixture was partitioned into H2O and 50% EtOAc-hexanes. The organic layer removed and the aqueous layer was extracted with 50% EtOAc-hexanes. The combined organic fractions were washed with 1M NaOH, H2O and saturated NaCl. The solution was dried over MgSO4 and eluted through a SPE SiOH column eluting first with 50% EtOAc-hexanes then with EtOAc. The EtOAc pool was concentrated and residual colorless glass was dissolved in Et2O. Hexane was added and the resulting white suspension was concentrated to afford the title compound as a white solid (57% yield). MS (apci) m/z=416.1 (M+H).


Example 9



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(2-methyl-1-morpholinopropan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

The title compound was prepared according to Example 4 using 2-methyl-1-morpholinopropan-2-amine (1.5 equiv). The compound was isolated as a white solid after SiO2 chromatography using EtOAc for elution (83% yield). MS (apci) m/z=485.2 (M+H).


Example 10



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method as described in Example 1, substituting tert-butyl amine with methyl amine, to provide the final product as a white solid (34 mg, 83% yield). MS (apci) m/z=358.1 (M+H).


Example 11



embedded image


(R)-1-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carbonyl)piperidine-4-carboxylic Acid
Step A: Preparation of (R)-ethyl 1-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl) pyrazole [1,5-a]pyrimidine-3-carbonyl)piperidine-4-carboxylate

Prepared by the method as described in Example 1, substituting tert-butyl amine with ethyl piperidine-4-carboxylate. The crude material was purified by preparative TLC plate, eluting first with EtOAc and then 10% MeOH/EtOAc to afford the title compound (49 mg, 88% yield). MS (apci) m/z=484.1 (M+H).


Step B: (R)-1-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carbonyl)piperidine-4-carboxylic Acid

(R)-ethyl 1-(5-(2-(2,5-di fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carbonyl)piperidine-4-carboxylate (49 mg, 0.10 mmol) was dissolved in 1:1 THF/MeOH (1.0 mL) and 1M LiOH (0.20 mL, 0.20 mmol) was added. The mixture was stirred at ambient temperature for 2 hours and the reaction mixture was concentrated. The residue was diluted in water and the mixture acidified with 2N HCl. The mixture was extracted with DCM and EtOAc. The combined organics were washed with brine, dried with MgSO4, filtered and concentrated. The residue was triturated with hexanes and the resulting white suspension was concentrated to afford the final product (43 mg, 92% yield) as a white solid. MS (apci) m/z=456.1 (M+H).


Example 12



embedded image


(R)-2-(1-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carbonyl)piperidin-4-yl)acetic Acid
Step A: Preparation of (R)-ethyl 2-(1-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carbonyl)piperidin-4-yl)acetate

Prepared by the method as described in Example 11, substituting ethyl piperidine-4-carboxylate with ethyl 2-(piperidin-4-yl)acetate in step A (48 mg, 83% yield). MS (apci) m/z=498.1 (M+H).


Step B: Preparation of (R)-2-(1-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carbonyl)piperidin-4-yl)acetic Acid

Prepared as described in Example 11 Step B to afford the final product (30 mg, 66% yield) as a white solid. MS (apci) m/z=470.1 (M+H).


Example 13



embedded image


(R)—N-cyclopropyl-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method as described in Example 1 substituting tert-butyl amine with cyclopropanamine. The crude material was purified by preparative TLC eluting with EtOAc then 10% MeOH/EtOAc to provide the final product as a white solid (28 mg, 63% yield). MS (apci) m/z=384.1 (M+H).


Example 14



embedded image


(R)—N-cyclobutyl-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method as described in Example 1 substituting tert-butyl amine with cyclobutanamine, to provide the final product as a white solid (41 mg, 88% yield). MS (apci) m/z=398.1 (M+H).


Example 15



embedded image


N-((2S)-bicyclo[2.2.1]heptan-2-yl)-5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method as described in Example 1, substituting tert-butyl amine with (2R)-bicyclo[2.2.1]heptan-2-amine. The crude material was purified by reverse phase chromatography eluting with 0-100% acetonitrile/water to yield the title compound as a white solid (47 mg, 92% yield.). MS (apci) m/z=438.2 (M+H).


Example 16



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(1-(hydroxymethyl)cyclopropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method as described in Example 8, using (1-aminocyclopropyl)methanol (1.5 equiv.) the procedure described for Example 8. The title compound was obtained as a white solid (35% yield). MS (apci) m/z=414.1 (M+H).


Example 17



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(2-hydroxy-2-methylpropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method as described in Example 8, using 1-amino-2-methylpropan-2-ol (4.0 equiv.). The title compound was obtained as a white solid (62% yield). MS (apci) m/z=416.1 (M+H).


Example 18



embedded image


(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)((S)-3-hydroxypyrrolidin-1-yl)methanone

The title compound was prepared by the method as described in Example 1 using (S)-pyrrolidin-3-ol (2.0 equiv). The EtOAc pool was concentrated and the residual colorless glass was dissolved in EtOAc. Hexanes were added and resulting white suspension was concentrated to give the title compound as a white solid (42% yield). MS (apci) m/z=414.1 (M+H).


Example 19



embedded image


(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)((R)-3-hydroxypyrrolidin-1-yl)methanone

Prepared by the method as described in Example 18 using (R)-pyrrolidin-3-ol (2.0 equiv.). The title compound was obtained as a white solid (99% yield). MS (apci) m/z=414.1 (M+H).


Example 20



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

The title compound was prepared following the method of Example 1, using tetrahydro-2H-pyran-4-amine (2.0 equiv.). The EtOAc pool was concentrated and the residual colorless glass was dissolved in EtOAc. Hexanes were added and resulting white suspension was concentrated to give the title compound as a white solid (68% yield). MS (apci) m/z=428.1 (M+H).


Example 21



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((1-methyl-1H-imidazol-4-yl)methyl) pyrazole[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 substituting tert-butyl amine with (1-methyl-1H-imidazol-4-yl)methanamine. The crude material was purified by reverse phase chromatography, eluting with 0-100% acetonitrile/water to yield the title compound as a white solid (22 mg, 43% yield.). MS (apci) m/z=438.1 (M+H).


Example 22



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((1-methyl-1H-pyrazol-4-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 substituting tert-butyl amine with (1-methyl-1H-pyrazol-4-yl)methanamine. The crude material was purified by reverse phase chromatography, eluting with 0-100% acetonitrile/water to yield the title compound as a white solid (34 mg, 67% yield.). MS (apci) m/z=438.1 (M+H).


Example 23



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(2-(1-methyl-1H-imidazol-5-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 substituting tert-butyl amine with 2-(1-methyl-1H-imidazol-5-yl)ethanamine. The crude material was purified by reverse phase chromatography, eluting with 0-100% acetonitrile/water to yield the title compound as a white solid (26 mg, 49% yield.). MS (apci) m/z=452.2 (M+H).


Example 24



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(2-(2-oxoimidazolidin-1-yl)ethyl) pyrazole[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1, substituting tert-butyl amine with 1-(2-aminoethyl)imidazolidin-2-one. The crude material was purified by reverse phase chromatography, eluting with 0-100% acetonitrile/water to yield the title compound as a white solid (23 mg, 43% yield.). MS (apci) m/z=456.1 (M+H).


Example 25



embedded image


(R)—N-(2-(1H-imidazol-4-yl)ethyl)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazole [1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1, substituting tert-butyl amine with histamine. The crude material was purified by reverse phase chromatography, eluting with 0-100% acetonitrile/water to yield the title compound as a white solid (17 mg, 34% yield.). MS (apci) m/z=438.2 (M+H).


Example 26



embedded image


5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N—((R)-2,3-dihydroxypropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1, substituting tert-butyl amine with (R)-3-aminopropane-1,2-diol. The crude material was purified by preparative TLC using EtOAc then 10% MeOH/EtOAc for elution to afford the title compound (19 mg, 39% yield) as a white solid. MS (apci) m/z=418.1 (M+H).


Example 27



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N,N-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 substituting tert-butyl amine with dimethylamine. The crude material was purified by preparative TLC eluting with EtOAc then 10% MeOH/EtOAc to afford the title compound (7 mg, 19% yield) as a white solid. MS (apci) m/z=372.1 (M+H).


Example 28



embedded image


(R)—N-(2-(1H-imidazol-1-yl)ethyl)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 substituting tert-butyl amine with 2-(1H-imidazol-1-yl)ethanamine dihydrobromide. The crude material was purified by reverse phase chromatography eluting with 0-100% acetonitrile/water to yield the title compound as a white solid (25 mg, 57% yield.). MS (apci) m/z=438.1 (M+H).


Example 29



embedded image


5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N—((S)-2,3-dihydroxypropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

A mixture of (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation C, 400 mg, 1.16 mmol), HATU (486 mg, 1.28 mmol), and (S)-3-aminopropane-1,2-diol (318 mg, 3.49 mmol) in dry DMF (3.0 mL) was stirred for 1-2 minutes at ambient temperature. Diisopropylethylamine (DIEA) (0.62 mL, 3.49 mmol) was added and the reaction was flushed with N2, sealed and stirred at ambient temperature for 18 hours. The reaction mixture was added to H2O (15 mL), mixed and extracted with EtOAc. The combined EtOAc extracts were washed with H2O, saturated NaHCO3 and dried over MgSO4/activated carbon. The solution was eluted through a SiO2 column eluting first with EtOAc then 10% MeOH/EtOAc. The 10% MeOH/EtOAc pool was concentrated and the residual, colorless glass was dissolved in a minimal amount of CH2Cl2. Hexane was added and the resulting white suspension was sonicated and concentrated to give the title product as a white solid (205 mg, 42%). MS (apci) m/z=418.1 (M+H).


Example 30



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
Step A: Preparation of 5-hydroxypyrazolo[1,5-a]pyrimidine-3-carbonitrile

To a mixture of 5-amino-1H-pyrazole-4-carbonitrile (2.70 g, 25.0 mmol) and Cs2CO3 (16.3 g, 50.0 mmol) in dry DMF (70 mL) was added ethyl 3-ethoxyacrylate (5.41 g, 37.5 mmol) and the mixture was heated at 100° C. for 4 hours. The mixture was cooled to ambient temperature and the resultant slurry was poured into deionized H2O (150 mL). The resulting aqueous solution was cooled on an ice bath and concentrated HCl was added slowly with mixing to pH=3.5. The resulting precipitate was collected, washed with H2O followed by Et2O. The solid was dried in vacuum to afford the product as a light beige powder (3.87 g, 97%). MS (apci) m/z=159.0 (M−1).


Step B: Preparation of (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile

A flask was charged with the product from Step A (2.80 g, 17.5 mmol), benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (9.28 g, 21.0 mmol) and dry DMF (35 mL). The suspension was stirred at ambient temperature for 2 minutes and (R)-2-(2,5-difluorophenyl)pyrrolidine (Preparation A, 3.84 g, 21.0 mmol) and diisopropylethylamine (6.78 g, 62.5 mmol) were sequentially added (mild exotherm). The mixture was stirred at ambient temperature for 3 hours and poured into H2O (175 mL). The mixture was extracted with 50% EtOAc-hexanes and the combined organic fractions were washed sequentially with 1M HCl, H2O, 1M Na2CO3 and saturated NaCl. The solution was dried over MgSO4/activated carbon and filtered through a short SiO2 plug (350 mL course frit funnel, ¼ full of SiO2, capped with a layer of MgSO4) using 50% EtOAc-hexanes for elution. The solution was concentrated to give the title compound as a brittle white foam that was crushed to a flowing white solid and dried in vacuum (5.50 g, 97%). MS (apci) m/z=326.2 (M+H).


Step C: Preparation of (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

The product from Step B (3.00 g, 8.85 mmol) was added in small portions over 5 minutes to concentrated H2SO4 (30 mL) and the mixture was stirred at ambient temperature for 2 hours (homogeneous after 5 minutes). The solution was slowly added to chilled H2O (300 mL) with stirring and the mixture was extracted with EtOAc. The combined EtOAc portions were washed with H2O, 1M Na2CO3 and saturated NaCl. The EtOAc solution was dried over MgSO4/activated carbon, filtered through a packed Celite pad and concentrated to give a white foam. The foam was dissolved in minimal CH2Cl2 and hexane was added to induce formation of a white precipitate. The mixture was concentrated to provide the title compound as a flowing white solid after drying in vacuum (2.80 g, 92%). MS (apci) m/z=344.1 (M+H).


Example 31



embedded image


(R)-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)(3-hydroxyazetidin-1-yl)methanone

The title compound was prepared according to the method of Example 1, using azetidin-3-ol hydrochloride (2.0 equiv.). In this instance, the dried EtOAc solution was eluted through a SPE SiOH column eluting first with EtOAc then with 10% MeOH-EtOAc. The MeOH-EtOAc pool was concentrated to afford the title compound as a white solid (43% yield). MS (apci) m/z=400.0 (M+H).


Example 32



embedded image


(R)-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)(3-hydroxy-3-methylazetidin-1-yl)methanone

The title compound was prepared according to the method of Example 1, using 3-methyl-azetidin-3-ol trifluoroacetate (2.0 equiv.). The dried EtOAc solution was eluted through a SPE SiOH column eluting first with EtOAc then with 10% MeOH-EtOAc. The MeOH-EtOAc pool was concentrated to afford the title compound as a white solid (71% yield). MS (apci) m/z=414.1 (M+H).


Example 33



embedded image


Trans-4-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamido)cyclohexanecarboxylic Acid
Step A: Preparation of (trans)-methyl 4-aminocyclohexanecarboxylate Hydrochloride

(Trans)-4-aminocyclohexanecarboxylic acid (200 mg, 1.40 mmol) was suspended in MeOH (5.5 mL) and cooled to −10° C. To this was added SOCl2 (204 μL, 2.79 mmol) dropwise and the mixture stirred for 15 minutes. The reaction mixture was warmed to ambient temperature for 15 minutes, followed by heating at reflux for 1 hour. After cooling, the mixture was concentrated to afford the title compound (260 mg, 96.1% yield). MS (apci) m/z=158.0 (M+H).


Step B: Preparation of (Trans)-methyl 4-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamido)cyclohexanecarboxylate

Prepared by the method described in Example 1 substituting tert-butyl amine with (trans)-methyl 4-aminocyclohexanecarboxylate hydrochloride. The crude material was purified by preparative TLC using EtOAc then 10% MeOH/EtOAc for elution to afford the title compound (38 mg, 91% yield) as a colorless oil. MS (apci) m/z=484.1 (M+H).


Step C: Preparation of (trans)-4-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamido)cyclohexanecarboxylic Acid

Prepared by the method as described in Example 11, step B to afford the title compound (29 mg, 79% yield) as a white solid. MS (apci) m/z=4701 (M+H).


Example 34



embedded image


5-((R)-2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl)-N-((trans)-4-hydroxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method as described in Example 1 using (R)-5-(2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation G) and (trans)-4-aminocyclohexanol. The crude material was purified by reverse phase chromatography, eluting with 0-60% acetonitrile/water to yield the title compound as a white solid (32 mg, 97% yield.). MS (apci) m/z=454.1 (M+H).


Example 35



embedded image


5-((R)-2-(3-fluorophenyl)pyrrolidin-1-yl)-N-((trans)-4-hydroxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method as described in Example 1 using (R)-5-(2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation E) and (trans)-4-aminocyclohexanol to yield the title compound as a white solid (31 mg, 62% yield.). MS (apci) m/z=424.1 (M+H).


Example 36



embedded image


(R)—N-tert-butyl-5-(2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method as described in Example 1 using (R)-5-(2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation E) to yield the title compound as a white solid (33 mg, 74% yield.). MS (apci) m/z=382.1 (M+H).


Example 37



embedded image


(R)—N-cyclopropyl-5-(2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method as described in Example 1 using (R)-5-(2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation E) and cyclopropylamine to yield the title compound as a white solid (23 mg, 54% yield.). MS (apci) m/z=366.1 (M+H).


Example 38



embedded image


(R)—N-(2-cyanopropan-2-yl)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 substituting tert-butyl amine with 2-amino-2-methylpropanenitrile. The crude material was purified by preparative TLC using EtOAc then 10% MeOH/EtOAc for elution to afford the title compound (15 mg, 41% yield) as a white solid. MS (apci) m/z=411.1 (M+H).


Example 39



embedded image


(R)—N-(cyanomethyl)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 substituting tert-butyl amine with 2-aminoacetonitrile to provide the final product as a white solid (31 mg, 94% yield). MS (apci) m/z=383.0 (M+H).


Example 40



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(1-fluoro-2-methylpropan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 substituting tert-butyl amine with 1-fluoro-2-methylpropan-2-amine to provide the title compound as a white solid (31 mg, 84% yield). MS (apci) m/z=418.0 (M+H).


Example 41



embedded image


N-cyclopropyl-5-((2R,4R)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
Step A: Preparation of (R)-3-(tert-butyldimethylsilyloxy)-4-chlorobutanenitrile

Tert-butyldimethyl silanecarbonitrile (20.0 g, 142 mmol), (R)-2-(chloromethyl)oxirane (13.1 g, 142 mmol) and tetrabutylammonium cyanide (0.380 g, 1.42 mmol) were mixed and heated at 100° C. for 15 hours. After cooling, the crude mixture was concentrated and the residue purified by silica chromatography eluting with 5% EtOAc/hexanes to afford (R)-3-(tert-butyldimethylsilyloxy)-4-chlorobutanenitrile (17.9 g, 54%) as a clear oil.


Step B: Preparation of (R)-3-(tert-butyldimethylsilyloxy)-5-(3-fluorophenyl)-3,4-dihydro-2H-pyrrole

(3-fluorophenyl)magnesium bromide (203 mL, 102 mmol, 0.5 M in ether) was slowly added via syringe to a solution of (R)-3-(tert-butyldimethylsilyloxy)-4-chlorobutanenitrile (9.50 g, 40.6 mmol) in MTBE (120 mL). The reaction was stirred for two hours and DME (35 mL) was slowly added over 15 minutes followed by EtOH (23 mL). After stirring overnight, brine (50 mL) and 1M NaOH (50 mL) were added and the reaction stirred for 1 hour. The reaction mixture was filtered through a pad of Celite and the collected solids were washed with EtOAc. The filtrate was washed with 1N NaOH and brine, filtered through phase-separator paper and concentrated to provide the title compound that was used directly in the next step. MS (apci) m/z=294.2 (M+H).


Step C: Preparation of (2R,4R)-4-(tert-butyldimethylsilyloxy)-2-(3-fluoro phenyl) pyrrolidine

(R)-3-(tert-butyldimethylsilyloxy)-5-(3-fluorophenyl)-3,4-dihydro-2H-pyrrole (6.21 g, 21.2 mmol) was dissolved in methanol (100 mL) and AcOH (10 mL). The reaction was cooled to −78° C. and the sodium borohydride (2.00 g, 52.9 mmol) was slowly added in small portions. The reaction was allowed to warm to ambient temperature overnight. The reaction mixture was concentrated and the residue was diluted with EtOAc and 1N NaOH. Additional NaOH pellets were added to basify the aqueous layer. The organic layer was separated and the aqueous layer was extracted with EtOAc. The combined organic layers were dried with MgSO4, filtered and concentrated. The residual oil was purified by silica chromatography eluting with 5% MeOH/EtOAc to afford (2R,4R)-4-(tert-butyldimethylsilyloxy)-2-(3-fluorophenyl)pyrrolidine (4.82 g, 77.1%) as a brown oil. MS (apci) m/z=296.1 (M+H).


Step D: Preparation of ethyl 5-((2R,4R)-4-(tert-butyldimethylsilyloxy)-2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate

Prepared according to the method of Preparation C, using (2R,4R)-4-(tert-butyldimethylsilyloxy)-2-(3-fluorophenyl)pyrrolidine in Step A. MS (apci) m/z=485.1 (M+H).


Step E: Preparation of 5-((2R,4R)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid

Ethyl 5-((2R,4R)-4-(tert-butyldimethyl silyloxy)-2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (205 mg, 0.422 mmol) was suspended in EtOH (2.0 mL) and 1M LiOH (0.845 ml, 0.845 mmol) was added. The mixture was heated at reflux for 4 hours and another portion of 1M LiOH (0.845 ml, 0.845 mmol) was added. The mixture was heated at reflux overnight, cooled to ambient temperature and concentrated. The residue was diluted in water and the mixture was treated with 2N HCl to achieve pH 1. The mixture was extracted with DCM and EtOAc and the combined extracts were dried with MgSO4, filtered and concentrated to afford 5-((2R,4R)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (124 mg, 86%) as a light orange solid.


Step F: Preparation of N-cyclopropyl-5-((2R,4R)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using 5-((2R,4R)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid and substituting tert-butyl amine with cyclopropylamine to provide the final product as a white solid (15 mg, 66% yield). MS (apci) m/z=382.1 (M+H).


Example 42



embedded image


N-tert-butyl-5-((2R,4R)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using 5-((2R,4R)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid and tert-butyl amine to provide the final product as a white solid (24 mg, 100% yield). MS (apci) m/z=398.1 (M+H).


Example 43



embedded image


5-((2R,4R)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)-N-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using 5-((2R,4R)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid and methylamine to provide the final product as a white solid (9.4 mg, 45% yield). MS (apci) m/z=356.1 (M+H).


Example 44



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(1-(methylsulfonyl)piperidin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using 1-(methylsulfonyl)piperidin-4-amine hydrochloride (1.5 equiv.). The title compound was isolated as a white solid (83% yield) after purification by SiO2 column (eluting with 50% EtOAc-hexanes, then EtOAc, and then 10% MeOH-EtOAc). MS (apci) m/z=505.0 (M+H).


Example 45



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(1-sulfamoylpiperidin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using 4-aminopiperidine-1-sulfonamide (1.5 equiv.). The title compound was isolated as a white solid (80% yield) after SiO2 column purification (eluting with 50% EtOAc-hexanes, then EtOAc, then 10% MeOH-EtOAc). MS (apci) m/z=506.0 (M+H).


Example 46



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(2-(methylsulfonamido)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using N-(2-aminoethyl)methanesulfonamide hydrochloride (2.0 equiv.). The title compound was isolated as a white solid (67% yield) after SiO2 column purification (eluting with 50% EtOAc-hexanes, then EtOAc, then 10% MeOH-EtOAc). MS (apci) m/z=465.0 (M+H).


Example 47



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(2-sulfamoylethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using 2-aminoethanesulfonamide (2.0 equiv.). The title compound was isolated as a white solid (67% yield) after SiO2 column purification (eluting with 50% EtOAc-hexanes, then EtOAc, then 10% MeOH-EtOAc). MS (apci) m/z=451.0 (M+H).


Example 48



embedded image


(R)—N-cyclopropyl-5-(2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using (R)-5-(2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation G) and cyclopropylamine to yield the title compound as a white solid (19 mg, 68% yield). MS (apci) m/z=396.0 (M+H).


Example 49



embedded image


(R)-5-(2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl)-N-(2-hydroxy-2-methylpropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using (R)-5-(2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation G) and 1-amino-2-methylpropan-2-ol to yield the title compound as a white solid (17 mg, 55% yield). MS (apci) m/z=428.1 (M+H).


Example 50



embedded image


5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(4-hydroxy-4-methylcyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (Diastereomer 1)
Step A: Preparation of diastereomeric tert-butyl-4-hydroxy-4-methylcyclohexyl Carbamates

A solution of tert-butyl 4-oxocyclohexylcarbamate (1.20 g, 5.63 mmol) in dry THF (28.1 mL, 5.63 mmol) was cooled to −78° C. and 3.0 M MeMgCl (5.72 mL, 17.2 mmol) was added. The reaction mixture was allowed to warm to ambient temperature and stirred for 48 hours. The reaction was quenched with saturated NH4Cl (10 mL) and concentrated in vacuo. The residue was diluted in water and DCM and solid citric acid was added until the phases separated. The organic layer was removed and washed with saturated NaHCO3, water and brine. The solution was dried with MgSO4 filtered and concentrated to give a mixture of diastereomeric products as a white solid. The two diastereomers were separated using silica chromatography eluting with a gradient of 20-80% EtOAc/Hexanes: Minor isomer (45.1 mg, 7% yield), major isomer (113 mg, 18% yield). MS (apci) m/z=130.0 (M+H-Boc).


Step B: Preparation of 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(4-hydroxy-4-methyl cyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (Diastereomer 1)

The minor isomer from Step A (45.1 mg, 0.197 mmol) was dissolved in DCM (1.0 mL) and 4N HCl in dioxane (492 μL, 1.97 mmol) was added. The reaction mixture was stirred at ambient temperature for 1 hour and was concentrated to afford 4-amino-1-methylcyclohexanol (minor isomer). The 4-amino-1-methylcyclohexanol was reacted with (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation C) according to the procedure outlined in Example 1 to provide the title product as a white solid (14 mg, 48% yield). MS (apci) m/z=456.1 (M+H).


Example 51



embedded image


5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(4-hydroxy-4-methylcyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (Diastereomer 2)

The major isomer from Step A in Example 50 (45.1 mg, 0.197 mmol) was dissolved in DCM (1.0 mL) and 4N HCl in dioxane (492 μL, 1.97 mmol) was added. The reaction mixture was stirred at ambient temperature for 1 hour and was concentrated to afford 4-amino-1-methylcyclohexanol (major isomer). The 4-amino-1-methylcyclohexanol was reacted with (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation C) according to the procedure outlined in Example 1 to provide the title product as a white solid (10.7 mg, 38% yield). MS (apci) m/z=456.1 (M+H).


Example 52



embedded image


(R)—N-cyclopropyl-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

To a solution of (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation I, 30.0 mg, 0.092 mmol) and HATU (52.1 mg, 0.137 mmol) in dry DMF (0.5 mL) was added cyclopropylamine (10.5 mg, 0.183 mmol) followed by diisopropylethylamine (35.5 mg, 0.275 mmol). The mixture was stirred under an atmosphere of N2 for 43 hours. The crude mixture was purified by reverse phase chromatography eluting with 0-50% acetonitrile/water to yield the title compound as a white solid (26 mg, 78% yield). MS (apci) m/z=367.0 (M+H).


Example 53



embedded image


(R)—N-tert-butyl-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method as described in Example 1 using (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation I) and 2-methylpropan-2-amine to yield the title compound as a white solid (23 mg, 67% yield). MS (apci) m/z=383.1 (M+H).


Example 54



embedded image


(R)-5-(2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl)-N-(2-morpholinoethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method as described in Example 4, using (R)-5-(2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation G) and 2-morpholinoethanamine (1.5 equiv.). The title compound was obtained as a white solid (65% yield). MS (apci) m/z=469.1 (M+H).


Example 55



embedded image


N—((S)-2,3-dihydroxypropyl)-5-((R)-2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method of Example 1, using (R)-5-(2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation G) and (S)-3-aminopropane-1,2-diol (2.0 equiv). The crude material was purified by SiO2 column chromatography, eluting with EtOAc then 10% MeOH-EtOAc to afford the title compound as a white solid (53% yield). MS (apci) m/z=430.1 (M+H).


Example 56



embedded image


N—((R)-2,3-dihydroxypropyl)-5-((R)-2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method of Example 1, using (R)-5-(2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation G) and (R)-3-aminopropane-1,2-diol (2.0 equiv). The crude material was purified by SiO2 column chromatography, eluting with EtOAc then 10% MeOH-EtOAc to afford the title compound as a white solid (46% yield). MS (apci) m/z=430.1 (M+H).


Example 57



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(2-methyl-1-(methylsulfonamido)propan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
Step A: Preparation of tert-butyl 2-amino-2-methylpropylcarbamate

Tert-butyl phenyl carbonate (0.421 mL, 2.270 mmol) was added to a solution of 2-methylpropane-1,2-diamine (200 mg, 2.270 mmol) in EtOH (4.5 mL) and the reaction mixture was heated at reflux overnight. The mixture was concentrated and the residue diluted in water. The mixture was acidified with 2N HCl to pH 4 and washed with DCM. The aqueous layer was treated with 1M NaOH (2 mL) and extracted with DCM. The combined organic layers were dried with MgSO4, filtered and concentrated to afford tert-butyl 2-amino-2-methylpropylcarbamate (158 mg, 37% yield) as a colorless oil. MS (apci) m/z=188.9 (M+H).


Step B: Preparation of (R)-tert-butyl 2-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamido)-2-methylpropylcarbamate

Prepared by the method described in Example 1 using tert-butyl 2-amino-2-methylpropylcarbamate to provide the title compound as a colorless oil (109 mg, 100% yield). MS (apci) m/z=515.2 (M+H).


Step C: Preparation of (R)—N-(1-amino-2-methylpropan-2-yl)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Hydrochloride

(R)-tert-butyl 2-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamido)-2-methylpropylcarbamate (109 mg, 0.212 mmol) was dissolved in DCM (1.0 mL) and 4N HCl in dioxane (0.530 mL, 2.12 mmol) was added. The mixture was stirred at ambient temperature for 4 hours and was concentrated afford the title compound (105 mg). MS (apci) m/z=415.2 (M+H).


Step D: Preparation of (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(2-methyl-1-(methylsulfonamido)propan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

(R)—N-(1-amino-2-methylpropan-2-yl)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride (24.0 mg, 0.0532 mmol) was dissolved in DCM (0.53 mL) and triethylamine (15.2 μL, 0.109 mmol) followed by MeSO2Cl (4.34 μL, 0.0559 mmol) were added sequentially. The mixture was stirred at ambient temperature for 2 hours and was diluted with EtOAc. The mixture was washed with water and brine and was dried with MgSO4. The solution was filtered and concentrated to afford the title compound (8.0 mg, 30% yield) as a white solid. MS (apci) m/z=493.1 (M+H).


Example 58



embedded image


(R)—N-(2-amino-2-methyl propyl)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1, using 2-methylpropane-1,2-diamine. The crude product was purified by reverse phase chromatography eluting with 0-100% acetonitrile/water to yield the title compound as a white solid (3.9 mg, 6.0% yield). MS (apci) m/z=415.1 (M+H).


Example 59



embedded image


(R)—N-tert-butyl-5-(4,4-difluoro-2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
Step A: Preparation of (R)—N-tert-butyl-5-(2-(3-fluorophenyl)-4-oxopyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

N-tert-butyl-5-((2R,4R)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (Example 42, 10 mg, 0.025 mmol) and the Dess-Martin reagent (16 mg, 0.038 mmol) in DCM (2.0 mL) were stirred at ambient temperature overnight. 1N NaOH (2.5 mL) was added and the reaction stirred for 30 minutes. Brine (2.5 mL) was added and the reaction was filtered through a phase separator frit, washing with several portions of DCM. The DCM solution was concentrated and the residue purified by reverse phase chromatography (20-70% acetonitrile/water) to provide the title compound (2.7 mg, 27% yield) as a clear oil. MS (apci) m/z=396.0 (M+H).


Step B: Preparation of (R)—N-tert-butyl-5-(4,4-difluoro-2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

(R)—N-tert-butyl-5-(2-(3-fluorophenyl)-4-oxopyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (1.40 mg, 3.54 μmol) and bis-(2-methoxyethyl)aminosulfur trifluoride (1.57 mg, 7.08 μmol) were mixed in DCM (2.0 mL) and the reaction was stirred at ambient temperature overnight. 1N NaOH (1.0 mL) was added and the reaction was stirred for 30 minutes. Brine (1.0 mL) was added and the mixture was filtered through a phase separator frit, washing with several portions of DCM. The DCM solution was concentrated and the residue purified by reverse phase chromatography (0-70% acetonitrile/water) to provide the title compound (1.30 mg, 88.0% yield) as a white solid. MS (apci) m/z=418.1 (M+H).


Example 60



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(1,3-dihydroxy-2-methyl propan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared according to the method of Example 1, using 2-amino-2-methylpropane-1,3-diol (2.0 equiv). The crude material was purified by SiO2 column chromatography, eluting with EtOAc and then 10% MeOH-EtOAc to provide the title compound as a white solid (54% yield). MS (apci) m/z=432.1 (M+H).


Example 61



embedded image


5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((3S,4R)-3-fluoropiperidin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Hydrochloride
Step A: Preparation of (3S,4R)-tert-butyl 4-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamido)-3-fluoropiperidine-1-carboxylate

Prepared according to the method of Example 1, using (3S,4R)-tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate (1.5 equiv). The title compound was obtained as a white solid (79% yield). MS (apci) m/z=545.21 (M+H).


Step B: Preparation of 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((3S,4R)-3-fluoropiperidin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Hydrochloride

To a solution of the title compound from Step A (50.0 mg, 0.092 mmol) in EtOAc (1.5 mL) was added 4M HCl in dioxane (0.460 mL, 1.85 mmol) and the mixture was stirred at ambient temperature for 6 hours (white precipitate formed). The mixture was diluted with dry Et2O (2 volumes) and sonicated to afford a fine white suspension. The solid was collected, washed with dry Et2O and dried under vacuum to give the title compound as a white solid (42 mg, 95% yield). MS (apci) m/z=445.1 (M+H).


Example 62



embedded image


N—((S)-2,3-dihydroxypropyl)-5-((R)-2-(5-fluoro-2-(trifluoromethyl)phenyl) pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using (R)-5-(2-(5-fluoro-2-(trifluoromethyl)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation M) and (S)-3-aminopropane-1,2-diol. The crude material was purified by reverse phase HPLC (0-60% acetonitrile/water) to provide the title compound (26 mg, 73% yield). MS (apci) m/z=468.1 (M+H).


Example 63



embedded image


N—((R)-2,3-dihydroxypropyl)-5-((R)-2-(5-fluoro-2-(trifluoromethyl)phenyl) pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using (R)-5-(2-(5-fluoro-2-(trifluoromethyl)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation M) and (R)-3-aminopropane-1,2-diol. The crude material was purified by reverse phase HPLC (0-60% acetonitrile/water) to provide the title compound (34 mg, 73% yield). MS (apci) m/z=468.1 (M+H).


Example 64



embedded image


(R)-5-(2-(5-fluoro-2-(trifluoromethyl)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using (R)-5-(2-(5-fluoro-2-(trifluoromethyl)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation M) and ammonium chloride. The crude material was purified by reverse phase HPLC (0-60% acetonitrile/water) to yield the title compound (23 mg, 78% yield.). MS (apci) m/z=394.0 (M+H).


Example 65



embedded image


(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-methoxypyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using O-methylhydroxylamine hydrochloride (2.0 equiv). The title compound was obtained as a white solid (53% yield). MS (apci) m/z=374.1 (M+H).


Example 66



embedded image


(R)—N-(cyclopropylmethoxy)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using O-(cyclopropylmethyl)hydroxylamine (2.0 equiv). The title compound was obtained as a white solid (31% yield). MS (apci) m/z=414.1 (M+H).


Example 67



embedded image


(R)-5-(5-(2,5-difluorophenyl)-2,2-dimethylpyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
Step A: Preparation of (R)-tert-butyl 5-(2,5-difluorophenyl)-2,2-dimethyl pyrrolidine-1-carboxylate

Prepared by the method described in Preparation A, Step A substituting tert-butyl pyrrolidine-1-carboxylate with tert-butyl 2,2-dimethylpyrrolidine-1-carboxylate to provide the title compound as a white solid (640 mg, 37% yield). MS (apci) m/z=212.1 (M+H−Boc).


Step B: Preparation of (R)-5-(2,5-difluorophenyl)-2,2-dimethylpyrrolidine Hydrochloride

Prepared by the method as described in Preparation A, Step B, using (R)-tert-butyl 5-(2,5-difluorophenyl)-2,2-dimethyl pyrrolidine-1-carboxylate to afford the title compound (420 mg, 97% yield). MS (apci) m/z=212.1 (M+H).


Step C: Preparation of (R)-ethyl 5-(5-(2,5-difluorophenyl)-2,2-dimethylpyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate

A sealed pressure tube was charged with (R)-5-(2,5-difluoro phenyl)-2,2-dimethylpyrrolidine HCl salt (300 mg, 1.21 mmol), diisopropylethylamine (423 μl, 2.42 mmol), ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (273 mg, 1.21 mmol) and isopropanol (2.0 mL). The tube was sealed and the mixture was heated at 160° C. for 3 days. Additional ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (273 mg, 1.21 mmol) was added and the reaction was heated at 160° C. 2 days. The reaction mixture was concentrated and the residue purified by reverse phase HPLC (eluting with 0-60% acetonitrile/H2O) to provide the title compound (136 mg, 28%) as a beige solid. MS (apci) m/z=401.1 (M+H).


Step D: Preparation of (R)-5-(5-(2,5-difluorophenyl)-2,2-dimethylpyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid

(R)-ethyl 5-(5-(2,5-difluorophenyl)-2,2-dimethylpyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (136 mg, 0.340 mmol) was dissolved in MeOH (5.0 mL) and 1N NaOH (3.40 mL, 3.40 mmol) was added. The reaction was stirred at ambient temperature for 5 days and then heated at reflux for 4 hours. The reaction mixture was cooled, poured onto a mixture of brine (10 mL) and 2N HCl (5 mL) and extracted with DCM. The combined organic extracts were filtered through PS paper and concentrated to provide the title compound (123 mg, 97% yield) as a beige solid. MS (apci) m/z=373.0 (M+H).


Step E: Preparation of (R)-5-(5-(2,5-difluorophenyl)-2,2-dimethylpyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using (R)-5-(5-(2,5-difluorophenyl)-2,2-dimethylpyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid and ammonium chloride. The crude material was purified by reverse phase HPLC (0-70% acetonitrile/water) to provide the title compound (8.5 mg, 33% yield.). MS (apci) m/z=372.1 (M+H).


Example 68



embedded image


(R)—N-cyclopropyl-5-(5-(2,5-difluorophenyl)-2,2-dimethylpyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using (R)-5-(5-(2,5-difluorophenyl)-2,2-dimethylpyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid and cyclopropylamine in Step D. The crude material was purified by reverse phase HPLC (0-75% acetonitrile/water) to provide the title compound (11 mg, 39% yield.). MS (apci) m/z=412.1 (M+H).


Example 69



embedded image


(R)—N-(2-cyanopropan-2-yl)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation I) and 2-amino-2-methylpropanenitrile to yield the title compound as a white solid (21 mg, 57% yield). MS (apci) m/z=394.1 (M+H).


Example 70



embedded image


(R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-(1-(methylsulfonyl)piperidin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method as described in Example 1 using (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation I) and 1-(methylsulfonyl)piperidin-4-amine to yield the title compound as a white solid (44 mg, 100% yield). MS (apci) m/z=488.1 (M+H).


Example 71



embedded image


(R)—N-(1-fluoro-2-methylpropan-2-yl)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation I) and 1-fluoro-2-methylpropan-2-amine to yield the title compound as a white solid (37 mg, 100% yield). MS (apci) m/z=401.0 (M+H).


Example 72



embedded image


(R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method as described in Example 1 using (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation I) and tetrahydro-2H-pyran-4-amine to yield the title compound as a white solid (34 mg, 90% yield). MS (apci) m/z=411.1 (M+H).


Example 73



embedded image


(R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-methoxypyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method as described in Example 1 using (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation I) and O-methylhydroxylamine to yield the title compound as a white solid (15 mg, 35% yield). MS (apci) m/z=357.0 (M+H).


Example 74



embedded image


(R)-5-(2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

To a suspension of (R)-5-(2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation E, 50.0 mg, 0.153 mmol) in CCl4 (1.0 mL) was added thionyl chloride (182 mg, 1.53 mmol) and the mixture was heated at reflux for 4 hours (homogeneous after 5 minutes). The mixture was cooled to ambient temperature and was concentrated to give a brittle foam. The foam was dissolved in dry THF (2 mL) and dimethylaminopyridine (DMAP) (3.74 mg, 0.031 mmol) was added. Anhydrous ammonia was bubbled into the mixture with stirring for 5 minutes. The reaction vessel was sealed and the reaction was stirred at ambient temperature for 18 hours. The mixture was added to H2O (4 mL) and extracted with EtOAc. The combined extracts were washed with 1M Na2CO3, H2O and saturated NaCl. The solution was dried over MgSO4/activated carbon and filtered through a SiO2 plug (EtOAc then 10% MeOH/EtOAc for elution). The solution was concentrated to give the title compound as a white solid (38 mg, 76%). MS (apci) m/z=326.0 (M+H).


Example 75



embedded image


((R)-5-(2-(3-fluorophenyl)pyrrolidin-1-yl)-N-methoxypyrazolo[1,5-a]pyrimidine-3-carboxamide

To a suspension of (R)-5-(2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation E, 50.0 mg, 0.153 mmol) in CCl4 (1.5 mL) was added thionyl chloride (182 mg, 1.53 mmol) and mixture heated at reflux for 4 hours (homogeneous). The mixture was cooled to ambient temperature and was concentrated to a brittle beige foam. DMAP (3.7 mg, 0.031 mmol), methylhydroxyl amine HCl (38.4 mg, 0.460 mmol) and dry THF (2 mL) were added and mixed. Diisopropylethylamine (79.2 mg, 0.613 mmol) was added, and the reaction flushed with N2 and stirred at ambient temperature for 18 hours. The mixture was diluted with H2O (4 mL) and extracted with EtOAc and the combined extracts were washed with 1M Na2CO3, H2O and saturated NaCl. The solution was dried over MgSO4/activated carbon and filtered through a SiO2 plug eluting with EtOAc. The mixture was concentrated to give a white foam that was dissolved in minimal CH2Cl2 and treated with dry hexanes to give a fine white suspension. The mixture was concentrated to give the title compound as white solid (42 mg, 77%). MS (apci) m/z=356.0 (M+H).


Example 76



embedded image


(R)-5-(2-(3-fluoro-5-(2-morpholinoethoxy)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
Step A: Preparation of (R)-tert-butyl 2-(3-fluoro-5-hydroxyphenyl)pyrrolidine-1-carboxylate

Prepared by the method as described in Preparation A, Step A, substituting 2-bromo-1,4-difluorobenzene with 3-bromo-5-fluorophenyl acetate to afford the title compounds (10.3 g, 62% yield). MS (apci) m/z=182.1 (M+H−Boc).


Step B: Preparation of (R)-3-fluoro-5-(pyrrolidin-2-yl)phenol Hydrochloride

To a solution of (R)-tert-butyl 2-(3-fluoro-5-hydroxyphenyl)pyrrolidine-1-carboxylate (10.3 g, 36.5 mmol) in DCM (20 mL) was added 4N HCl in dioxane (36.5 mL, 146 mmol) and the mixture was stirred at ambient temperature for 15 hours. The resulting precipitate was filtered and washed with DCM to afford (R)-3-fluoro-5-(pyrrolidin-2-yl)phenol hydrochloride (5.81 g, 73.3% yield).


Step C: Preparation of (R)-ethyl 5-(2-(3-fluoro-5-hydroxyphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate

Prepared by the method as described in Preparation C, Step A, using (R)-2-(2,5-difluorophenyl)pyrrolidine and (R)-3-fluoro-5-(pyrrolidin-2-yl)phenol hydrochloride. The crude material was purified by reverse phase HPLC (0-60% acetonitrile/water) to provide yield the title compound (775 mg, 94% yield). MS (apci) m/z=370.9 (M+H).


Step D: Preparation of (R)-ethyl 5-(2-(3-fluoro-5-(2-morpholinoethoxy) phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate

(R)-ethyl 5-(2-(3-fluoro-5-hydroxyphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (167 mg, 0.451 mmol), 4-(2-chloroethyl)morpholine hydrochloride (168 mg, 0.902 mmol), and K2CO3 (312 mg, 2.25 mmol) were suspended in DMF (5 mL) and stirred at ambient temperature for 15 hours. The crude reaction mixture was purified by reverse phase HPLC (0-60% acetonitrile/water) to provide the title compound (218 mg, 100% yield). MS (apci) m/z=484.1 (M+H).


Step E: Preparation of (R)-5-(2-(3-fluoro-5-(2-morpholinoethoxy)phenyl) pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid

Prepared using the hydrolysis conditions described in Preparation C, Step B. The crude material was purified by reverse phase HPLC (0-40% acetonitrile/water) to yield the title compound (208 mg, 94% yield). MS (apci) m/z=456.1 (M+H).


Step F: Preparation of (R)-5-(2-(3-fluoro-5-(2-morpholinoethoxy)phenyl) pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using (R)-5-(2-(3-fluoro-5-(2-morpholinoethoxy)phenyl) pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ammonium chloride to yield the title compound as a white solid (19 mg, 69% yield.). MS (apci) m/z=455.1 (M+H).


Example 77



embedded image


(R)—N-cyclopropyl-5-(2-(3-fluoro-5-(2-methoxyethoxy)phenyl)pyrrolidin-1-yl)pyrazole [1,5-a]pyrimidine-3-carboxamide
Step A: Preparation of (R)-ethyl 5-(2-(3-fluoro-5-(2-methoxyethoxy) phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate

(R)-ethyl 5-(2-(3-fluoro-5-hydroxyphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (Example 76 Step B, 174 mg, 0.470 mmol), 1-bromo-2-methoxyethane (196 mg, 1.41 mmol), and K2CO3 (325 mg, 2.35 mmol) were suspended in DMF (5 mL) and stirred at ambient temperature for 15 hours. The crude reaction mixture was purified by reverse phase HPLC (0-60% acetonitrile/water) to provide yield the title compound (183 mg, 91% yield). MS (apci) m/z=429.0 (M+H).


Step B: Preparation of (R)-5-(2-(3-fluoro-5-(2-methoxyethoxy)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid

(R)-ethyl 5-(2-(3-fluoro-5-(2-methoxyethoxy)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (178 mg, 0.415 mmol) was suspended in a mixture of 1N NaOH (5 mL) and MeOH (5 mL). The reaction mixture was stirred at ambient temperature until complete and quenched with 2N HCl (25 mL). The mixture was extracted with ethyl acetate and the combined organic fractions were concentrated to give the title compound (177 mg, 100% yield). MS (apci) m/z=401.0 (M+H).


Step C: Preparation of (R)—N-cyclopropyl-5-(2-(3-fluoro-5-(2-methoxyethoxy) phenyl)pyrrolidin-1-yl)pyrazolo[5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using (R)-5-(2-(3-fluoro-5-(2-methoxyethoxy)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid and cyclopropylamine to yield the title compound as a white solid (16 mg, 52% yield). MS (apci) m/z=440.1 (M+H).


Example 78



embedded image


(R)-5-(2-(3-fluoro-5-(2-methoxyethoxy)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 77 using ammonium chloride in Step C. The crude material was purified by reverse phase HPLC (0-60% acetonitrile/water) to provide the title compound (16 mg, 53% yield.). MS (apci) m/z=400.1 (M+H).


Example 79



embedded image


(R)—N-cyclopropyl-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation K) and cyclopropanamine. The combined organic extracts were concentrated and the residue was purified by reverse phase HPLC (0-70% acetonitrile/water) to provide the title compound (19 mg, 57% yield.). MS (apci) m/z=397.0 (M+H).


Example 80



embedded image


(R)—N-tert-butyl-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation K). The combined organic extracts were concentrated and the residue was purified by reverse phase HPLC (0-80% acetonitrile/water) to provide the title compound (23 mg, 68% yield). MS (apci) m/z=413.0 (M+H).


Example 81



embedded image


(R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)-N-(1-fluoro-2-methylpropan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation K) and 1-fluoro-2-methylpropan-2-amine. The combined organic extracts were concentrated and the residue was purified by reverse phase HPLC (0-90% acetonitrile/water) to provide the title compound (28 mg, 78% yield). MS (apci) m/z=431.0 (M+H).


Example 82



embedded image


(R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation K) and 7N NH3 in MeOH. The combined organic extracts were concentrated and the residue was purified by reverse phase HPLC (0-80% acetonitrile/water) to provide the title compound (15 mg, 38% yield). MS (apci) m/z=357.0 (M+H).


Example 83



embedded image


(R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)-N-methoxypyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 1 using (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation K) and O-methylhydroxylamine. The combined organic extracts were concentrated and the residue was purified by reverse phase HPLC (0-80% acetonitrile/water) to yield the title compound (29 mg, 67% yield). MS (apci) m/z=387.0 (M+H).


Example 84



embedded image


(R)-1-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamido)cyclopropanecarboxylic Acid
Step A: Preparation of (R)-ethyl 1-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamido)cyclopropanecarboxylate

Using ethyl 1-aminocyclopropanecarboxylate hydrochloride (2.0 equiv) in the procedure described for the synthesis of Example 1, the title compound was obtained as a white solid (61% yield). MS (apci) m/z=456.1 (M+H).


Step B: Preparation of (R)-1-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamido)cyclopropanecarboxylic Acid

To a solution of the above ester (39 mg, 0.086 mmol) in 2:1 THF-MeOH (1.5 mL) was added 1M aq. LiOH (0.257 mL, 257 mmol) and the mixture was stirred at ambient temperature for 18 hours. The mixture was concentrated and the residual solid was dissolved in H2O (3 mL). The solution was treated with 1M HCl to pH=3. The resulting precipitate was collected, washed with water and dried in vacuum to yield the title compound as a white solid (31 mg, 83%). MS (apci) m/z=428.0 (M+H).


Example 85



embedded image


(R)—N-cyclopropyl-5-(2-(3-fluoro-5-(2-morpholinoethoxy)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 76, substituting ammonium chloride with cyclopropylamine in Step F. The crude material was purified by reverse phase HPLC (0-60% acetonitrile/water) to provide the title compound (30 mg, 99% yield.). MS (apci) m/z=495.1 (M+H).


Example 86



embedded image


(R)-5-(2-(5-fluoro-2-(2-morpholinoethoxy) phenyl) pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
Step A: Preparation of (R)-tert-butyl 2-(2-acetoxy-5-fluorophenyl)pyrrolidine-1-carboxylate

Prepared by the method as described in Preparation A, Step A, substituting 2-bromo-1,4-difluorobenzene with 2-bromo-4-fluorophenyl acetate to afford the title compound (5.75 g, 35% yield). MS (apci) m/z=224.1 (M+H−Boc).


Step B: Preparation of (R)-4-fluoro-2-(pyrrolidin-2-yl)phenol Hydrochloride

Prepared according to the procedure outlined for Example 76, Step B, to afford the title compound (2.64 g, 59.3% yield). MS (apci) m/z=182.1 (M+H).


Step C: Preparation of (R)-ethyl 5-(2-(3-fluoro-5-hydroxyphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate

Prepared by the method as described in Preparation C, Step A, using ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate and (R)-4-fluoro-2-(pyrrolidin-2-yl)phenol hydrochloride. The crude material was purified by reverse phase HPLC (0-65% acetonitrile/water) to provide the title compound (686 mg, 84% yield). MS (apci) m/z=371.0 (M+H).


Step D: Preparation of (R)-ethyl 5-(2-(3-fluoro-5-(2-morpholinoethoxy) phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate

Prepared according to the procedure described in Example 76, Step D, using (R)-ethyl 5-(2-(3-fluoro-5-hydroxyphenyl)pyrrolidin-1-yl)pyrazolo[1,5pyrimidine-3-carboxylate. The crude reaction mixture was purified by reverse phase HPLC (0-60% acetonitrile/water) to provide the title compound (250 mg, 96% yield). MS (apci) m/z=484.1 (M+H).


Step E: Preparation of (R)-5-(2-(5-fluoro-2-(2-morpholinoethoxy) phenyl) pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid Hydrochloride

To a solution of (R)-ethyl 5-(2-(3-fluoro-5-(2-morpholinoethoxy) phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (250 mg, 535 mmol) in MeOH (10 ml) was added 1N NaOH (aqueous, 6 mL). The reaction was stirred at ambient temperature for 1 week, then concentrated, treated with 4N HCl in dioxane (5 ml) and concentrated. The crude material was purified by reverse phase HPLC (0-50% acetonitrile/water) to yield the title compound. MS (apci) m/z=456.1 (M+H).


Step F: Preparation of (R)-5-(2-(5-fluoro-2-(2-morpholinoethoxy) phenyl) pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 76, Step F, using ((R)-5-(2-(5-fluoro-2-(2-morpholinoethoxy) phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid hydrochloride and ammonium chloride to yield the title compound as a white solid (42.2 mg, 91% yield.). MS (apci) m/z=455.1 (M+H).


Example 87



embedded image


(R)—N-cyclopropyl-5-(2-(5-fluoro-2-(2-morpholinoethoxy)phenyl) pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 76, Step F using ((R)-5-(2-(5-fluoro-2-(2-morpholinoethoxy)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid hydrochloride and cyclopropylamine to yield the title compound as a white solid (35.4 mg, 70% yield.). MS (apci) m/z=495.1 (M+H).


Example 88



embedded image


5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N—((S)-2,3-dihydroxypropoxy)pyrazolo[1,5-a]pyrimidine-3-carboxamide
Step A: Preparation of 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N—(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrazolo[1,5-a]pyrimidine-3-carboxamide

To a suspension of (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation C, 100 mg, 0.290 mmol) in CCl4 (1.5 mL) was added thionyl chloride (0.10 mL, 1.37 mmol) and the mixture was heated at reflux for 2.5 hours. The mixture was cooled to ambient temperature and was concentrated to give a residual brittle foam. The foam was dissolved in dry THF (2.0 mL) and the solution was sequentially treated with DMAP, DIEA and (S)—O-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)hydroxylamine (85.5 mg, 0.581 mmol). The reaction was stirred at ambient temperature for 4.5 hours and was concentrated to approx. 0.5 mL. The mixture was diluted with H2O (5 mL) and extracted with 50% EtOAc-hexanes. The combined extracts were washed with 1M HCl, H2O, 1M Na2CO3 and saturated NaCl. The solution was dried over MgSO4 and activated carbon, then filtered through a short SiO2 plug, eluting first with 50% EtOAc-hexanes then 10% MeOH-EtOAc. The MeOH-EtOAc pool was concentrated to give a colorless foam. The foam was dissolved in minimal CH2Cl2 and treated with hexanes to give a white suspension. The suspension was concentrated to afford the title compound as white solid that was dried in vacuum (137 mg, 100%). MS (apci) m/z=474.1 (M+H).


Step B: Preparation of 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N—((S)-2,3-dihydroxypropoxy)pyrazolo[1,5-a]pyrimidine-3-carboxamide

To a solution of 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N—(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy) pyrazolo[1,5-a]pyrimidine-3-carboxamide (135 mg, 0.285 mmol) in THF (4.0 mL) was added 6M HCl (1.0 mL) dropwise and the mixture was stirred at ambient temperature for 1.5 hours. The reaction mixture was concentrated to approximately 1 mL and was diluted with H2O (5 mL). The resulting milky white mixture was extracted with EtOAc and the combined extracts were washed with 1M Na2CO3 and saturated NaCl. The EtOAc solution was dried over MgSO4 and filtered through a packed Celite pad capped with a layer of MgSO4. The solution was concentrated to give a colorless foam that was dissolved in minimal CH2Cl2 and treated with hexanes to give a white suspension. The suspension was concentrated to give the title compound as a white solid that was dried in vacuum (102 mg, 82%). MS (apci) m/z=434.0 (M+H).


Example 89



embedded image


(R)-5-(2-(5-fluoro-2-(2-methoxyethoxy)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
Step A: Preparation of (R)-methyl 5-(2-(5-fluoro-2-(2-methoxyethoxy)phenyl) pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate

Prepared by the method described in Example 86, Step D, substituting 4-(2-chloroethyl)morpholine hydrochloride with 1-bromo-2-methoxyethane to afford the title compound (209 mg, 80% yield). MS (apci) m/z=415.0 (M+H).


Step B: Preparation of (R)-5-(2-(5-fluoro-2-(2-methoxyethoxy)phenyl) pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid

Prepared from (R)-methyl 5-(2-(5-fluoro-2-(2-methoxyethoxy)phenyl) pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate by the method described in Example 77, Step B to afford the title compound (163 mg, 84% yield). MS (apci) m/z=401.0 (M+H).


Step C: Preparation (R)-5-(2-(5-fluoro-2-(2-methoxyethoxy)phenyl) pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 76, Step F using (R)-5-(2-(5-fluoro-2-(2-methoxyethoxy)phenyl) pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid and ammonium chloride to yield the title compound as a white solid (32.6 mg, 55% yield.). MS (apci) m/z=400.1 (M+H).


Example 90



embedded image


(R)—N-cyclopropyl-5-(2-(5-fluoro-2-(2-methoxyethoxy)phenyl) pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 89, Step C substituting ammonium chloride with cyclopropylamine to yield the title compound as a white solid (7.9 mg, 12% yield.). MS (apci) m/z=495.1 (M+H).


Example 91



embedded image


(R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-(1-methyl cyclopropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
Step A: Preparation of tert-butyl 1-methylcyclopropylcarbamate

Diphenylphosphoryl azide (2.63 mL, 12.2 mmol) was added to a mixture of 1-methylcyclopropanecarboxylic acid (1.22 g, 12.2 mmol) and TEA (1.70 mL, 12.2 mmol) in anhydrous tert-BuOH (25 mL, 12.2 mmol) under nitrogen, followed by heating first at 50° C. for 15 minutes, then at 100° C. for 16 hours. After cooling to ambient temperature, the reaction was concentrated. The crude material was taken up in ether (50 mL), washed with saturated NaHCO3 and water (50 mL each), and dried (MgSO4), giving the crude product as white solid (0.81 g, 38% yield), which was used directly in the next step without further purification.


Step B: Preparation of 1-methylcyclopropanamine hydrochloride

A solution of 1-methylcyclopropylcarbamate (250 mg, 1.46 mmol) in HCl (4N dioxane, 3.65 mL, 14.6 mmol) was stirred at ambient temperature for 1 hour. It was then concentrated, triturated with ether, and filtered, giving the product as white solid (78 mg, 50%).


Step C: Preparation of (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-(1-methylcyclopropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

To a DMF (0.6 mL) solution of (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation I, 10.5 mg, 0.0321 mmol) and HATU (14.6 mg, 0.0385 mmol) was added 1-methylcyclopropanamine hydrochloride (4.14 mg, 0.0385 mmol) and DIEA (0.0168 mL, 0.0962 mmol). After stirring for 10 minutes, the reaction mixture was directly purified by reverse-phase chromatography (5 to 50% acetonitrile/water) to yield the final product as white solid (10 mg, 82%). LCMS (apci) m/z=381.1 (M+H).


Example 92



embedded image


(R)-(5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)(3-hydroxy-3-methylazetidin-1-yl)methanone
Step A: Preparation of 3-methylazetidin-3-ol 2,2,2-trifluoroacetate

To a solution of 1-benzhydryl-3-methylazetidin-3-ol (0.46 g, 1.82 mmol) in EtOH (15 mL) was added TFA (0.14 mL, 1.82 mmol) and Pd(OH)2/C (0.127 g, 0.182 mmol). The reaction was subjected to hydrogenation (50 psi) on a Parr shaker at ambient temperature overnight. The reaction mixture was filtered, concentrated and triturated with Et2O. The fine white solid was filtered to yield the product as a TFA salt.


Step B: Preparation of (R)-(5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)(3-hydroxy-3-methyl azetidin-1-yl)methanone

To a DMF (1.0 mL) solution of (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation I, 85 mg, 0.26 mmol) was added HATU (118 mg, 0.31 mmol) and 3-methylazetidin-3-ol 2,2,2-trifluoroacetate (63 mg, 0.31 mmol) at ambient temperature, followed by addition of DIEA (0.14 mL, 0.78 mmol) at 0° C. After stirring for 5 minutes at ambient temperature, the reaction was directly purified by reverse-phase chromatography (5 to 45% acetonitrile/water) to yield the final product as white solid (84 mg, 82%). LCMS (apci) m/z=397.1 (M+H).


Example 93



embedded image


(R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-isopropylpyrazolo[1,5-a]pyrimidine-3-carboxamide

To a DMF (1.0 mL) solution of (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation I, 80 mg, 0.244 mmol) was added HATU (112 mg, 0.293 mmol) and propan-2-amine (0.0250 ml, 0.293 mmol) at ambient temperature, followed by drop-wise addition of DIEA (0.128 ml, 0.733 mmol) at 0° C. After stirring for 5 minutes at ambient temperature, the reaction was poured into 1:1 water/saturated NaHCO3 (15 mL) and the layers were separated. The aqueous layer was extracted with EtOAc (3×15 mL). The combined organic layers were dried (Na2SO4), filtered and concentrated. The crude material was purified by reverse-phase chromatography (5 to 54% acetonitrile/water) to yield the final product as white solid (26 mg, 29%). LCMS (apci) m/z=369.1 (M+H).


Example 94



embedded image


(R)-(5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)(pyrrolidin-1-yl)methanone

To a solution of (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation I, 50 mg, 0.15 mmol) in anhydrous CH2Cl2 (2 mL) was added HOBt (41 mg, 0.31 mmol) followed by EDCI (88 mg, 0.46 mmol). The solution was stirred for 15 minutes, then treated with triethylamine (64 μL, 0.46 mmol) followed by pyrrolidine (38 μL, 0.46 mmol). After stirring at ambient temperature overnight, the reaction mixture was partitioned between saturated NH4Cl (20 mL) and CH2Cl2 (20 mL). The aqueous layer was extracted with CH2Cl2 (2×10 mL). The combined organic phases were washed with brine (10 mL), dried over Na2SO4 and concentrated. The crude material was purified by silica chromatography (2 to 5% MeOH/CH2Cl2) to yield the final product as white solid (38 mg, 65%). LCMS (apci) m/z=381.1 (M+H).


Example 95



embedded image


(R)—N-(5-fluoropyridin-2-yl)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

To a DMF (0.25 mL) solution of (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation I, 25 mg, 0.076 mmol) and HATU (35 mg, 0.092 mmol) was added 5-fluoropyridin-2-amine (10 mg, 0.092 mmol), followed by drop-wise addition of DIEA (0.040 mL, 0.23 mmol) at ambient temperature. The reaction was heated at 70° C. overnight, cooled, and directly purified by reverse-phase chromatography (5 to 66% acetonitrile/water) to yield the final product as white solid (25 mg, 78%). LCMS (apci) m/z=422.0 (M+H).


Example 96



embedded image


Step A: Preparation of 3-methoxyazetidine 2,2,2-trifluoroacetate

A solution of tert-butyl 3-methoxyazetidine-1-carboxylate (270 mg, 1.44 mmol) in 1:1 TFA/DCM (1 mL) was stirred at ambient temperature for 1 hour and concentrated. The crude product was directly used in the next step assuming quantitative yield.


Step B: Preparation of (R)-(5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)(3-methoxyazetidin-1-yl)methanone

To a DMF (0.3 mL) solution of (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation I, 30 mg, 0.092 mmol) and HATU (42 mg, 0.11 mmol) was added 3-methoxyazetidine 2,2,2-trifluoroacetate (22 mg, 0.11 mmol), followed by dropwise addition of DIEA (0.048 mL, 0.27 mmol). After stirring for 30 minutes at ambient temperature, the reaction was directly purified by reverse-phase chromatography (5 to 50% acetonitrile/water) to yield the final product as white solid (25 mg, 69%). LCMS (apci) m/z=397.1 (M+H).


Example 97



embedded image


N-(3-chloro-2-fluoropropyl)-5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

To a DMF (0.3 mL) solution of (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation I, 30 mg, 0.092 mmol) and HATU (42 mg, 0.11 mmol) was added 3-fluoroazetidine hydrochloride (12 mg, 0.11 mmol), followed by DIEA (0.048 ml, 0.27 mmol) at ambient temperature. After stirring for 2 hours, the reaction was directly purified by reverse-phase chromatography (5 to 58% acetonitrile/water) to yield the product as white solid (8.8 mg, 23%). The isolated product was presumed to result from ring-opening of the azetidine starting material. LCMS (apci) m/z=421.0 (M+H).


Example 98



embedded image


(R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-(1-(trifluoromethyl)cyclopropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
Step A: Preparation of tert-butyl 1-(trifluoromethyl)cyclopropylcarbamate

Diphenylphosphoryl azide (0.462 mL, 2.14 mmol) was added drop-wise to a stirred mixture of 1-(trifluoromethyl)cyclopropanecarboxylic acid (300 mg, 1.95 mmol), TEA (0.271 mL, 1.95 mmol) and 4 A molecular sieves in anhydrous tert-BuOH (4 mL) under nitrogen at ambient temperature. The reaction was heated to reflux for 18 hours, then cooled, filtered, and concentrated, and the residue was taken up in ether (20 mL). The organic layer was washed with saturated NaHCO3 and water (20 mL each), dried (Na2SO4), filtered and concentrated, giving the crude product as white solid (0.32 g, 72%). The crude product was used directly in the next step without further purification.


Step B: Preparation of 1-(trifluoromethyl)cyclopropanamine Hydrochloride

A solution of tert-butyl 1-(trifluoromethyl)cyclopropylcarbamate (0.3 g, 1.3 mmol) in HCl (4 N dioxane, 6.7 mL, 27 mmol) was stirred at ambient temperature overnight. The reaction was then concentrated to yield the crude product as white solid, which was used directly in the next step assuming quantitative yield.


Step C: Preparation of (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-(1-(trifluoromethyl)cyclopropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

To a DMF (0.4 mL) solution of (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation I, 50 mg, 0.15 mmol) and HATU (87 mg, 0.23 mmol) was charged 1-(trifluoromethyl)cyclopropanamine hydrochloride (37 mg, 0.23 mmol), followed by drop-wise addition of DIEA (0.080 mL, 0.46 mmol). After stirring first at ambient temperature for 15 minutes and then at 85° C. overnight, the reaction was cooled and directly purified by reverse-phase chromatography (5 to 60% acetonitrile/water) to yield the final product as off-white solid (15 mg, 23%). LCMS (apci) m/z=435.0 (M+H).


The compounds listed in Table A were prepared according to the method described in Example 91, 92, 93 or 94, by reacting (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation I) with appropriate amine starting materials in the presence of an amide coupling reagent (e.g. HATU, EDCI/HOBt) and an organic base (e.g. DIEA, TEA) in an appropriate solvent (e.g. DMF, DCM).












TABLE A





Ex. #
Structure
Chemical Name
Data







 99


embedded image


5-((R)-2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-((trans)-4- hydroxycyclohexyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 425.1 (M + H)





100


embedded image


5-((R)-2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-((cis)-4- hydroxycyclohexyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 425.1 (M + H)





101


embedded image


(R)-N-cyclobutyl-5-(2-(5- fluoropyridin-3-yl)pyrrolidin-1- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 381.1 (M + H)





102


embedded image


(R)-5-(2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-(1- methylcyclobutyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 395.1 (M + H)





103


embedded image


5-((R)-2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-((1S,2S)-2- hydroxycyclopentyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 411.1 (M + H)





104


embedded image


5-((R)-2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-((1S,2R)-2- hydroxycyclopentyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 411.1 (M + H)





105


embedded image


5-((R)-2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-((1S,3S)-3- hydroxycyclopentyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 411.1 (M + H)





106


embedded image


(R)-N-(cyclopropylmethyl)-5-(2-(5- fluoropyridin-3-yl)pyrrolidin-1- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 381.1 (M + H)





107


embedded image


(R)-5-(2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-(1- (hydroxymethyl)cyclopropyl)pyrazolo [1,5-a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 397.1 (M + H)





108


embedded image


(R)-(5-(2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)pyrazolo[1,5- a]pyrimidin-3-yl)(3- hydroxyazetid- 1-yl)methanone
LCMS (apci) m/z = 383.1 (M + H)





109


embedded image


5-((R)-2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-((S)-2- hydroxypropyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 385.1 (M + H)





110


embedded image


5-((R)-2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-((R)-2- hydroxypropyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 385.1 (M + H)





111


embedded image


(R)-5-(2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-(2-hydroxy-2- methylpropyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS(apci) m/z = 399.1 (M + H)





112


embedded image


(R)-5-(2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-(2- hydroxyethyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 371.1 (M + H)





113


embedded image


N-(1-cyclopropylethyl)-5-((R)-2-(5- fluoropyridin-3-yl)pyrrolidin-1- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 395.1 (M + H)





114


embedded image


(R)-5-(2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N- methylpyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 341.1 (M + H)





115


embedded image


5-((R)-2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-((R)-1- hydroxypropan-2-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 385.1 (M + H)





116


embedded image


5-((R)-2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-((S)-1- hydroxypropan-2-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 385.1 (M + H)





117


embedded image


(R)-5-(2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 327.0 (M + H)





118


embedded image


5-((R)-2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-(1- methoxypropan-2-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 399.1 (M + H)





119


embedded image


5-((R)-2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-(2-hydroxy-3- methoxypropyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 415.1 (M + H)





120


embedded image


5-((R)-2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-((trans)-2- hydroxycyclopentyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 411.1 (M + H)





121


embedded image


5-((R)-2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-((S)-1-hydroxy- 3-methylbutan-2-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 413.1 (M + H)





122


embedded image


5-((R)-2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-((R)-1-hydroxy- 3-methylbutan-2-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 413.1 (M + H)





123


embedded image


N-((R)-1-cyclopropylethyl)-5-((R)-2- (5-fluoropyridin-3-yl)pyrrolidin-1- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 395.1 (M + H)





124


embedded image


N-((S)-1-cyclopropylethyl)-5-((R)-2- (5-fluoropyridin-3-yl)pyrrolidin-1- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 395.1 (M + H)





125


embedded image


(R)-5-(2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-(3-hydroxy-2,2- dimethylpropyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 413.1 (M + H)





126


embedded image


(R)-azetidin-1-yl(5-(2-(5- fluoropyridin-3-yl)pyrrolidin-1- yl)pyrazolo[1,5-a]pyrimidin-3- yl)methanone
LCMS (apci) m/z = 367.1 (M + H)





127


embedded image


(R)-(5-(2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)pyrazolo[1,5- a]pyrimidin-3-yl)(3- (hydroxymethyl)azetidin-1- yl)methanone
LCMS (apci) m/z = 397.1 (M + H)





128


embedded image


(5-((R)-2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)pyrazolo[1,5- a]pyrimidin-3-yl)((S)-3- hydroxypyrrolidin-1-yl)methanone
LCMS (apci) m/z = 397.1 (M + H)





129


embedded image


5-((R)-2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-((R)-1,1,1- trifluoropropan-2-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 423.0 (M + H)





130


embedded image


5-((R)-2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-((S)-1,1,1- trifluoropropan-2-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 423.0 (M + H)





131


embedded image


(R)-5-(2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-(2,2,2- trifluoroethyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS(apci) m/z = 409.0 (M + H)





132


embedded image


(R)-5-(2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-(1-hydroxy-2- methy]propan-2-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 399.1 (M + H)





133


embedded image


5-((R)-2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-((1R,2R)-2- hydroxycyclopentyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 411.1 (M + H)





134


embedded image


(R)-N-(2,2-difluoroethyl)-5-(2-(5- fluoropyridin-3-yl)pyrrolidin-1- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 391.0 (M + H)





135


embedded image


5-((R)-2-(5-fluoropyridin-3- yl)pyrrolidin-1-y1)-N-((1R,2S)-2- hydroxycyclopentyl)pyrazolo[1,5- a]pyrimidine-3-carboxainide
LCMS (apci) m/z = 411.1 (M + H)





136


embedded image


5-((R)-2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-((1R,2R)-2- hydroxycyclohexyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 425.1 (M + H)





137


embedded image


(R)-(5-(2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)pyrazolo[1,5- a]pyrimidin-3-yl)(piperidin-1- yl)methanone
LCMS (apci) m/z = 395.1 (M + H)





138


embedded image


5-((R)-2-(5-fluoropyridin-3- yl)pyrrolidin-1-yl)-N-((2R,3S,4S)-3- (hydroxymethyl)bicyclo[2.2.1]heptan- 2-yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 451.2 (M + H)









Example 139



embedded image


(R)-(5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)(3-hydroxyazetidin-1-yl)methanone

To a DMF (0.4 mL) solution of (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation K, 30 mg, 0.084 mmol) was added HATU (38 mg, 0.10 mmol) and azetidin-3-ol hydrochloride (11 mg, 0.10 mmol) at ambient temperature, followed by dropwise addition of DIEA (0.044 ml, 0.25 mmol) at 0° C. After stirring for 20 minutes at ambient temperature, the reaction was directly purified by reverse-phase chromatography (5 to 50% acetonitrile/water) to yield the final product as white solid (26 mg, 75%). LCMS (apci) m/z=413.1 (M+H).


Example 140



embedded image


5-((R)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)-N-((trans)-4-hydroxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

To a solution of (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation K, 30 mg, 0.084 mmol) in anhydrous CH2Cl2 (2 mL) was added HOBt (34 mg, 0.25 mmol) followed by EDCI (48 mg, 0.25 mmol). The solution was stirred for 30 minutes, then treated with (trans)-4-aminocyclohexanol (29 mg, 0.25 mmol) followed by triethylamine (35 μL, 0.25 mmol). After stirring at ambient temperature for 5 hours, the reaction mixture was diluted with EtOAc, washed with saturated NH4Cl (20 mL), saturated NaHCO3, and brine, then dried (Na2SO4), filtered and concentrated. The crude material was purified by silica chromatography (4% MeOH/CH2Cl2) to yield the final product as white solid (23 mg, 60%). LCMS (apci) m/z=455.1 (M+H).


Example 141



embedded image


(R)-tert-butyl 3-(5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamido)propylcarbamate

To a mixture of (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation K, 200 mg, 0.560 mmol) and HATU (255 mg, 0.672 mmol) in DMF (2 mL) was added DIEA (292 μL, 1.68 mmol), followed by dropwise addition of tert-butyl 3-aminopropylcarbamate (117 mg, 0.672 mmol) at ambient temperature. After stirring for 3 hours, the reaction was directly purified by reverse-phase chromatography (5 to 70% acetonitrile/water) to yield the final product as white solid (250 mg, 87%). LCMS (apci) m/z=414.1 (M+H-Boc).


Example 142



embedded image


(R)—N-(3-aminopropyl)-5-(2-(5-fluoro-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

A mixture of (R)-tert-butyl 3-(5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamido)propylcarbamate (Example 141, 70 mg, 0.14 mmol) and HCl (4 N dioxane, 1.7 mL, 6.8 mmol) in a pressure reaction tube was heated at 85° C. for 12 hours then concentrated under reduced pressure. The crude material was purified by reverse-phase chromatography (5 to 40% acetonitrile/water) to yield the final product as white solid. LCMS (apci) m/z=400.1 (M+H).


Example 143



embedded image


N—((S)-2,3-dihydroxypropyl)-5-((R)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
Step A: Preparation of N—(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-5-((R)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared according to the method described in Example 140, replacing (trans)-4-aminocyclohexanol with (S)-(2,2-dimethyl-1,3-dioxolan-4-yl)methanamine. LCMS (apci) m/z=471.0 (M+H-Boc).


Step B: Preparation of N—((S)-2,3-dihydroxypropyl)-5-((R)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

To a solution of N—(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-5-((R)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (36 mg, 0.077 mmol) in THF (2 mL) was added HCl (3 N aq.) at ambient temperature. The resulting mixture was stirred for 5 hours. The reaction was diluted with EtOAc, washed with saturated NH4Cl and brine, then dried (MgSO4), filtered and concentrated. The crude material was rinsed with ether to yield the final product as white solid (30 mg, 91%). LCMS (apci) m/z=431.1 (M+H).


Example 144



embedded image


N—((S)-3-chloro-2-hydroxypropyl)-5-((R)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
Step A: Preparation of (S)-1-amino-3-chloropropan-2-ol hydrochloride

To a solution of benzaldehyde (4.50 g, 42.4 mmol) in EtOH (12 mL) was added aqueous ammonia (4.01 g, 65.9 mmol) in several portions. After stirring for 10 minutes, (S)-2-(chloromethyl)oxirane (3.81 g, 41.2 mmol) was added and the reaction mixture was stirred for 2 hours at ambient temperature. The reaction mixture was then heated at 35-40° C. with a heating mantle for 6 hours, followed by stirring at ambient temperature for 18 hours. The reaction was concentrated to 5 mL and toluene (5 mL) was added. The mixture was heated to 36° C. and a solution of concentrated HCl (6.09 g, 61.8 mmol) and water (5.9 mL) was added slowly over 5 minutes to maintain an internal reaction temperature range of 36-41° C. The biphasic mixture was heated at 42-45° C. for 3 hours. The organic phase was separated and washed with water (10 mL). The aqueous phases were combined and ethanol (10 mL) was added. The mixture was concentrated to 10 mL, and ethanol (6×10 mL) was added, concentrating after each addition. After the last concentration step, the slurry was warmed to reflux, cooled to ambient temperature, and then placed at −20° C. for 18 hours. The product was collected by vacuum filtration, washed with cold ethanol, and vacuum-dried, to provide the product as white solid (3.58 g, 60% yield).


Step B: Preparation of N—((S)-3-chloro-2-hydroxypropyl)-5-((R)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 139, replacing azetidin-3-ol hydrochloride with (S)-1-amino-3-chloropropan-2-ol hydrochloride. LCMS (apci) m/z=449.0 (M+H)


Example 145



embedded image


N—((R)-3-chloro-2-hydroxypropyl)-5-((R)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
Step A: Preparation of (R)-1-amino-3-chloropropan-2-ol Hydrochloride

Prepared by the method described in Example 144, Step A, replacing (S)-2-(chloromethyl)oxirane with (R)-2-(chloromethyl)oxirane.


Step B: Preparation of N—((R)-3-chloro-2-hydroxypropyl)-5-((R)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 139, replacing azetidin-3-ol hydrochloride with (R)-1-amino-3-chloropropan-2-ol hydrochloride. LCMS (apci) m/z=449.0 (M+H)


Example 146



embedded image


(R)—N-(2-chloroethoxy)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
Step A: Preparation of 2-(2-chloroethoxy)isoindoline-1,3-dione

A 1 L round-bottomed flask was charged 2-hydroxyisoindoline-1,3-dione (16.6 g, 98.71 mmol), followed by DMF (100 mL), then 1-bromo-2-chloroethane (25.2 mL, 296.1 mmol), and then triethylamine (42.1 mL, 296.1 mmol). After stirring at ambient temperature overnight, the reaction mixture was filtered (GF/F) and rinsed with DMF. The filtrate (250 mL) was poured into ice-water (2 L) while stirring, and the resulting precipitate was filtered, rinsed with water, and dried, yielding the crude product as a white solid (21 g). The crude product was triturated with heptane (3×400 mL), filtered and air-dried, giving the product as white solid (17.6 g, 79%).


Step B: Preparation of O-(2-chloroethyl)hydroxylamine hydrochloride

A 1 L three-necked round-bottomed flask was charged HCl (6 M aq., 295 mL, 1773 mmol), followed by 2-(2-chloroethoxy)isoindoline-1,3-dione (10 g, 44.3 mmol) with stirring. A water condenser was attached and the reaction was refluxed at 100° C. for 2 hours, then stirred at ambient temperature overnight. The reaction mixture was filtered. Absolute EtOH was added to the filtrate and filtrate was concentrated. The crude material was triturated from hot EtOH to yield the first crop of product as white solid (2.2 g). The mother liquor was concentrated and triturated as described, yielding a second crop of product (1.7) g.


Step C: Preparation of (R)—N-(2-chloroethoxy)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 139, replacing azetidin-3-ol hydrochloride with O-(2-chloroethyl)hydroxylamine hydrochloride. LCMS (apci) m/z=434.9 (M+H)


The compounds listed in Table B were prepared according to the method described in Example 139 or Example 140, by reacting (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation K) with an appropriate amine starting material in the presence of an amide coupling reagent (e.g. HATU, EDCI/HOBt) and an organic base (e.g. DIEA, TEA) in an appropriate solvent (e.g. DMF, DCM).












TABLE B





Ex. #
Structure
Chemical Name
Data







147


embedded image


(R)-(5-(2-(5-fluoro-2- methoxypyridin-3-yl)pyrrolidin-1- yl)pyrazolo[1,5-a]pyrimidin-3- yl)(3-hydroxy-3-methylazetidin-1- yl)methanone
LCMS (apci) m/z = 427.1 (M + H)





148


embedded image


(R)-5-(2-(5-fluoro-2- methoxypyridin-3-yl)pyrrolidin-1- yl)-N-(3- hydroxypropyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 415.1 (M + H)





149


embedded image


N-(2,3-dihydroxypropyl)-5-((R)-2- (5-fluoro-2-methoxypyridin-3- yl)pyrrolidin-1-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 431.1 (M + H)





150


embedded image


N-((R)-2,3-dihydroxypropyl)-5- ((R)-2-(5-fluoro-2-methoxypyridin- 3-yl)pyrrolidin-1-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 431.0 (M + H)





151


embedded image


(R)-5-(2-(5-fluoro-2- methoxypyridin-3-yl)pyrrolidin-1- yl)-N-(4- hydroxybutyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 429.1 (M + H)





152


embedded image


(R)-N-(2-tert-butoxyethoxy)-5-(2- (5-fluoro-2-methoxypyridin-3- yl)pyrrolidin-1-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 473.0 (M + H)





153


embedded image


(R)-5-(2-(5-fluoro-2- methoxypyridin-3-yl)pyrrolidin-1- yl)-N-methylpyrazolo[1,5- a]pyrimidine-3-carboxamide
MS (apci) m/z = 371.1 (M + H)





154


embedded image


5-((R)-2-(5-fluoro-2- methoxypyridin-3-yl)pyrrolidin-1- yl)-N-((1S,3S)-3- hydroxycyclopentyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
MS (apci) m/z = 441.1 (M + H)





155


embedded image


(R)-5-(2-(5-fluoro-2- methoxypyridin-3-yl)pyrrolidin-1- yl)-N-(2- hydroxyethyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
MS (apci) m/z = 401.1 (M + H)





156


embedded image


5-((R)-2-(5-fluoro-2- methoxypyridin-3-y1)pyrrolidin-1- yl)-N-((S)-2- hydroxypropyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
MS (apci) m/z = 415.1 (M + H)





157


embedded image


5-((R)-2-(5-fluoro-2- methoxypyridin-3-yl)pyrrolidin-1- yl)-N-((R)-2- hydroxypropyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
MS (apci) m/z = 415.1 (M + H)





158


embedded image


(R)-5-(2-(5-fluoro-2- methoxypyridin-3-yl)pyrrolidin-1- yl)-N-(2-hydroxy-2- methylpropyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
MS (apci) m/z = 429.1 (M + H)





159


embedded image


(R)-5-(2-(5-fluoro-2- methoxypyridin-3-yl)pyrrolidin-1- yl)-N-(1-(2- hydroxyethyl)piperidin-4- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
MS (apci) m/z = 484.2 (M + H)





160


embedded image


(R)-N-(1,3-dihydroxypropan-2-yl)- 5-(2-(5-fluoro-2-methoxypyridin-3- yl)pyrrolidin-1-y1)pyrazolo[1,5- a]pyrimidine-3-carboxamide
MS (apci) m/z = 431.1 (M + H)





161


embedded image


(R)-5-(2-(5-fluoro-2- methoxypyridin-3-yl)pyrrolidin-1- yl)-N-(6-oxo-1,6-dihydropyridin-3- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
MS (apci) m/z = 450.0 (M + H)





162


embedded image


(R)-5-(2-(5-fluoro-2- methoxypyridin-3-yl)pyrrolidin-1- yl)-N-(1-(methylsulfonyl)piperidin- 4-yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
MS (apci) m/z = 518.1 (M + H)





163


embedded image


(R)-N-(2-chloroethyl)-5-(2-(5- fluoro-2-methoxypyridin-3- yl)pyrrolidin-1-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 419.1 (M + H)





164


embedded image


(R)-N-(2-bromoethoxy)-5-(2-(5- fluoro-2-methoxypyridin-3- yl)pyrrolidin-1-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 479.0 (M + H)









The compounds listed Table C were prepared by the method described in Examples 1, 139 or 140, by reacting (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation C) with an appropriate amine starting material in the presence of an amide coupling reagent (e.g. HATU, EDCI/HOBt) and an organic base (e.g. DIEA, TEA) in an appropriate solvent (e.g. DMF, DCM).












TABLE C





Ex. #
Structure
Chemical Name
Data







165


embedded image


5-(2-(2,5-difluorophenyl)pyrrolidin- 1-yl)-N-(2- hydroxyethyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 388.1 (M + H)





166


embedded image


5-((R)-2-(2,5- difluorophenyl)pyrrolidin-1-yl)-N-(2- hydroxypropyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 402.1 (M + H)





167


embedded image


5-((R)-2-(2,5- difluorophenyl)pyrrolidin-1-yl)-N-(2- hydroxypropyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 402.1 (M + H)





168


embedded image


5-((R)-2-(2,5- difluorophenyl)pyrrolidin-1-yl)-N-(3- hydroxy-2,2- dimethylpropyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 430.2 (M + H)





169


embedded image


5-((R)-2-(2,5- difluorophenyl)pyrrolidin-1-yl)-N- ((1S,3S)-3- hydroxycyclopentyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 428.1 (M + H)





170


embedded image


5-((R)-2-(2,5- difluorophenyl)pyrrolidin-1-yl)-N-(2- (4-hydroxypiperidin-1- yl)ethyl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 471.2 (M + H)





171


embedded image


5-((R)-2-(2,5- difluorophenyl)pyrrolidin-1-yl)-N-(2- (4-methylpiperazin-1- yl)ethyl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 470.2 (M + H)





172


embedded image


5-((R)-2-(2,5- difluorophenyl)pyrrolidin-1-yl)-N-(2- methoxyethyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 402.1 (M + H)





173


embedded image


5-((R)-2-(2,5- difluorophenyl)pyrrolidin-1-yl)-N- (1,3-dihydroxypropan-2- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 418.1 (M + H)





174


embedded image


5-((R)-2-(2,5- difluorophenyl)pyrrolidin-1-yl)-N- ((2S,3R)-1,3-dihydroxybutan-2- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 432.1 (M + H)





175


embedded image


5-((R)-2-(2,5- difluorophenyl)pyrrolidin-1-yl)-N- ((2S,3S)-1,3-dihydroxybutan-2- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 432.1 (M + H)





176


embedded image


5-((R)-2-(2,5- difluorophenyl)pyrrolidin-1-yl)-N- ((2R,3S)-1,3-dihydroxybutan-2- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 432.1 (M + H)





177


embedded image


5-((R)-2-(2,5- difluorophenyl)pyrrolidin-1-yl)-N- ((S)-1-hydroxypropan-2- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 402.1 (M + H)





178


embedded image


5-((R)-2-(2,5- difluorophenyl)pyrrolidin-1-yl)-N- ((S)-1-hydroxybutan-2- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 416.1 (M + H)





179


embedded image


5-((R)-2-(2,5- difluorophenyl)pyrrolidin-1-yl)-N- ((S)-1-hydroxy-3-methylbutan-2- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 430.1 (M + H)





180


embedded image


5-((R)-2-(2,5- difluorophenyl)pyrrolidin-1-yl)-N- ((S)-1-hydroxy-3,3-dimethylbutan-2- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 444.2 (M + H)









Example 181



embedded image


N-cyclopropyl-5-(2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

To a solution of (R)-5-(2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation O, 50 mg, 0.15 mmol) in DCM (2 mL) was added HOBt (40 mg, 0.29 mmol) followed by EDCI (84 mg, 0.44 mmol). The solution was stirred at ambient temperature for 15 minutes, then treated with triethylamine (61 μL, 0.44 mmol) followed by cyclopropylamine (31 μL, 0.44 mmol). After stirring for 16 hours the mixture was partitioned between saturated NH4Cl solution (20 mL) and DCM (20 mL) and the aqueous layer was extracted with DCM (2×10 mL). The combined organic phases were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography, eluting with 2-4% MeOH/DCM, to afford the title product as white solid (44 mg, 79%). MS (apci) m/z=381.1 (M+H).


Example 182



embedded image


N-cyclopropyl-5-(2-(2-ethyl-5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared according to the method of Example 181, substituting (R)-5-(2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid with (R)-5-(2-(2-ethyl-5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation Q). MS (apci) m/z=395.1 (M+H).


The compounds listed in Table D were prepared by the method described in Example 181 or 182, by reacting (R)-5-(2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation O) or (R)-5-(2-(2-ethyl-5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation Q) with an appropriate amine starting material in the presence of an amide coupling reagent (e.g. EDCI/HOBt) and an organic base (e.g. TEA) in an appropriate solvent (e.g. DCM).












TABLE D





Ex. #
Structure
Chemical Name
Data







183


embedded image


(R)-N-tert-butyl-5-(2-(5-fluoro-2- methylpyridin-3-yl)pyrrolidin-1- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 397.1 (M + H)





184


embedded image


(R)-5-(2-(5-fluoro-2-methylpyridin- 3-yl)pyrrolidin-1-yl)-N- isopropylpyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 383.1 (M + H)





185


embedded image


(R)-N-cyclobutyl-5-(2-(5-fluoro-2- methylpyridin-3-yl)pyrrolidin-1- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 395.1 (M + H)





186


embedded image


(R)-5-(2-(5-fluoro-2-methylpyridin- 3-yl)pyrrolidin-1-yl)-N- methylpyrazolo[1,5-a]pyrimidine- 3-carboxamide
LCMS (apci) m/z = 355.1 (M + H)





187


embedded image


(R)-5-(2-(5-fluoro-2-methylpyridin- 3-yl)pyrrolidin-1-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 341.0 (M + H)





188


embedded image


(R)-5-(2-(5-fluoro-2-methylpyridin- 3-yl)pyrrolidin-1-yl)-N-(2- hydroxyethyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 385.1 (M + H)





189


embedded image


(R)-5-(2-(5-fluoro-2-methylpyridin- 3-yl)pyrrolidin-1-yl)-N-((R)-2- hydroxypropyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 399.1 (M + H)





190


embedded image


(R)-5-(2-(5-fluoro-2-methylpyridin- 3-yl)pyrrolidin-1-yl)-N-(1- methylcyclopropyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 395.1 (M + H)





191


embedded image


(R)-5-(2-(5-fluoro-2-methylpyridin- 3-yl)pyrrolidin-1-yl)-N-(2- methoxyethyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 399.1 (M + H)





192


embedded image


(R)-(5-(2-(5-fluoro-2- methylpyridin-3-yl)pyrrolidin-1- yl)pyrazolo[1,5-a]pyrimidin-3- yl)(3-hydroxyazetidin-1- yl)methanone
LCMS (apci) m/z = 397.1 (M + H)





193


embedded image


(R)-5-(2-(5-fluoro-2-methylpyridin- 3-yl)pyrrolidin-1-yl)-N-(1- (hydroxymethyl)cyclopropyl)- pyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 411.1 (M + H)





194


embedded image


5-((R)-2-(5-fluoro-2-methylpyridin- 3-yl)pyrrolidin-1-yl)-N-((trans)-4- hydroxycyclohexyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 439.1 (M + H)





195


embedded image


5-((R)-2-(5-fluoro-2-methylpyridin- 3-yl)pyrrolidin-1-yl)-N-((cis)-4- hydroxycyclohexyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 439.2 (M + H)





196


embedded image


5-((R)-2-(5-fluoro-2-methylpyridin- 3-yl)pyrrolidin-1-yl)-N-((1S,3S)-3- hydroxycyclopentyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 425.1 (M + H)





197


embedded image


5-((R)-2-(5-fluoro-2-methylpyridin- 3-yl)pyrrolidin-1-yl)-N-((1R,2R)-2- hydroxycyclopentyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 425.1 (M + H)





198


embedded image


5-((R)-2-(5-fluoro-2-methylpyridin- 3-yl)pyrrolidin-1-yl)-N-((R)- quinuclidin-3-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 450.2 (M + H)





199


embedded image


5-((R)-2-(2-ethyl-5-fluoropyridin- 3-yl)pyrrolidin-1-yl)-N-((trans)-4- hydroxycyclohexyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 453.2 (M + H)





200


embedded image


5-((R)-2-(2-ethyl-5-fluoropyridin- 3-yl)pyrrolidin-1-yl)-N-((1S,3S)-3- hydroxycyclopentyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 439.1 (M + H)





201


embedded image


(R)-5-(2-(2-ethyl-5-fluoropyridin- 3-yl)pyrrolidin-1-yl)-N-(2-hydroxy- 2-methylpropyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 427.1 (M + H)









Example 202



embedded image


(R)—N-tert-butyl-5-(2-(5-fluoro-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

A pressure flask was charged with (R)—N-tert-butyl-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (Example 80, 10 mg, 0.024 mmol), dioxane (0.7 mL) and 2M HCl (0.100 mL, 0.200 mmol). The flask was sealed and the reaction mixture was stirred at 80° C. for 5 days. The mixture was cooled to ambient temperature and concentrated. The residue was purified by reverse-phase column chromatography (0-50% acetonitrile/water) to afford the title compound (8.2 mg, 85%). MS (apci) m/z=399.1 (M+H).


Example 203



embedded image


(R)—N-(2-chloroethyl)-5-(2-(5-fluoro-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 202, replacing (R)—N-tert-butyl-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide with (R)—N-(2-chloroethyl)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (Example 163, 100 mg, 0.239 mmol), replacing 2 M HCl with 4 M HCl dioxane solution, and reaction was conducted at 100° C. for 90 minutes. LCMS (apci) m/z=405.0 (M+H).


Example 204



embedded image


N-cyclopropyl-5-((2R)-2-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
Step A: Preparation of ethyl 5-((2R)-2-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate

A mixture of (R)-ethyl 5-(2-(5-fluoro-2-hydroxyphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (Example 86, Step C, 140 mg, 0.378 mmol), 4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane (114 mg, 0.756 mmol), potassium carbonate (261 mg, 1.89 mmol) and sodium bromide (77.8 mg, 0.756 mmol) in dry DMF (5 mL) was heated at 100° C. for 14 days. The mixture was concentrated and the residue purified by chromatography to afford the title compound (45 mg, 25% yield). MS (apci) m/z=485.0 (M+H).


Step B: Preparation of 5-((2R)-2-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid

The compound was prepared according to the method of Example 86, Step E, using ethyl 5-((2R)-2-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (47 mg, 100%). MS (apci) m/z=457.0 (M+H).


Step C: Preparation of N-cyclopropyl-5-((2R)-2-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared according to the method of Example 86, Step F, using 5-((2R)-2-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid and cyclopropyl amine to yield the title compound as a white solid (33.0 mg, 99% yield.). MS (apci) m/z=496.1 (M+H).


Example 205



embedded image


5-((2R)-2-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared according to the procedure described in Example 204 using ammonium chloride in place of cyclopropyl amine in Step C (white solid, 13 mg, 85% yield.). MS (apci) m/z=456.0 (M+H).


Example 206



embedded image


N-cyclopropyl-5-((2R)-2-(3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared according to the method of Example 204 using (R)-ethyl 5-(2-(3-fluoro-5-hydroxyphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (Example 76, Step C) in Step A (36 mg, 82% yield). MS (apci) m/z=496.1 (M+H).


Example 207



embedded image


5-((2R)-2-(3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared according to the method of Example 204, using (R)-ethyl 5-(2-(3-fluoro-5-hydroxyphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (Example 76, Step C) in Step A and ammonium chloride in Step C to yield the title compound as a white solid (19 mg, 55% yield.). MS (apci) m/z=456.0 (M+H).


Example 208



embedded image


N-cyclopropyl-5-((2R)-2-(3-(2,3-dihydroxypropoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

A solution of N-cyclopropyl-5-((2R)-2-(3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (Example 206, 30 mg, 0.061 mmol) in dioxane (0.5 mL) was charged with two drops of 6N HCl and shaken for two minutes. DIEA (5 drops) was added and the mixture directly purified by reverse phase column chromatography (0-50% acetonitrile/water) to afford N-cyclopropyl-5-((2R)-2-(3-(2,3-dihydroxypropoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (23 mg, 83% yield) as a clear film. MS (apci) m/z=456.1 (M+H).


Example 209



embedded image


5-((2R)-2-(3-(2,3-dihydroxypropoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared from 5-((2R)-2-(3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (Example 207) according to the procedure of Example 208 (8.5 mg, 55% yield). MS (apci) m/z=416.0 (M+H).


Example 210



embedded image


N-cyclopropyl-5-((2R)-2-(2-(2,3-dihydroxypropoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared from N-cyclopropyl-5-((2R)-2-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (Example 204) using the procedure of Example 208 (19 mg, 65% yield). MS (apci) m/z=456.1 (M+H).


Example 211



embedded image


5-((2R)-2-(2-(2,3-dihydroxypropoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared from 5-((2R)-2-(3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (Example 205) using the procedure of Example 208 (10 mg, 95% yield). MS (apci) m/z=416.0 (M+H).


Example 212



embedded image


5-((2R,5S)-2-(5-fluoropyridin-3-yl)-5-(hydroxymethyl)pyrrolidin-1-yl)-N—((R)-1,1,1-trifluoropropan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
Step A: Preparation of (S)-ethyl 2-(tert-butoxycarbonylamino)-5-(5-fluoropyridin-3-yl)-5-oxopentanoate

A solution of 3-bromo-5-fluoropyridine (4.28 g, 24.3 mmol) in dry THF (25 mL) was cooled to −40 to −50° C. and 2M isopropylmagnesium chloride in THF (10.2 mL, 20.4 mmol) was added. The mixture was allowed to warm to 0° C. and was stirred for 30 minutes. The mixture was cooled to −20° C. and a solution of (S)-1-tert-butyl 2-ethyl 5-oxopyrrolidine-1,2-dicarboxylate (5.00 g, 19.4 mmol) in dry THF (15 mL) was added. The mixture was allowed to reach ambient temperature over 30 minutes and was stirred at ambient temperature for 30 minutes. The reaction was slowly quenched with 2M HCl (10 mL, 20.0 mmol) followed by 10% aqueous NH4Cl (10 mL). The mixture was stirred for 10 minutes and was transferred to a separatory funnel using MTBE rinses (10 mL). Heptane (15 mL) was added and the organic layer was removed. The organic layer was washed 10% aqueous NH4Cl (25 mL) and DI H2O (25 mL). The organic layer was concentrated to provide the crude product as a yellow oil (7.03 g, 102%).


Step B: Preparation of (2S,5R)-ethyl 5-(5-fluoropyridin-3-yl)pyrrolidine-2-carboxylate

(S)-ethyl 2-(tert-butoxycarbonylamino)-5-(5-fluoropyridin-3-yl)-5-oxopentanoate (4.80 g, 13.55 mmol) was treated with TFA (24 mL) and the mixture was stirred at ambient temperature for 45 minutes. The mixture was concentrated and the residue was dissolved in H2O (10 mL) and EtOAc (50 mL) was added. The mixture was treated slowly with saturated aqueous K2CO3 (15 mL). The aqueous layer was separated and the organic layer was washed with 10% aqueous NH4Cl. The EtOAc layer was concentrated to give crude (S)-ethyl 5-(5-fluoropyridin-3-yl)-3,4-dihydro-2H-pyrrole-2-carboxylate as an amber oil (2.67 g, 83% yield). The oil was dissolved in isopropyl alcohol (20 mL) and was treated with 10% Pd/C (0.266 g, 0.250 mmol). The reaction vessel was purged with hydrogen gas (3×) and mixture was stirred at ambient temperature under 1 atm of hydrogen for 16 hours. The reaction was purged with nitrogen and filtered through a Celite pad. The filtrate was concentrated to furnish the title compound as an amber oil that began to solidify upon standing (2.58 g, 96%).


Step C: Preparation of ((2S,5R)-5-(5-fluoropyridin-3-yl)pyrrolidin-2-yl)methanol

To a solution of (2S,5R)-ethyl 5-(5-fluoropyridin-3-yl)pyrrolidine-2-carboxylate (1.10 g, 4.62 mmol) in dry THF (20 mL) was added 2M LiAlH4 in THF (3.00 mL, 6.00 mmol). The reaction was stirred at ambient temperature for 30 minutes and Na2SO4 10H2O (3.00 g, 9.31 mmol) was added in small portions. The mixture was stirred for 3 hours at ambient temperature and was filtered. The collected solid was washed with EtOAc and the washes combined with the filtrate. The solution was concentrated to provide crude ((2S,5R)-5-(5-fluoropyridin-3-yl)pyrrolidin-2-yl)methanol (0.95 g, 105% yield) that was used directly in the next step. MS (apci) m/z=197.1 (M+H).


Step D: Preparation of ethyl 5-((2R,5S)-2-(5-fluoropyridin-3-yl)-5-(hydroxymethyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate

A mixture of ((2S,5R)-5-(5-fluoropyridin-3-yl)pyrrolidin-2-yl)methanol (0.910 g, 4.64 mmol), ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (Preparation B, 1.05 g, 4.64 mmol) and DIEA (1.10 mL, 6.00 mmol) in isopropyl alcohol (1.0 mL) was heated at 90° C. for 16 hours. The reaction mixture was concentrated and the residue was purified by reverse phase column chromatography (0-50% acetonitrile/water) followed by normal phase column chromatography (2-5% MeOH/DCM) to afford ethyl 5-((2R,5S)-2-(5-fluoropyridin-3-yl)-5-(hydroxymethyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (0.250 g, 14% yield) as a viscous, clear oil. MS (apci) m/z=386.0 (M+H).


Step E: Preparation of 5-((2R,5S)-2-(5-fluoropyridin-3-yl)-5-(hydroxymethyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid

A mixture of ethyl 5-((2R,5S)-2-(5-fluoropyridin-3-yl)-5-(hydroxymethyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (0.250 g, 0.649 mmol) and 2M sodium hydroxide (3.24 mL, 6.48 mmol) in MeOH (10 mL) was stirred at ambient temperature for 4 days followed by 50° C. for 5 hours. The reaction was cooled to ambient temperature and 4M HCl in dioxane (1.78 mL, 7.14 mmol) was added. The mixture was concentrated and the residue was purified by reverse phase column chromatography (0-40% acetonitrile/water) to afford 5-((2R,5S)-2-(5-fluoropyridin-3-yl)-5-(hydroxymethyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (210 mg, 90% yield) as a white solid. MS (apci) m/z=358.0 (M+H).


Step F: Preparation of 5-((2R,5S)-2-(5-fluoropyridin-3-yl)-5-(hydroxymethyl)pyrrolidin-1-yl)-N—((R)-1,1,1-trifluoropropan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

To a mixture of 5-((2R,5S)-2-(5-fluoropyridin-3-yl)-5-(hydroxymethyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (10.0 mg, 0.028 mmol), (R)-1,1,1-trifluoropropan-2-amine (6.33 mg, 0.056 mmol) and HATU (10.5 mg, 0.045 mmol) in dry DMF (0.2 mL) was added DIEA (15.0 μL, 0.084 mmol). The reaction vessel was flushed with nitrogen, sealed, and the reaction stirred at ambient temperature for 16 hours. The reaction mixture was directly purified by reverse phase column chromatography (0-50% CH3CN/H2O) to provide the title compound (6.50 mg, 51% yield) as a white solid. MS (apci) m/z=453.0 (M+H).


Example 213



embedded image


5-((2R,5S)-2-(5-fluoropyridin-3-yl)-5-(hydroxymethyl)pyrrolidin-1-yl)-N—((S)-1,1,1-trifluoropropan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared according to the method of Example 212, Step F, using (S)-1,1,1-trifluoropropan-2-amine (white solid; 5.5 mg, 43%). MS (apci) m/z=453.0 (M+H).


Example 214



embedded image


5-((2R,5S)-2-(5-fluoropyridin-3-yl)-5-(hydroxymethyl)pyrrolidin-1-yl)-N-(1-methylcyclopropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared according to the method of Example 212, Step F, using 1-methylcyclopropane amine (white solid; 2.5 mg, 22%). MS (apci) m/z=411.1 (M+H).


Example 215



embedded image


5-((2R,5S)-2-(5-fluoropyridin-3-yl)-5-(hydroxymethyl)pyrrolidin-1-yl)-N-isopropylpyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared according to the method of Example 212, Step F, using isopropyl amine (white solid; 2.5 mg, 12%). MS (apci) m/z=399.1 (M+H).


Example 216



embedded image


5-((2R,4S)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)-N—((S)-1,1,1-trifluoropropan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
Step A: Preparation of (ethyl 5-((2R,4S)-4-acetoxy-2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate

To a mixture of ethyl 5-((2R,4R)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (Example 41, Step E, 260 mg, 0.702 mmol) and PPh3 (460 mg, 1.75 mmol) in THF (10.0 mL) was added DIAD (276 μL, 1.40 mmol) followed by acetic acid (80.4 μL, 1.40 mmol). The reaction was stirred at ambient temperature for 48 hours and then concentrated. The residue was purified by reverse phase column chromatography (0-70% acetonitrile/water) to afford ethyl 5-((2R,4S)-4-acetoxy-2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (228 mg, 79% yield). MS (apci) m/z=413.0 (M+H).


Step B: Preparation of 5-((2R,4S)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid

A mixture of ethyl 5-((2R,4S)-4-acetoxy-2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (225 mg, 0.546 mmol) and NaOH (131 mg, 1.64 mmol) in MeOH (1.0 mL) was stirred at ambient temperature for 60 hours followed by 3 hours at 60° C. The mixture was cooled to ambient temperature and 4M HCl in dioxane (1 mL) was added. The mixture was concentrated and the residue was treated with DCM. The mixture was filtered through Celite and concentrated to afford 5-((2R,4S)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (188 mg, 10% yield) as a white solid. MS (apci) m/z=343.0 (M+H).


Step C: Preparation of 5-((2R,4S)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)-N—((S)-1,1,1-trifluoropropan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared according to the method of Example 212, Step F, using 5-((2R,4S)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid and (S)-1,1,1-trifluoropropan-2-amine (white solid; 2.1 mg, 16% yield). MS (apci) m/z=438.0 (M+H).


Example 217



embedded image


5-((2R,4S)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)-N-isopropylpyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared according to the method of Example 212, Step F, using 5-((2R,4S)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Example 216, Step B) and isopropyl amine. The title compound was obtained as a white solid (5.5 mg, 49% yield). MS (apci) m/z=384.1 (M+H).


Example 218



embedded image


5-((2R,4S)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)-N-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared according to the method of Example 212, Step F, using 5-((2R,4S)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Example 216, Step B) and methyl amine. The title compound was obtained as a white solid (6.1 mg, 29% yield). MS (apci) m/z=356.1 (M+H).


Example 219



embedded image


5-((2 S, 5R)-5-(5-fluoropyridin-3-yl)-2-(hydroxymethyl)-2-methylpyrrolidin-1-yl)-N-isopropylpyrazolo[1,5-a]pyrimidine-3-carboxamide
Step A: Preparation of (2S,5R)-1-tert-butyl 2-ethyl 5-(5-fluoropyridin-3-yl)pyrrolidine-1,2-dicarboxylate

A mixture of (2S,5R)-ethyl 5-(5-fluoropyridin-3-yl)pyrrolidine-2-carboxylate (Example 212, Step B, 1.00 g, 4.20 mmol), di-tert-butyl dicarbonate (0.962 g, 4.41 mmol) and PS-DMAP (0.210 g, 0.210 mmol, 1.00 mmol/g load) in dry DCM (20 mL) was mixed at ambient temperature for 18 hours. The reaction mixture was filtered and the filtrate was concentrated. The residue was purified on a silica gel column (2-10% MeOH/DCM) to afford (2S,5R)-1-tert-butyl 2-ethyl 5-(5-fluoropyridin-3-yl)pyrrolidine-1,2-dicarboxylate (1.36 g, 96% yield) as a yellow oil. MS (apci) m/z=339.0 (M+H).


Step B: Preparation of (2S,5R)-1-tert-butyl 2-ethyl 5-(5-fluoropyridin-3-yl)-2-methylpyrrolidine-1,2-dicarboxylate

A solution of (2S,5R)-1-tert-butyl 2-ethyl 5-(5-fluoropyridin-3-yl)pyrrolidine-1,2-dicarboxylate (250 mg, 0.739 mmol) in THF (10 mL) was cooled to −78° C. and 0.5 M KHMDS in toluene (1.77 mL, 0.885 mmol) was added dropwise. The reaction was stirred for 1 hour at −78° C. and MeI (59.9 μL, 0.960 mmol) was added. The reaction was allowed to warm to ambient temperature and saturated aqueous NaCl (20 mL) was added. The mixture was extracted with EtOAc (2×50 mL) and the combined organic extracts were filtered and concentrated to afford (2S,5R)-1-tert-butyl 2-ethyl 5-(5-fluoropyridin-3-yl)-2-methylpyrrolidine-1,2-dicarboxylate (255 mg, 98% yield) as a clear oil. MS (apci) m/z=353.1 (M+H).


Step C: Preparation of (2S,5R)-tert-butyl 5-(5-fluoropyridin-3-yl)-2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate

A solution of (2S,5R)-1-tert-butyl 2-ethyl 5-(5-fluoropyridin-3-yl)-2-methylpyrrolidine-1,2-dicarboxylate (240 mg, 0.681 mmol) in THF (10 mL) was cooled to −78° C. and 1M LiAlH4 in THF (1.50 mL, 1.50 mmol) was added dropwise. The reaction was allowed to warm to 0° C. and was quenched with small portions of Na2SO4-10H2O (967 mg, 6.81 mmol). The mixture was filtered and concentrated to afford (2S,5R)-tert-butyl 5-(5-fluoropyridin-3-yl)-2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate (200 mg, 95% yield). MS (apci) m/z=311.1 (M+H).


Step D: Preparation of ((2S,5R)-5-(5-fluoropyridin-3-yl)-2-methylpyrrolidin-2-yl)methanol Hydrochloride

To a solution of (2S,5R)-tert-butyl 5-(5-fluoropyridin-3-yl)-2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate (200 mg, 0.644 mmol) in DCM (5 mL) was added 4M HCl in dioxane (1.61 mL, 6.44 mmol). The reaction was stirred at ambient temperature for 16 hours and then concentrated to afford ((2S,5R)-5-(5-fluoropyridin-3-yl)-2-methylpyrrolidin-2-yl)methanol hydrochloride (130 mg, 96% yield). MS (apci) m/z=211.1 (M+H).


Step E: Preparation of ethyl 5-((2S,5R)-5-(5-fluoropyridin-3-yl)-2-(hydroxymethyl)-2-methylpyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate

A sealed reaction vessel was charged with ((2S,5R)-5-(5-fluoropyridin-3-yl)-2-methylpyrrolidin-2-yl)methanol hydrochloride (0.135 g, 0.547 mmol), ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (Preparation B, 0.136 g, 0.602 mmol), DIEA (0.124 mL, 0.711 mmol) and isopropyl alcohol (1 mL). The vessel was sealed and the mixture was heated at 190° C. for 48 hours. The reaction was cooled to ambient temperature and concentrated. The residue was purified by reverse phase column chromatography (0-50% acetonitrile/water) to afford ethyl 5-((2S,5R)-5-(5-fluoropyridin-3-yl)-2-(hydroxymethyl)-2-methylpyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (55 mg, 25% yield) as a viscous clear oil. MS (apci) m/z=400.1 (M+H).


Step F: Preparation of 5-((2S,5R)-5-(5-fluoropyridin-3-yl)-2-(hydroxymethyl)-2-methylpyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid

A mixture of ethyl 5-((2S,5R)-5-(5-fluoropyridin-3-yl)-2-(hydroxymethyl)-2-methylpyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (52.0 mg, 0.130 mmol) and NaOH (26.0 mg, 0.325 mmol) in MeOH (1.0 mL) was stirred at ambient temperature for 60 hours. The reaction was treated with HCl (4 N dioxane, 163 μL, 0.651 mmol) and concentrated. The residue was treated with DCM and filtered through Celite. The solution was concentrated to afford 5-((2S,5R)-5-(5-fluoropyridin-3-yl)-2-(hydroxymethyl)-2-methylpyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (29 mg, 60% yield) as a white solid. MS (apci) m/z=372.0 (M+H).


Step G: Preparation of 5-((2S,5R)-5-(5-fluoropyridin-3-yl)-2-(hydroxymethyl)-2-methylpyrrolidin-1-yl)-N-isopropylpyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared according to the method of Example 212, Step F, using 5-((2S,5R)-5-(5-fluoropyridin-3-yl)-2-(hydroxymethyl)-2-methylpyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid and isopropyl amine. The title compound was obtained as a white solid (7.2 mg, 46% yield). MS (apci) m/z=413.1 (M+H).


Example 220



embedded image


5-((2S,5R)-5-(5-fluoropyridin-3-yl)-2-(hydroxymethyl)-2-methylpyrrolidin-1-yl)-N—((S)-1,1,1-trifluoropropan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared according to the method of Example 212, Step F, using 5-((2S,5R)-5-(5-fluoropyridin-3-yl)-2-(hydroxymethyl)-2-methylpyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Example 219, Step F) and (S)-1,1,1-trifluoropropan-2-amine. The title compound was obtained as a white solid (5.4 mg, 31% yield). MS (apci) m/z=467.1 (M+H).


Example 221



embedded image


(R)-(5-(2-(2-amino-5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)(azetidin-1-yl)methanone

A mixture of (R)—N-(3-aminopropyl)-5-(2-(5-fluoro-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride (Example 142, 83 mg, 0.190 mmol) and POCl3 (697 μL, 7.62 mmol) was sealed and heated at 100° C. for 5 minutes. The reaction mixture was diluted with 1 mL heptane and azeotroped twice to yield the crude product. The crude material was purified by reverse-phase chromatography (5 to 40% acetonitrile/water) to yield the title product as white solid (2 mg, 3%). LCMS (apci) m/z=382.3 (M+H).


Example 222



embedded image


(R)-tert-butyl 3-(5-(2-(2-chloro-5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamido)propylcarbamate
Step A: Preparation of (R)-tert-butyl 2-(2-chloro-5-fluoropyridin-3-yl)pyrrolidine-1-carboxylate

A solution of tert-butyl pyrrolidine-1-carboxylate (1 mL 5.70 mmol) and (−)-sparteine (1.31 mL, 5.70 mmol) in anhydrous MTBE (30 mL) was first cooled to −78° C. under nitrogen, followed by addition of sec-butyl lithium (4.07 mL, 1.4M, 5.70 mmol) drop-wise over 15 minutes with a syringe, maintaining the temperature below −75° C. The pale yellowish solution was stirred at −78° C. for 3 hours before being treated with zinc chloride (3.80 mL, 1.0 M, 3.80 mmol) dropwise over 15 minutes while maintaining the temperature below −73° C. The mixture was stirred at −78° C. for 30 minutes, then placed into an ambient temperature water bath and stirred for another hour. At this point a large amount of white precipitate was present. The mixture was treated with 3-bromo-2-chloro-5-fluoropyridine (1.00 g, 4.75 mmol) in MTBE (5 mL), followed by addition of palladium acetate (53 mg, 0.24 mmol) and tri-t-butylphosphine tetrafluoroborate (83 mg, 0.28 mmol). The mixture was allowed to stir at ambient temperature overnight to reach completion. The mixture was treated with NH4OH (1 mL), stirred for 30 minutes and filtered through GF/F paper, washing with MTBE. The filtrate was washed with 10% citric acid (30 mL) and the aqueous layer was back-washed with MTBE (2×30 mL). The combined organic phases were washed with brine (20 mL), dried (MgSO4), and concentrated to afford the crude product as dark yellowish oil. This crude material was purified on a silica 50 g Biotage SNAP cartridge eluting with 10% EtOAc in hexanes to afford the desired product as colorless oil (0.5 g, 35%). MS (apci pos) m/z=201.1 (M+H-Boc).


Step B: Preparation of (R)-2-chloro-5-fluoro-3-(pyrrolidin-2-yl)pyridine Dihydrochloride

To a dioxane (5 mL) solution of (R)-tert-butyl 2-(2-chloro-5-fluoropyridin-3-yl)pyrrolidine-1-carboxylate (500 mg, 1.66 mmol) was added HCl (4 N dioxane, 20 mL), followed by stirring at ambient temperature overnight. The mixture was concentrated and treated with Et2O, then vacuum-dried, to provide the product as a white solid (0.36 g, 80%). MS (apci pos) m/z=201.1 (M+H). The enantiomeric excess (ee %) of the product was determined to be >92% according to the method described in Preparation A.


Step C: Preparation of (R)-ethyl 5-(2-(2-chloro-5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate

To a solution of ethyl 5-hydroxypyrazolo[1,5-a]pyrimidine-3-carboxylate (Preparation B, Step A, 275 mg, 1.33 mmol) in anhydrous DMF (5 mL) was added (Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) (646 mg, 1.46 mmol). The heterogeneous mixture was stirred for 10 minutes before adding DIEA (1.16 mL, 6.6 mmol), followed by addition of (R)-2-chloro-5-fluoro-3-(pyrrolidin-2-yl)pyridine dihydrochloride (363 mg, 1.33 mmol). The reaction was stirred at ambient temperature overnight to reach completion. The mixture was partitioned between 10% citric acid (30 mL) and EtOAc (30 mL), and the aqueous layer was extracted with EtOAc (2×20 mL). The combined organic phases were washed successively with water (20 mL), saturated NaHCO3 (20 mL), water (20 mL) and brine (3×20 mL), then dried (Na2SO4) and concentrated to afford the crude product as an orange foam. The crude material was purified on a 25 g Biotage SNAP silica cartridge eluting with 1% MeOH/DCM to afford the desired product as cream-colored foam (0.35 g, 68%). MS (apci pos) m/z=390.0 (M+H).


Step D: Preparation of (R)-5-(2-(2-chloro-5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid

Prepared by the method described in Preparation C, Step B, replacing (R)-ethyl 5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate with (R)-ethyl 5-(2-(2-chloro-5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate. MS (apci pos) m/z=361.9 (M+H).


Step E: Preparation of (R)-tert-butyl 3-(5-(2-(2-chloro-5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamido)propylcarbamate

Prepared according to the method described in Example 141, replacing (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid with (R)-5-(2-(2-chloro-5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid to yield the title product as white solid. LCMS (apci pos) m/z=418.2 (M+H-Boc).


Example 223



embedded image


(R)—N-(3-aminopropyl)-5-(2-(2-chloro-5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

A mixture of (R)-tert-butyl 3-(5-(2-(2-chloro-5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamido)propylcarbamate (Example 222, 6 mg, 0.012 mmol) and HCl (4 N dioxane, 145 μL, 0.58 mmol) was stirred at ambient temperature for 2 hours and concentrated to yield the product as white solid. LCMS (apci pos) m/z=418.1 (M+H).


Example 224



embedded image


(R)—N-(2-tert-butoxyethoxy)-5-(2-(2-chloro-5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared according to the method described in Example 222, Step E, replacing tert-butyl 3-aminopropylcarbamate with O-(2-tert-butoxyethyl)hydroxylamine hydrochloride to yield the title product as white solid (58 mg, 87%). LCMS (apci) m/z=476.9 (M+H).


Example 225



embedded image


(R)-5-(2-(2-chloro-5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-(2-hydroxyethoxy)pyrazolo[1,5-a]pyrimidine-3-carboxamide

(R)—N-(2-tert-butoxyethoxy)-5-(2-(2-chloro-5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (Example 224, 57 mg, 0.120 mmol) was treated with HCl (4 N dioxane, 1.49 mL, 5.98 mmol), followed by two drops of MeOH to make a clear colorless solution. After stirring 30 minutes at ambient temperature, the reaction was concentrated and dried to yield the title product as white solid, assuming quantitative yield. LCMS (apci) m/z=421.0 (M+H)


Example 226



embedded image


(R)—N-tert-butyl-5-(2-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

Prepared by the method described in Example 140, using (R)-5-(2-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation R) and 2-methylpropan-2-amine. The residue was purified by silica column chromatography, eluting with 3% MeOH/DCM to yield the title compound (26 mg, 75% yield). MS (apci) m/z=413.1 (M+H).


The compounds listed in the following Table were also prepared according to the method described in Example 140, by reacting (R)-5-(2-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation R) with the appropriate amine starting material in the presence of an amide coupling reagent (e.g. EDCI/HOBt), an organic base (for example, TEA) in a solvent (for example, DCM).












TABLE E





Ex. #
Structure
Chemical Name
Data







227


embedded image


(R)-5-(2-(5-fluoro-1-methyl-2-oxo- 1,2-dihydropyridin-3-yl)pyrrolidin-1- yl)-N-isopropylpyrazolo[1,5- a]pyrimidine-3-carboxamide
MS (apci) m/z = 399.1 (M + H)





228


embedded image


(R)-N-cyclopropyl-5-(2-(5-fluoro-1- methyl-2-oxo-1,2-dihydropyridin-3- yl)pyrrolidin-1-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
MS (apci) m/z = 397.1 (M + H)





229


embedded image


(R)-5-(2-(5-fluoro-1-methyl-2-oxo- 1,2-dihydropyridin-3-yl)pyrrolidin-1- yl)-N-(6-methylpyridin-3- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
MS (apci) m/z = 448.1 (M + H)





230


embedded image


(R)-N-cyclobutyl-5-(2-(5-fluoro-1- methyl-2-oxo-1,2-dihydropyridin-3- yl)pyrrolidin-1-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
MS (apci) m/z = 411.1 (M + H)





231


embedded image


(R)-5-(2-(5-fluoro-1-methyl-2-oxo- 1,2-dihydropyridin-3-yl)pyrrolidin-1- yl)-N-(pyridin-3-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
MS (apci) m/z = 434.1 (M + H)





232


embedded image


(R)-N-(cyclopropylmethyl)-5-(2-(5- fluoro-1-methyl-oxo-1,2- dihydropyridin-3-yl)pyrrolidin-1- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
MS (apci) m/z = 411.1 (M + H)





233


embedded image


5-((R)-2-(5-fluoro-1-methyl-2-oxo- 1,2-dihydropyridin-3-yl)pyrrolidin-1- yl)-N-((S)-1-hydroxy-3,3- dimethylbutan-2-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
MS (apci) m/z = 457.1 (M + H)





234


embedded image


5-((R)-2-(5-fluoro-1-methyl-2-oxo- 1,2-dihydropyridin-3-yl)pyrrolidin-1- yl)-N-((1R,2R)-2- hydroxycyclohexyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
MS (apci) m/z = 455.1 (M + H)





235


embedded image


N-((R)-1-cyclopropylethyl)-5-((R)-2- (5-fluoro-1-methyl-2-oxo-1,2- dihydropyridin-3-yl)pyrrolidin-1- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
MS (apci) m/z = 425.1 (M + H)





236


embedded image


N-((S)-1-cyclopropylethyl)-5-((R)-2- (5-fluoro-1-methyl-2-oxo-1,2- dihydropyridin-3-yl)pyrrolidin-1- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
MS (apci) m/z = 425.1 (M + H)





237


embedded image


(R)-5-(2-(5-fluoro-1-methyl-2-oxo- 1,2-dihydropyridin-3-yl)pyrrolidin-1- yl)-N-(1- methylcyclopropyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
MS (apci) m/z = 411.1 (M + H)





238


embedded image


5-((R)-2-(5-fluoro-1-methyl-2-oxo- 1,2-dihydropyridin-3-yl)pyrrolidin-1- yl)-N-((trans)-4- hydroxycyclohexyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
MS (apci) m/z = 455.1 (M + H)





239


embedded image


(R)-5-(2-(5-fluoro-1-methyl-2-oxo- 1,2-dihydropyridin-3-yl)pyrrolidin-1- yl)-N-(5-fluoropyridin-2- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
MS (apci) m/z = 452.1 (M + H)









Example 240



embedded image


(R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)-N-(3-methyl-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

To a suspension of (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Preparation K, 101 mg, 0.283 mmol) in THF (5 mL) was added triethylamine (34.3 mg, 0.339 mmol), followed by the addition of 2,4,6-trichlorobenzoyl chloride (75.8 mg, 0.311 mmol). The suspension was stirred for 2 hours and then 3-methyl-1H-pyrazol-5-amine (35.7 mg, 0.367 mmol) was introduced. The reaction was heated at 60° C. for 3 hours. After cooling to room temperature, the reaction was partitioned between EtOAc (20 mL) and saturated aqueous NaHCO3 (10 mL). After phase-separation, the aqueous layer was extracted with EtOAc (2×10 mL). The combined organics were dried (Na2SO4), filtered and concentrated. The residue was purified via silica chromatography (EtOAc/MeOH 20:1) to yield the title product (23 mg, 19%). LCMS (apci) m/z=437.0 (M+H).


The compounds listed in Table F were also prepared according to the method described in Example 240, using (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid, Preparation K) and an appropriate amine.












TABLE F





Ex. #
Structure
Chemical Name
Data







241


embedded image


(R)-5-(2-(5-fluoro-2- methoxypyddin-3-yl)pyrrolidin-1- yl)-N-(1-methyl-1H-pyrazol-3- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 437.0 (M + H)





242


embedded image


(R)-N-(3-cyclopropyl-1H-pyrazol- 5-yl)-5-(2-(5-fluoro-2- methoxypyridin-3-yl)pyrrolidin-1- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 463.0 (M + H)





243


embedded image


(R)-N-(3-ethyl-1H-pyrazol-5-yl)-5- (2-(5-fluoro-2-methoxypyridin-3- yl)pyrrolidin-1-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
LCMS (apci) m/z = 451.0 (M + H)





244


embedded image


(R)-5-(2-(5-fluoro-2- methoxypyridin-3-yl)pyrrolidin-1- yl)-N-(1-isopropyl-1H-pyrazol-3- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
LCMS (apci) m/z = 465.0 (M + H)









The compounds in Table G can also be prepared according to the method of Example 240.











TABLE G





Ex. #
Structure
Name







245


embedded image


(R)-5-(2-(5-fluoro-2-methoxypyridin- 3-yl)pyrrolidin-1-yl)-N-(2-methyl-1H- imidazol-4-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide





246


embedded image


(R)-N-(1,2-dimethyl-1H-imidazol-4- yl)-5-(2-(5-fluoro-2-methoxypyridin-3- yl)pyrrolidin-1-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide








Claims
  • 1. A compound of Formula II
  • 2. The compound of claim 1, wherein: X is CH2; andY is (i) fluorophenyl optionally substituted with a substituent selected from —O(1-4C alkyl)hetCyc3, -(1-4C alkyl)hetCyc3, —O(1-4C alkyl)O(1-3C alkyl) and —O(3-6C dihydroxyalkyl), (ii) pyridyl substituted with one or more substituents independently selected from F, methyl and ethyl, or (iii) 5-fluoropyridin-2(1H)-one optionally substituted with (1-4C)alkyl.
  • 3. The compound of claim 1, wherein R3 is H.
  • 4. A compound of Formula III
  • 5. The compound of claim 4, wherein: X is CH2; andY is (i) fluorophenyl optionally substituted with a substituent selected from —O(1-4C alkyl)hetCyc3, -(1-4C alkyl)hetCyc3, —O(1-4C alkyl)O(1-3C alkyl) and —O(3-6C dihydroxyalkyl), (ii) pyridyl substituted with one or more substituents independently selected from F, methyl and ethyl, or (iii) 5-fluoropyridin-2(1H)-one optionally substituted with (1-4C)alkyl.
  • 6. The compound of claim 4, wherein R3 is H.
  • 7. A compound of Formula IV
  • 8. The compound of claim 7, wherein: X is CH2; andY is (i) fluorophenyl optionally substituted with a substituent selected from —O(1-4C alkyl)hetCyc3, -(1-4C alkyl)hetCyc3, —O(1-4C alkyl)O(1-3C alkyl) and —O(3-6C dihydroxyalkyl), (ii) pyridyl substituted with one or more substituents independently selected from F, methyl and ethyl, or (iii) 5-fluoropyridin-2(1H)-one optionally substituted with (1-4C)alkyl.
  • 9. The compound of claim 7, wherein R3 is H.
  • 10. A compound of Formula VIII
  • 11. The compound of claim 10, wherein: R1 is H or -(1-6C alkyl);R2 is H, -(1-6C)alkyl, -(1-6C)fluoroalkyl, -(1-6C)hydroxyalkyl, -(2-6C)dihydroxyalkyl, -(1-6C alkyl)CN, -(1-6C alkyl)SO2NH2, -(1-6C alkyl)NHSO2(1-3C alkyl), -(1-6C alkyl)NH2, -(1-6C alkyl)NH(1-4C alkyl), -(1-6C alkyl)N(1-4C alkyl)2, -(1-6C alkyl)hetCyc1, -(1-6C alkyl)hetAr1, hetAr2, hetCyc2, —O(1-6C alkyl), —O(3-6C cycloalkyl), or Cyc1;or NR1R2 forms a 4-6 membered azacyclic ring optionally substituted with one or more substituents independently selected from -(1-6C)alkyl, —OH, —CO2H and -(1-3C alkyl)CO2H;Cyc1 is a 3, 4 or 5 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, —OMe, —CO2H and -(1-4C alkyl)OH; andX is CH2.
  • 12. The compound of claim 10, wherein R3 is H.
  • 13. A compound of Formula IX
  • 14. The compound of claim 13, wherein: R1 is H or -(1-6C alkyl);X is CH2; andY is (i) fluorophenyl optionally substituted with a substituent selected from —O(1-4C alkyl)hetCyc3, -(1-4C alkyl)hetCyc3, —O(1-4C alkyl)O(1-3C alkyl) and —O(3-6C dihydroxyalkyl), (ii) pyridyl substituted with one or more substituents independently selected from F, methyl and ethyl, or (iii) 5-fluoropyridin-2(1H)-one optionally substituted with (1-4C)alkyl.
  • 15. The compound of claim 13, wherein R3 is H.
  • 16. A compound of Formula X
  • 17. The compound of claim 16, wherein: R1 is H or -(1-6C alkyl);R2 is H, -(1-6C)alkyl, -(1-6C)fluoroalkyl, -(1-6C)hydroxyalkyl, -(2-6C)dihydroxyalkyl, -(1-6C alkyl)CN, -(1-6C alkyl)SO2NH2, -(1-6C alkyl)NHSO2(1-3C alkyl), -(1-6C alkyl)NH2, -(1-6C alkyl)NH(1-4C alkyl), -(1-6C alkyl)N(1-4C alkyl)2, -(1-6C alkyl)hetCyc1, -(1-6C alkyl)hetAr1, hetAr2, hetCyc2, —O(1-6C alkyl), —O(3-6C cycloalkyl), or Cyc1;or NR1R2 forms a 4-6 membered azacyclic ring optionally substituted with one or more substituents independently selected from -(1-6C)alkyl, —OH, —CO2H and -(1-3C alkyl)CO2H;Cyc1 is a 3, 4 or 5 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, —OMe, —CO2H and -(1-4C alkyl)OH; andX is CH2.
  • 18. The compound of claim 16, wherein R3 is H.
Parent Case Info

This application is a continuation of U.S. application Ser. No. 15/401,913, filed Jan. 9, 2017, which is a continuation of U.S. application Ser. No. 14/321,246, filed Jul. 1, 2014, which is a continuation of U.S. application Ser. No. 13/382,858, filed Jan. 6, 2012, which is a national stage application filed under § 371 of International Application No. PCT/US2010/041538, filed Jul. 9, 2010, which claims the benefit of U.S. Provisional Application No. 61/346,767, filed May 20, 2010 and U.S. Provisional Application No. 61/224,196, filed Jul. 9, 2009, the contents of each of which are hereby incorporated by reference in their entireties.

US Referenced Citations (123)
Number Name Date Kind
5760068 Talley et al. Jun 1998 A
5844092 Presta et al. Dec 1998 A
5877016 Presta et al. Mar 1999 A
5910574 Presta et al. Jun 1999 A
6025166 Presta et al. Feb 2000 A
6027927 Presta et al. Feb 2000 A
6153189 Presta et al. Nov 2000 A
7384632 Devaux et al. Jun 2008 B2
7491794 Blatt et al. Feb 2009 B2
7514446 Davis-Ward et al. Apr 2009 B2
7550470 Fraley Jun 2009 B2
7612067 Barbosa et al. Nov 2009 B2
7615383 Devaux et al. Nov 2009 B2
7863289 Spevak et al. Jan 2011 B2
8026247 Bold et al. Sep 2011 B2
8106167 Wild, Jr. et al. Jan 2012 B2
8114989 Wang et al. Feb 2012 B2
8119592 Beigelman et al. Feb 2012 B2
8148107 Macdonald et al. Apr 2012 B2
8299021 Blatt et al. Oct 2012 B2
8299057 Lombardi Borgia et al. Oct 2012 B2
8338417 Li et al. Dec 2012 B2
8399442 Berdini et al. Mar 2013 B2
8450322 Andrews et al. May 2013 B2
8501756 Artman, III et al. Aug 2013 B2
8513263 Haas et al. Aug 2013 B2
8552002 Ding et al. Oct 2013 B2
8637256 Ernst Jan 2014 B2
8637516 Fan et al. Jan 2014 B2
8642035 Luehrsen Feb 2014 B2
8673347 Traversa et al. Mar 2014 B2
8691221 Pavone et al. Apr 2014 B2
8791123 Allen Jul 2014 B2
8815901 Furet et al. Aug 2014 B2
8865698 Haas et al. Oct 2014 B2
8911734 Latham et al. Dec 2014 B2
8912194 Ciomei Dec 2014 B2
8912204 Ibrahim et al. Dec 2014 B2
8933084 Andrews Jan 2015 B2
8937071 Eidam et al. Jan 2015 B2
8946226 Ciomei et al. Feb 2015 B2
9006256 Matsui Apr 2015 B2
9035063 Eidam et al. May 2015 B2
9102671 Molteni et al. Aug 2015 B2
9127013 Haas et al. Sep 2015 B2
9187489 Takeda et al. Nov 2015 B2
9242977 Takeuchi et al. Jan 2016 B2
9260437 Ibrahim et al. Feb 2016 B2
9273051 Chen et al. Mar 2016 B2
9447135 Rohr et al. Sep 2016 B2
9493476 Andrews et al. Nov 2016 B2
9511050 Toretsky et al. Dec 2016 B2
9682979 Allen Jun 2017 B2
9701681 Kim et al. Jun 2017 B2
9782415 Allen Oct 2017 B2
9796724 Allen Oct 2017 B2
9902741 Andrews et al. Feb 2018 B2
20050209195 Menta et al. Sep 2005 A1
20060094699 Kampen et al. May 2006 A1
20060128725 Guzi Jun 2006 A1
20060211696 Hibi et al. Sep 2006 A1
20070025540 Travis Feb 2007 A1
20070042941 Hirashima et al. Feb 2007 A1
20070082900 Guzi et al. Apr 2007 A1
20070082902 Paruch et al. Apr 2007 A1
20090041717 Macdonald et al. Feb 2009 A1
20090099167 Bold et al. Apr 2009 A1
20090130229 Lanzi et al. May 2009 A1
20090227556 Obaishi Sep 2009 A1
20100029633 Allen et al. Feb 2010 A1
20100152219 Block et al. Jun 2010 A1
20100297115 Blaustein Nov 2010 A1
20100324065 Ibrahim et al. Dec 2010 A1
20110053934 Angell et al. Mar 2011 A1
20110166122 Andrews et al. Jul 2011 A1
20110195948 Haas et al. Aug 2011 A1
20110268725 Shelton Nov 2011 A1
20110301157 Bold et al. Dec 2011 A1
20120108568 Allen et al. May 2012 A1
20130203776 Andrews et al. Aug 2013 A1
20130217662 Andrews et al. Aug 2013 A1
20140121239 Aftab May 2014 A1
20140194403 Haas et al. Jul 2014 A1
20140227287 Kamohara et al. Aug 2014 A1
20150005499 Haas et al. Jan 2015 A1
20150018336 Chen et al. Jan 2015 A1
20150031667 Allen et al. Jan 2015 A1
20150051222 Barbugian et al. Feb 2015 A1
20150073036 Hawryluk et al. Mar 2015 A1
20150166564 Allen et al. Jun 2015 A1
20150218132 Wu Aug 2015 A1
20150218652 Doebele et al. Aug 2015 A1
20150283132 Lim et al. Oct 2015 A1
20150306086 Wilcoxen Oct 2015 A1
20150315657 Rhodes et al. Nov 2015 A1
20160000783 Takeuchi et al. Jan 2016 A1
20160009785 Lipson et al. Jan 2016 A1
20160137654 Arrigo et al. May 2016 A1
20160228441 Haas et al. Aug 2016 A1
20160251357 Andrews et al. Sep 2016 A1
20160272725 Stransky et al. Sep 2016 A1
20170107232 Andrews et al. Apr 2017 A1
20170112842 Andrews et al. Apr 2017 A1
20170112849 Andrews et al. Apr 2017 A1
20170114059 Andrews et al. Apr 2017 A1
20170114067 Haas et al. Apr 2017 A1
20170114068 Andrews et al. Apr 2017 A1
20170114069 Allen et al. Apr 2017 A1
20170165267 Arrigo et al. Jun 2017 A1
20170224662 Motheram et al. Aug 2017 A1
20170260589 Nanda et al. Sep 2017 A1
20170281632 Cox et al. Oct 2017 A1
20170283435 Andrews et al. Oct 2017 A1
20170296544 Reynolds et al. Oct 2017 A1
20180021342 Arrigo et al. Jan 2018 A1
20180030548 Nanda et al. Feb 2018 A1
20180030549 Nanda et al. Feb 2018 A1
20180119228 Nanda et al. May 2018 A1
20180127427 Haas et al. May 2018 A1
20180133222 Cox et al. May 2018 A1
20180140604 Tuch et al. May 2018 A1
20180142306 Nanda et al. May 2018 A1
20180207162 Arrigo et al. Jul 2018 A1
Foreign Referenced Citations (170)
Number Date Country
1938311 Mar 2007 CN
101119996 Feb 2008 CN
101208093 Jun 2008 CN
1873157 Jan 2008 EP
1948633 Aug 2011 EP
2004-087707 Mar 2004 JP
2004-277337 Oct 2004 JP
2005-008581 Jan 2005 JP
2006-518364 Aug 2006 JP
2007-504276 Mar 2007 JP
2007-514712 Jun 2007 JP
2008-523034 Jul 2008 JP
2008-285464 Nov 2008 JP
2009-502734 Jan 2009 JP
2009-511487 Mar 2009 JP
2009-541242 Nov 2009 JP
2010-508315 Mar 2010 JP
2011-520887 Jul 2011 JP
2012-506446 Mar 2012 JP
2012-507569 Mar 2012 JP
2013-226108 Nov 2013 JP
2014-082984 May 2014 JP
WO 199849167 Nov 1998 WO
WO 2003080064 Oct 2003 WO
WO 2004022561 Mar 2004 WO
WO 2004052286 Jun 2004 WO
WO 2004052315 Jun 2004 WO
WO 2004074290 Sep 2004 WO
WO 2004082458 Sep 2004 WO
WO 2004087707 Oct 2004 WO
WO 2004089415 Oct 2004 WO
WO 2004089471 Oct 2004 WO
WO 2005044835 May 2005 WO
WO 2005049033 Jun 2005 WO
WO 2005051366 Jun 2005 WO
WO 2006052913 May 2006 WO
WO 2006087538 Aug 2006 WO
WO 2006115452 Nov 2006 WO
WO 2006123113 Nov 2006 WO
WO 2006131051 Dec 2006 WO
WO 2006131952 Dec 2006 WO
WO 2007002325 Jan 2007 WO
WO 2007002433 Jan 2007 WO
WO 2007013673 Feb 2007 WO
WO 2007015824 Feb 2007 WO
WO 2007022999 Mar 2007 WO
WO 2007024680 Mar 2007 WO
WO 2007025090 Mar 2007 WO
WO 2007025540 Mar 2007 WO
WO 2007038314 Apr 2007 WO
WO 2007044410 Apr 2007 WO
WO 2007044449 Apr 2007 WO
WO 2007044893 Apr 2007 WO
WO 2007048066 Apr 2007 WO
WO 2007057399 May 2007 WO
WO 2007062805 Jun 2007 WO
WO 2007084815 Jul 2007 WO
WO 2007087245 Aug 2007 WO
WO 2007102679 Sep 2007 WO
WO 2007110344 Oct 2007 WO
WO 2007113000 Oct 2007 WO
WO 2007129161 Nov 2007 WO
WO 2007136103 Nov 2007 WO
WO 2008016131 Feb 2008 WO
WO 2008030579 Mar 2008 WO
WO 2008031551 Mar 2008 WO
WO 2008037477 Apr 2008 WO
WO 2008052734 May 2008 WO
WO 2008058126 May 2008 WO
WO 2008079903 Jul 2008 WO
WO 2008079906 Jul 2008 WO
WO 2008079909 Jul 2008 WO
WO 2008080001 Jul 2008 WO
WO 2008080015 Jul 2008 WO
WO 2008115974 Sep 2008 WO
WO 2008116898 Oct 2008 WO
WO 2008155421 Dec 2008 WO
WO 2009007748 Jan 2009 WO
WO 2009012283 Jan 2009 WO
WO 2009013126 Jan 2009 WO
WO 2009014637 Jan 2009 WO
WO 2009017838 Feb 2009 WO
WO 2009052145 Apr 2009 WO
WO 2009053442 Apr 2009 WO
WO 2009060197 May 2009 WO
WO 2009071480 Jun 2009 WO
WO 2009092049 Jul 2009 WO
WO 2009118411 Oct 2009 WO
WO 2009140128 Nov 2009 WO
WO 2009143018 Nov 2009 WO
WO 2009143024 Nov 2009 WO
WO 2009152083 Dec 2009 WO
WO 2010012733 Feb 2010 WO
WO 2010031816 Mar 2010 WO
WO 2010033941 Apr 2010 WO
WO 2010048314 Apr 2010 WO
WO 2010051549 May 2010 WO
WO 2010058006 May 2010 WO
WO 2010111527 Sep 2010 WO
WO 2010145998 Dec 2010 WO
WO 2011006074 Jan 2011 WO
WO 2011092120 Aug 2011 WO
WO 2011133637 Oct 2011 WO
WO 2011146336 Nov 2011 WO
WO 2012024650 Feb 2012 WO
WO 2012034091 Mar 2012 WO
WO 2012034095 Mar 2012 WO
WO 2012053606 Apr 2012 WO
WO 2012101029 Aug 2012 WO
WO 2012101032 Aug 2012 WO
WO 2012109075 Aug 2012 WO
WO 2012113774 Aug 2012 WO
WO 2012116217 Aug 2012 WO
WO 2012139930 Oct 2012 WO
WO 2012143248 Oct 2012 WO
WO 2012152763 Nov 2012 WO
WO 2012158413 Nov 2012 WO
WO 2013014039 Jan 2013 WO
WO 2013050446 Apr 2013 WO
WO 2013050448 Apr 2013 WO
WO 2013059740 Apr 2013 WO
WO 2013074518 May 2013 WO
WO 2013102059 Jul 2013 WO
WO 2013174876 Nov 2013 WO
WO 2013183578 Dec 2013 WO
WO 2014011900 Jan 2014 WO
WO 2014019908 Feb 2014 WO
WO 2014036387 Mar 2014 WO
WO 2014047572 Mar 2014 WO
WO 2014071358 May 2014 WO
WO 2014072220 May 2014 WO
WO 2014078322 May 2014 WO
WO 2014078323 May 2014 WO
WO 2014078325 May 2014 WO
WO 2014078328 May 2014 WO
WO 2014078331 May 2014 WO
WO 2014078372 May 2014 WO
WO 2014078378 May 2014 WO
WO 2014078408 May 2014 WO
WO 2014078417 May 2014 WO
WO 2014078454 May 2014 WO
WO 2014160521 Oct 2014 WO
WO 2014184069 Nov 2014 WO
WO 2014194127 Dec 2014 WO
WO 2015017528 Feb 2015 WO
WO 2015017533 Feb 2015 WO
WO 2015039006 Mar 2015 WO
WO 2015057873 Apr 2015 WO
WO 2015058129 Apr 2015 WO
WO 2015061572 Apr 2015 WO
WO 2015108992 Jul 2015 WO
WO 2015112806 Jul 2015 WO
WO 2015124697 Aug 2015 WO
WO 2015161274 Oct 2015 WO
WO 2015161277 Oct 2015 WO
WO 2015175788 Nov 2015 WO
WO 2015183836 Dec 2015 WO
WO 2015184443 Dec 2015 WO
WO 2015191666 Dec 2015 WO
WO 2015191667 Dec 2015 WO
WO 2016011141 Jan 2016 WO
WO 2016011144 Jan 2016 WO
WO 2016011147 Jan 2016 WO
WO 2016022569 Feb 2016 WO
WO 2016027754 Feb 2016 WO
WO 2016075224 May 2016 WO
WO 2016077841 May 2016 WO
WO 2016081450 May 2016 WO
WO 2016196141 Dec 2016 WO
WO 2016196671 Dec 2016 WO
Non-Patent Literature Citations (366)
Entry
Extended European Search Report in European Application No. 17199899.0, dated Feb. 26, 2018, 7 pages.
Adriaenssens et al., “Nerve Growth Factor Is a Potential Therapeutic Target in Breast Cancer,” Cancer Res., 2008, 68(2):346-351.
Alassiri et al., “ETV6-NTRK3 Is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic Tumors,” Am J Surg Pathol., Aug. 2016;40(8):1051-1061.
Albaugh et al., “Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models,” ACS Medicinal Chemistry Letters, 2012, 3(2):140-145.
American Cancer Society,“Sarcoma: Adult Soft Tissue Cancer,” Jun. 2014, retrieved on Apr. 27, 2015, http://www.cancer.org/cancer/sarcoma-adultsofttissuecancer/detailedguide/sarcoma-adult-soft-tissue-cancer-key-statistics, 45 pages.
Asaumi et al., “Expression of neurotrophins and their receptors (TRK) during fracture healing,” Bone, 2000, 26(6):625-633.
Bardelli et al., “Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers,” Science, May 2003, 300(5621):949.
Bardelli, “Mutational analysis of the tyrosine kinome in colorectal cancers,” Science, 2003, 300:949.
Behrens et al., “Gö 6976 is a potent inhibitor of neurotrophin-receptor intrinsic tyrosine kinase,” J. Neurochem., Mar. 1999, 72(3):919-924.
Beimfohr et al., “NTRK1 re-arrangement in papillary thyroid carcinomas of children after the Chernobyl reactor accident,” Int. J Cancer, Mar. 15, 1999;80(6):842-847.
Bensinger et al., “Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor,” Stem Cells, Jan. 1996;14(1):90-105.
Bensinger et al., “Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor [see comments].,” Blood, Mar. 15, 1995;85(6):1655-8.
Bertrand et al., “The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition,” Journal of molecular biology, Oct. 26, 2012;423(3):439-53.
Bonanno et al., Journal of Thoracic Oncology,vol. 11, No. 4, Supp. Suppl. 1, pp. S67. Abstract No. 28P; 6th European Lung Cancer Conference, ELCC 2016, Geneva, Switzerland.
Bongarzone et al., “Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma,” J Clin. Endocrinol. Metab., May 1996, 81(5):2006-2009.
Bouhana et al., “Abstract #1798: Identification of Pan-Trk Inhibitors for the Treatment of Trk-Driven Cancers,” Poster, Presented at Proceedings of the AACR 103rd Annual Meeting, Apr. 15, 2012.
Bourgeois et al., “Molecular Detection of the ETV6-NTRK3 Gene Fusion Differentiates Congenital Fibrosarcoma From Other Childhood Spindle Cell Tumors,” Am. J Surg. Pathol., Jul. 2000, 24(7):937-946.
Branford, S., et al. “High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance,” Blood, May 2002, 99, 3472-3475.
Brodeur, “Neuroblastoma: biological insights into a clinical enigma,” Nat. Rev. Cancer, 2003, 3:203-216.
Bruse et al., “Improvements to Bead Based Oligonucleotide Ligation SNP Genotyping Assays,” Biotechniques, Nov. 2008, 45:559-571.
Brzezianska et al., “Rearrangements of NTRK1 oncogene in papillary thyroid carcinoma,” Neuroendocrinology Letters, 2007, 28(3):221-229.
Burris et al., “Pharmacokinetics (PK) of LOXO-101 During the First-in-Human Phase I Study in Patients with Advanced Solid Tumors,” Interim Update AACR Annual Meeting, Mar. 2015, Philadelphia, PA., 1 page.
Calero et al., “Sunitinib suppress neuroblastoma growth through degradation of MYCN and inhibition of angiogenesis,” PLoS One, Apr. 23, 2014;9(4):e95628. doi:10.1371/journal.pone.0095628. eCollection 2014.
Camoratto et al., “CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity,” Int. J Cancer, Aug. 1997, 72:673-679.
Campos et al., “Enantioselective, palladium-catalyzed alpha-arylation of N-Boc-pyrrolidine,” J. Am. Chem Soc., 2006, 128:3538-3539.
Cancer.gov' [online]. “National Cancer Institute: Oral TRK Inhibitor LOXO-101 (Larotrectinib) for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors,” ClinicalTrials.gov Identifier: NCT02637687, [retrieved on Jul. 17, 2017] Retrived from the Internet: URL<https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/view?cdrid=781000>, 5 pages.
Cancer.sanger.ac.uk' [online]. “COSMIC, Catalog of Somatic Mutations in Cancer: Cosmic » Mutation » Overview » NTRK1 p. V321M / c.961G>A,” Catalog of Somatic Mutations in Cancer (COSMIC) database, [retrieved on Jul. 17, 2017] Retrived from the Internet: URL<cancer.sanger.ac.uk/cosmic/mutation/ overview?id=1259646>, 1 page.
Cancer.sanger.ac.uk' [online]. “COSMIC, Catalog of Somatic Mutations in Cancer: Cosmic » Mutation » Overview » NTRK1 p. D679N / c.2035G>A,” Catalog of Somatic Mutations in Cancer (COSMIC) database, [retrieved on Jul. 17, 2017] Retrived from the Internet: URL<cancer.sanger.ac.uk/cosmic/mutation/overview?id=897427>, 1 page.
Cancer.sanger.ac.uk' [online]. “COSMIC, Catalog of Somatic Mutations in Cancer: Cosmic » Mutation » Overview » NTRK3 p. D537Y / c.1609G>T,” Catalog of Somatic Mutations in Cancer (COSMIC) database, [retrieved on Jul. 17, 2017] Retrived from the Internet: URL<cancer.sanger.ac.uk/cosmic/mutation/ overview?id=966118>, 1 page.
Cancer.sanger.ac.uk' [online]. “COSMIC, Catalog of Somatic Mutations in Cancer: Cosmic » Mutation » Overview » NTRK3 p. D609V / c.1826A>T,” Catalog of Somatic Mutations in Cancer (COSMIC) database, [retrieved on Jul. 17, 2017] Retrived from the Internet: URL:<cancer.sanger.ac.uk/cosmic/mutation/ overview?id=124878>, 1 page.
Cancer.sanger.ac.uk' [online]. “COSMIC, Catalog of Somatic Mutations in Cancer: Cosmic » Mutation » Overview » NTRK3 p. G608S / c.1822G>A,” Catalog of Somatic Mutations in Cancer (COSMIC) database, [retrieved on Jul. 17, 2017] Retrived from the Internet: URL<cancer.sanger.ac.uk/cosmic/mutation/ overview?id=88799>, 1 page.
Cancer.sanger.ac.uk' [online]. “COSMIC, Catalog of Somatic Mutations in Cancer: Cosmic » Mutation » Overview » NTRK3 p. L282M / c.844C>A,” Catalog of Somatic Mutations in Cancer (COSMIC) database, [retrieved on Jul. 17, 2017] Retrived from the Internet: URL<cancer.sanger.ac.uk/cosmic/mutation/ overview?id=401588>, 1 page.
Cancer.sanger.ac.uk' [online]. “COSMIC, Catalog of Somatic Mutations in Cancer: Cosmic » Mutation » Overview » NTRK3 p. V539M / c.1615G>A,” Catalog of Somatic Mutations in Cancer (COSMIC) database, [retrieved on Jul. 17, 2017] Retrived from the Internet: URL<cancer.sanger.ac.ukkosmic/mutation/ overview?id=1708512>, 1 page.
Caria et al., “Cytogenetic and molecular events in adenoma and well-differentiated thyroid follicular-cell neoplasia,” Cancer Genet. Cytogenet., 2010, 203:21-29.
Carpinelli et al., “PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer,” Mol Cancer Ther, Dec. 2007;6(12 Pt 1):3158-3168.
Carvalho et al., Neuro-Oncology 17:iiil-iii40, 2015, Abstract No. HH-09, 1 page.
Catalog of Somatic Mutations in Cancer (COSMIC) database, cancer.sanger.ac.uk/cosmic/mutation/overview?id=1517968, downloaded on May 31, 2016, 2 pages.
Catalog of Somatic Mutations in Cancer (COSMIC) database, cancer.sanger.ac.uk/cosmic/mutation/overview?id=1636266, downloaded on May 31, 2016, 2 pages.
Catalog of Somatic Mutations in Cancer (COSMIC) database, cancer.sanger.ac.uk/cosmic/mutation/overview?id=1688778, downloaded on May 31, 2016, 2 pages.
Catalog of Somatic Mutations in Cancer (COSMIC) database, cancer.sanger.ac.uk/cosmic/mutation/overview?id=3711772, downloaded on May 31, 2016, 2 pages.
Catalog of Somatic Mutations in Cancer (COSMIC) database, cancer.sanger.ac.uk/cosmic/mutation/overview?id=471203, downloaded on May 31, 2016, 2 pages.
Catalog of Somatic Mutations in Cancer (COSMIC) database, cancer.sanger.ac.uk/cosmic/mutation/overview?id=48622, downloaded on May 31, 2016, 2 pages.
Chang-Qi et al., “Brain derived neurotrophic factor (BDNF) contributes to the pain hypersensitivity following surgical incision in the rats,” Molecular Pain, 2008, 4:27.
Cherry et al., “Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights,” Curr Med Chem. Mar. 2004;11(6):663-73.
Chinese Office Action in Chinese Patent Application No. CN 201180025013.9, dated Apr. 28, 2014, 11 pages.
Chinese Office Action in Chinese Patent Application No. CN201080040095.X, dated Feb. 27, 2015, 8 pages (English translation).
Chintakuntlawar et al., “High-grade transformation of acinic cell carcinoma: an inadequately treated entity?” Oral Surg Oral Med Oral Pathol Oral Radiol. May 2016;121(5):542-549.e1.
Cho et al., “Expression of mRNA for brain-derived neurotrophic factor in the dorsal root ganglion following peripheral inflammation,” Brain Research, 1997, 749:358-362.
Choi et al', “(R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors,” ACS medicinal chemistry letters, Mar. 19, 2015;6(5):562-7.
Chung et al., “Infantile fibrosarcoma,” Cancer, Aug. 1976, 38(2):729-739.
Colombian Office Action in Colombian Application No. CO 12-022-116-4, dated Feb. 14, 2014, 8 pages.
Colombian Office Action in Colombian Application No. CO 12-229421-4, dated Jan. 21, 2014, 6 pages.
Créancier et al., “Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma,” Cancer Lett., Aug. 2015, 365(1):107-111.
Croucher et al., “TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts,” Cancer Chemother Pharmacol. Jan. 2015;75(1):131-41. doi: 10.1007/s00280-014-2627-1. Epub Nov. 14, 2014.
Cruz, “Lung cancer: epidemiology, etiology and prevention,” Clinics in Chest Medicine, 2011, 32(4): 1-61.
Cui et al., “Abstract #MA 07.09: ALK/ROS1/Inhibitor TPX-0005 Effectively Overcomes Clinical Resistance Solvent Front Mutations,” Abstracts, Nov. 2017, p. S1829.
Dang et al., “Expression of nerve growth factor receptors is correlated with progression and prognosis of human pancreatic cancer,” J. Gastroenterology and Hepatology, 2006, 21(5): 850-858.
Davidson et al., “Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma,” Clin. Cancer Res., 2003, 9(6):2248-2259.
Davies et al., “Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cell,” PLoS One, 2013, 8(12):e82236, 13 pages.
Delafoy et al., “Role of nerve growth factor in the trinitrobenzene sulfonic acid-induced colonic hypersensitivity,” Pain, 2003, 105:489-497.
Demaria et al., “Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy,” Clin Cancer Res, Oct. 2001;7(10):3025-30.
Di Mola et al., “Nerve growth factor and Trk high affinity receptor (TrkA) gene expression in inflammatory bowel disease,” Gut, 2000, 46(5):670-678.
Dinér et al., “Preparation of 3-substituted-1-isopropyl-1H-pyrazolo [3,4-d]pyrimidin-4-amines as RET kinase inhibitors,” J. Med. Chem., May 2012, 55 (10), 4872-4876.
Dionne et al., “Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587),” Clin. Cancer Research, 1998, 4(8):1887-1898.
Doebele et al., “An oncogenic NTRK fusion in a soft tissue sarcoma patient with response to the tropomysin-related kinase (TRK) inhibitor LOXO-101,” Cancer Discovery, Jul. 2015, 5(10):1049-1057.
Doebele et al., “Phase II Trial of Stereotactic Body Radiation Therapy Combined with Erlotinib for Patients With Limited but Progressive Metastatic Non-Small-Cell Lung Cancer,” J. Clin. Oncol., 2014, 32:9 pages.
Dolle et al., “Nerve growth factor-induced migration of endothelial cells,” J. Pharmacol Exp Ther, 2005, 315(3):1220-1227.
Dou et al., “Increased nerve growth factor and its receptors in atopic dermatitis: an immunohistochemical study,” Archives of Dermatological Research, 2006, 298(1):31-37.
Drexler et al., “Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas,” Leukemia, Sep. 2000, 14:1533-1559.
Drilon et al., “Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naive patients with advanced solid tumors harboring gene rearrangements,” Cancer research, vol. 76, No. 14, Supp. Supplement., Abstract No. 15 CT007; Presented at the 107th Annual Meeting of the American Association for Cancer Research, AACR 2016. New Orleans, LA; Apr. 16-20, 2016, 35 pages.
Drilon et al., “What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC),” Annals of Oncology., Feb. 15, 2016, 27(5):920-926.
Du et al., “Expression of NGF family and their receptors in gastric carcinoma: a cDNA microarray study,” World Journal of Gastroenterology, http://www.wjgnet.com/1007-9327/full/v9/i7/1431.htm, Jul. 2003, 9(7):1431-1434.
Duranti et al., “Homologation of Mexiletine alkyl chanin and stereoselective blockade of skelatal muscle sodium channels,” Euro. J. Med. Chem., 2000, 35:147-156.
Egren et al., Cancer Res. 75(15 Supplement): 4793, 2015; Abstract only, 3 pages.
Eguchi et al., “Absence of t(12;15) associated ETV6-NTRK3 fusion transcripts in pediatric acute leukemias,” Afed Pediatr. Oneal., Oct. 2001, 37:417.
Eguchi et al., “Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25),” Blood, 1999, 93(4):1355-1363.
Eisenhauer et al., “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1),” Eur J Cancer, Jan. 2009, 45(2):228-247.
Endometrial Cancer Gene Database, ecgene.bioinfominzhao.org/gene_mutation.cgi?gene=4915, downloaded on May 31, 2016, 13 pages.
Engman et al., “Syngeneic transplant in mantle cell lymphoma: a rare event and review of the literature,” Clin Adv Hematol Oncol. May 2009;7(5):321-3.
Esmo, “TRK Cancer-Causing Mutation Discovered in 1982 Finally Target of Clinical Trials: Matching drugs to long-overlooked oncogene,” European Society of Medical Oncology, Jan. 2015, 2 pages.
Essand et al., “Genetically engineered T cells for the treatment of cancer,” J Intern Med. Feb. 2013;273(2):166-81. doi: 10.1111/joim.12020.
Estrada-Bernal et al., “Abstract #: C65: TRK kinase domain mutations that induce resistance to a pan-TRK inhibitor,” Poster, Presented at Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Boston MA, Nov. 5-9, 2015; Mol Cancer Ther, Dec. 2015, 14(12)(Suppl. 2): 1 page.
Estrada-Bernal et al., “Abstract #: LB-118: Identification of TRKA and TRKB kinase domain mutations that induce resistance to a pan-TRK inhibitor,” Poster, Presented at Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, New Orleans LA, Apr. 16-20, 2016; Cancer Res, Jul. 2016, 76(14): 1 page.
European Search Report in European Application No. 13197815.7, dated Apr. 1, 2014, 5 pages.
Euthus et al., “ETV6-NTRK3—Trk-ing the primary event in human secretory breast cancer,” Cancer Cell, 2002, 2(5):347-348.
Evans et al., “Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts,” Clin. Cancer Res., Nov. 1999, 5(11):3594-3602.
Extended European Search Report in European Application No. 17163978.4, dated Jul. 17, 2017, 5 pages.
Flannery et al., “Immunomodulation: NK cells activated by interferon-conjugated monoclonal antibody against human osteosarcoma,” Eur J Cancer Clin Oncol. Jun. 1984;20(6):791-8.
Frattini et al., “The integrated landscape of driver genomic alterations in glioblastoma,” Nature Genet., 2013, 45:1141-1149.
Freund-Michel and Frossard, “The nerve growth factor and its receptors in airway inflammatory diseases,” Pharmacology & Therapeutics, 2008, 117(1):52-76.
Frey et al., “7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors,” J. Med. Chem, Jul. 2008, 51(13):3777-3787.
Gaudet et al., “Allele-specific PCR in SNP genotyping,” Methods Mol Biol. 2009;578:415-24. doi: 10.1007/978-1-60327-411-1_26.
Geiger et al., “Functional Characterization of Human Cancer-Derived TRKB Mutations,” PLoS ONE, Feb. 17, 2011, 6(2):e16871.
Geiger et al., “The neurotrophic receptor TrkB in anoikis resistance and metastasis: a perspective,” J Cancer Res., Aug. 2005, 65(16):7033-7036.
GenBank Accession No. AAB33109.1, “trkB [Homo sapiens],” Jul. 27, 1995, 1 page.
GenBank Accession No. AAB33111.1, “trkC [Homo sapiens],” Jul. 27, 1995, 1 page.
GenBank Accession No. NM_ 002529, “high affinity nerve growth factor receptor isoform 2 precursor [Homo sapiens],” May 11, 2014, 4 pages.
GenBank Accession No. NM_001007792 “Homo sapiens neurotrophic tyrosine kinase, receptor, type 1 (NTRK1), transcript variant 3, mRNA,” May 10, 2014, 5 pages.
GenBank Accession No. NM_001012338, “Homo sapiens neurotrophic tyrosine kinase, receptor, type 3 (NTRK3), transcript variant 1, mRNA,” May 10, 2014, 6 pages.
GenBank Accession No. NM_006180, “Homo sapiens neurotrophic tyrosine kinase, receptor, type 2 (NTRK2), transcript variant a, mRNA,” May 12, 2014, 9 pages.
GenBank Accession No. NP 001007793, “high affinity nerve growth factor receptor isoform 3 [Homo sapiens],” May 10, 2014, 3 pages.
GenBank Accession No. NP_ 002520 “high affinity nerve growth factor receptor isoform 2 precursor [Homo sapiens],” May 11, 2014, 4 pages.
GenBank Accession No. NP_001007157, “NT-3 growth factor receptor isoform c precursor [Homo sapiens],” May 10, 2014, 3 pages.
GenBank Accession No. NP_001012331.1, “high affinity nerve growth factor receptor isoform 1 precursor [Homo sapiens],” May 10, 2014, 4 pages.
GenBank Accession No. NP_001012338, “NT-3 growth factor receptor isoform a precursor [Homo sapiens],” May 10, 2014, 3 pages.
GenBank Accession No. NP_006171, “BDNF/NT-3 growth factors receptor isoform a precursor [Homo sapiens],” May 12, 2014, 4 pages.
GenBank Accession No. S76473.1, “trkB [human, brain, mRNA, 3194 nt],” Jul. 27, 1995, 2 pages.
GenBank Accession No. S76475.1, “trkC [human, brain, mRNA, 2715 nt],” Jul. 27, 1995, 2 pages.
Genevois et al., “Dependence receptor TrkC is a putative colon cancer tumor suppressor,” Proc. Nat. Acad. Sci. U.S.A. Feb. 19, 2013, 110(8):3017-3022.
Gimm et al., “Mutation analysis of NTRK2 and NTRK3, encoding 2 tyrosine kinase receptors, in sporadic human medullary thyroid carcinoma reveals novel sequence variants,” International Journal of Cancer, Apr. 1, 2001, 92(1):70-74.
Greco et al., “Rearrangements of NTRK1 gene in papillary thyroid carcinoma,” Molecular and Cellular Endocrinology, 2010, 321(1):44-49.
Green & Wuts, eds, “Protective Groups in Organic Synthesis,” John Wiley & Sons Inc, May 8, 1999.
Gruber-Olipitz et al., “Neurotrophin 3/TrkC-regulated proteins in the human medulloblastoma cell line DAOY,” J. Proteome Research, 2008, 7(5):1932-1944.
Gwak et al., “Attenuation of mechanical hyperalgesia following spinal cord injury by administration of antibodies to nerve growth factor in the rat.” Neurosci. Lett., 2003, 336:117-120.
Haller et al., “Paediatric and adult soft tissue sarcomas with NTRK1 gene fusions: a subset of spindle cell sarcomas unified by a prominent myopericytic/haemangiopericytic pattern,” J Pathol, Apr. 2016, 238(5):700-710.
Hamdouchi Et A L “Imidazo[1,2-b]pyridazines, novel nucleus with potent and broad spectrum activity against human picornaviruses: design, synthesis, and biological evaluation” J Med Chem., Sep. 25, 2003;46(20):2333-4341.
Hansen et al., “Autophagic cell death induced by TrkA receptor activation in human glioblastoma cells,” J. of Neurochemistry, 2007, 103:259-275.
Harada et al., “Role and Relevance of TrkB Mutations and Expression in Non-Small Cell Lung Cancer,” Clinical Cancer Research, Jan. 17, 2011, 17(9):2638-2645.
Harris et al., “Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study,” JAMA Oncol, Jan. 2016; 10.1001/jamaonco1.2015.5689, 8 pages.
Harwood et al., “Experimental organic chemistry—Principles and practice,” Experimental Chemistry—Organic Chemistry and Reaction, Jan. 1, 1989, 127-132.
Herzberg et al., “NGF involvement in pain induced by chronic constriction injury of the rat sciatic nerve,” Neuroreport, 1997, 8:1613-1618.
Hinrichs et al., “Exploiting the curative potential of adoptive T-cell therapy for cancer,” Immunol Rev. Jan. 2014;257(1):56-71. doi: 10.1111/imr.12132.
Hobbs et al., “Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients,” J Clin Med. Mar. 19, 2015;4(3):488-503. doi: 10.3390/jcm4030488.
Hong et al., “Clinical Safety and activity from a Phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions,” 2016 AACR Annual Meeting, Apr. 17, 2016, 32 pages.
Hong et al., Abstract PR13: Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions, Molecular Cancer Therapeutics 2015:14(12 Supplement 2):PR13.; Abstract only, 4 pages.
Howell et al., “Dynamic allele-specific hybridization. A new method for scoring single nucleotide polymorphisms,” Nat Biotechnol. Jan. 1999;17(1):87-8.
Hu et al., “Decrease in bladder overactivity with REN1820 in rats with cyclophosphamide induced cystitis,” J. Urology, 2005, 173(3):1016-1021.
Hu et al., “Identification of brain-derived neurotrophic factor as a novel angiogenic protein in multiple myeloma” Cancer Genetics and Cytogenetics, 2007, 178:1-10.
Huehls et al., “Bispecific T-cell engagers for cancer immunotherapy,” Immunol Cell Biol. Mar. 2015;93(3):290-6. doi: 10.1038/icb.2014.93. Epub Nov. 4, 2014.
Hyrcza et al., vol. 469, Supp. Supplement 1, pp. S17. Abstract No. OFP-1997-7; 31st International Congress of the International Academy of Pathology and the 28th Congress of the European Society of Pathology, Cologne, Germany. Sep. 25-29, 2016.
Igaz et al., “Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice,” Inflamm Res., 2001, 50:435-441.
Ihle et al., “The Roles of Jaks and Stats in Cytokine Signaling,” Canc. J. Sci. Am., 1998, 4(1):84-91.
Imamura et al., “Allogeneic hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: potential benefit of medium-dose etoposide conditioning,” Exp Hematol Oncol, Jul. 16, 2015;4:20. doi: 10.1186/s40164-015-0015-0. eCollection 2015.
International Preliminary Report on Patentability in International Application No. PCT/US2009/057729, dated Mar. 22, 2011, 7 pages.
International Preliminary Report on Patentability in International Application No. PCT/US2009/061519, dated Apr. 26, 2011, 6 pages.
International Preliminary Report on Patentability in International Application No. PCT/US2010/041538, dated Jan. 10, 2012, 7 pages.
International Preliminary Report on Patentability in International Application No. PCT/US2011/036452, dated Nov. 29, 2012, 6 pages.
International Preliminary Report on Patentability in International Application No. PCT/US2015/060953, dated May 16, 2017, 7 pages.
International Preliminary Report on Patentability in International Application No. PCT/US2016/035327, dated Dec. 14, 2017, 9 pages.
International Search Report and Written Opinion for International Application No. PCT/US2016/035327, dated Aug. 18, 2016, 15 pages.
International Search Report and Written Opinion in International Application No. PCT/US2009/0161519, dated Feb. 2, 2010, 8 pages.
International Search Report and Written Opinion in International Application No. PCT/US2009/057729, dated Feb. 4, 2010, 10 pages.
International Search Report and Written Opinion in International Application No. PCT/US2010/041538, dated Oct. 1, 2010, 10 pages.
International Search Report and Written Opinion in International Application No. PCT/US2011/036452, dated Aug. 18, 2011, 9 pages.
International Search Report and Written Opinion in International Application No. PCT/US2015/060953, dated Feb. 8, 2016, 12 pages.
International Search Report and Written Opinion in International Application No. PGT/US2016/058951, dated Feb. 7, 2017, 20 pages.
International Search Report and Written Opinion in International Application No. PCT/US2017/025932, dated May 31, 2017, 16 pages.
International Search Report and Written Opinion in International Application No. PCT/US2017/025939, dated May 31, 2017, 16 pages.
International Search Report and Written Opinion in International Application No. PCT/US2017/033257, dated Jul. 24, 2017, 13 pages.
Isdori et al., “Advancement in high dose therapy and autologous stem cell rescue in lymphoma,” World J Stem Cells, Aug. 2015, 7(7):1039-1046.
Iyer et al., “AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts,” Cancer Chemother Pharmacol. Sep. 2012;70(3):477-86. doi: 10.1007/s00280-012-1879-x. Epub May 24, 2012.
Iyer, R., “Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.” Cancer letters 372.2 (2016): 179-186. (Year: 2016).
Jaggar et al., “Inflammation of the rat urinary bladder is associated with a referred thermal hyperalgesia which is nerve growth factor dependent,” Br. J. Anaesth, 1999, 83:442-448.
Japanese Office Action in Japanese Application No. JP 2013-511239, dated Mar. 4, 2015, 2 pages (English translation).
Jin et al., “TrkC plays an essential role in breast tumor growth and metastasis,” Carcinogenesis, 2010, 31(11):1939-1947.
Jones et al., “Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma,” Nature Genetics, 2013, 45:927-932.
Katayama et al., “Mechanisms of Acquired Crizotinib Resistance in ALKRearranged Lung Cancers,” Sci Transl Med, Feb. 2012, 4(120): 120ra17.
Keysar et al., “A patient tumor transplant model of Squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins,” Molecular Oncology, 2013, 7(4):776-790.
Kim et al., “NTRK1 fusion in glioblastoma multiforme,” PloS ONE, 2014, 9(3):e91940.
Klijn et al., “A comprehensive transcriptional portrait of human cancer cell lines,” Nat Biotechnol., 2015, 33(3):306-312.
Knezevich et al., “A novel ETV6- NTRK3 gene fusion in congenital fibrosarcoma,” Nat Genet, Feb. 1998:18(2):184-187.
Knezevich et al., “ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma,” Cancer Res, Nov. 1998:58(22):5046-5048.
Koboldt et al., “The next-generation sequencing revolution and its impact on genomics,” Cell, Sep. 26, 2013;155(1):27-38. doi: 10.1016/j.cell.2013.09.006.
Kolokythas et al., “Nerve growth factor and tyrosine kinase A receptor in oral squamous cell carcinoma: is there an association with perineural invasion?” J. Oral Maxillofacial Surgery, 2010, 68(6):1290-1295.
Konicek et al., Cancer research, vol. 76, No. 14, Supp. Supplement. Abstract Number: 2647; 107th Annual Meeting of the American Association for Cancer Research, AACR 2016. New Orleans, LA; Apr. 16-20, 2016; Abstract only, 3 pages.
Kremer et al., “The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo,” Arth. & Rheum., 2009, 60:1895-1905.
Kruettgen et al., “The dark side of the NGF family: neurotrophins in neoplasias,” Brain Pathology, 2006, 16:304-310.
Lamb et al., “Nerve growth factor and gastric hyperalgesia in the rat,” Neurogastrenterol. Motil., 2003, 15:355-361.
Lannon et al., “ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages,” Semin Cancer Biol, Jun. 2005:15(3):215-223.
Lecht et al., “Angiostatic effects of K252a, a Trk inhibitor, in murine brain capillary endothelial cells,” Mol Cell Biochem, Jun. 2010;339(1-2):201-13. doi: 10.1007/s11010-010-0386-9. Epub Feb. 11, 2010.
Leukemia, Wikipedia the Free Encyclopedia, Dec. 8, 2001, https://en.wikipedia.org/wiki/Leukemia, 15 pages.
Li et al., “Brain derived neurotrophic factor (BDNF) contributes to the pain hypersensitivity following surgical incision in the rats,” Molecular Pain, 2008, 4(28):1-11.
Li et al., “Correlation of expressions of GFAP, NT-3, Trk and NCAM with neurotropic molecular mechanism and clinical factors in adenoid cystic carcinoma of salivary gland,” Chinese Journal of Cancer Prevention and Treatment, 2009, 16(6): 428-430 (with English abstract).
Li et al., “In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy,” J Immunol, Sep. 1, 2009;183(5):3195-203. doi: 10.4049/jimmuno1.0803773. Epub Aug. 10, 2009.
Li et al., “Lumbar 5 ventral root transection-induced upregulation of nerve growth factor in sensory neurons and their target tissues: a mechanism in neuropathic pain,” Mol. Cell. Neurosci., 2003, 23:232-250.
Li et al., “Trk inhibitor attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo,” Cancer Biol. Ther., Feb. 2015, 16(3):477-483.
Lin et al., Neuro-Oncol, vol. 18, Supp. Supplement 3, pp. iii58, Abstract No. HG-48; 17th International Symposium on Pediatric Neuro-Oncology, ISPNO 2016. Liverpool, UK, Jun. 12, 2016-Jun. 15, 2016.
Linch et al., “Systemic treatment of soft-tissue sarcoma [mdash] gold standard and novel therapies,”Nature Reviews Clinical Oncology, 2014, 11(4):187-202.
Loh et al., “Treatment of infantile fibrosarcoma with chemotherapy and surgery: results from the Dana-Father Cancer Institute and Children's Hospital, Boston,” J Pediatr Hematol Oncol, Dec. 2002:24(9):722-726.
Lorigan et al., “Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation For Research and Treatment of Cancer Soft Tissue and Bone Sarcoma. Group Study,” J. Clin Oncol., 2007, 25(21):3144-3150.
Lovly et al., “Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions,” Cancer Discov., 2014, 4(8):889-895.
Ma and Woolf, “The progressive tactile hyperalgesia induced by peripheral inflammation is nerve growth factor dependent,” Neuroreport, 1997, 8:807-810.
Makretsov et al., “A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma,” Genes, Chromosomes and Cancer, Jun. 2004:40(2):152-157.
Marchetti et al., “Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung,” Human Mutation, 2008, 29(5):609-616.
Marras et al., “Genotyping SNPs with molecular beacons,” Methods Mol Biol, 2003;212:111-28.
Marras et al., Single Nucleotide Polymorphism: Methods and Protocols. Methods in Molecular Biology, Kwok, P.-Y., Ed., Totowa, NJ, Humana Press, vol. 212, pp. 111-128, 2003.
Martin-Zanca et al., “A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences,” Nature, 1986, 319:743-748.
Matayoshi, “Actions of brain-derived neurotrophic factor on spinal nociceptive transmission during inflammation in the rat,” J. Physiol., 2005, 569:685-695.
McCahon et al., “Non-Resectable Congenital Tumors with the ETV6-NTRK3 Gene Fusion Are Highly Responsive to Chemotherapy,” Med. Pediatr. Oncol., May 2003, 40(5):288-292.
McCarthy et al., “Tropomyosin receptor kinase inhibitors: a patent update 2009-2013,” Expert Opin Ther Pat. Jul. 2014;24(7):731-44. doi: 10.1517/13543776.2014.910195. Epub May 8, 2014.
McMahon et al., “The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule,” Nat. Med., 1995, 1:774-780.
McMahon., “VEGF Receptor Signaling in Tumor Angiogenesis,” The Oncologist, 2000, 5(1): 3-10.
Mekinist, Highlights of Prescribing Information, Initial Approval 2013, revised Nov. 2015, Novartis Pharmaceuticals Corp., 27 pages.
Melo-Jorge et al., The Chagas' disease parasite Trypanosoma cruzi exploits nerve growth factor receptor TrkA to infect mammalian hosts Cell Host & Microbe, 2007, 1(4):251-261.
Meyer et al., “Remarkable leukemogenic potency and quality of a constitutively active neurotrophin receptor, deltaTrkA,” Leukemia, 2007, 21:2171-2180.
Miranda et al., “Functional characterization of NTRK1 mutations Identified in melanoma,” Genes Chromosomes & Cancer, Jun. 26, 2014, 53(10):875-880.
Montagnoli et al., “Anti-proliferative effects of GW441756, a novel inhibitor of NGFreceptor tyrosine kinase a (TRKA), in human sarcoma,” Italian Journal of Anatomy and Embryology, Nov. 11, 2010, 115:117.
Montalli et al., “Mammaglobin and DOG-1 expression in polymorphous low-grade adenocarcinoma: an appraisal of its origin and morphology,” J Oral Pathol Med., Mar. 2017, 46(3):182-187.
Myers, “Synthesis of Chiral Amines by Asymmetric Additions to tert-Butylsulfinimines (Ellman Auxiliary),” Chem 115, retrieved on May 18, 2016, retreived from the Internet. URL: <faculty.chemistry.harvard.edu/files/myers/files/15-ellman_auxiliary.pdf>, 6 pages.
Nagasubramanian et al “Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101,” Pediatr Blood Cancer., Aug. 2016, 63(8):1468-70.
Nagasubruamanian et al., “Brief Report: Infantile Fibrsarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101,” Pediatric Blood & Cancer, 2016, DOI 10.1002, 3 pages.
Nakagawara, “Trk receptor tyrosine kinases a bridge between cancer and neural development,” Cancer Letters, 2001, 169(2):107-114.
Narayanan et al., “Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation,” PLoS One, Dec. 26, 2013;8(12):e83380. doi: 10.1371/journal.pone.0083380. eCollection 2013.
National Cancer Institute at the National Institutes of Health, posted on or before Jan. 5, 2000, retrieved on Jan. 13, 2015, http://www.cancer.gov/, 2 pages.
National Comprehensive Cancer Network, posted on or before Dec. 3, 1998, retrieved on Jan. 13, 2015, http://www.nccn.org/, 1 page.
NCT02050919, “Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma,” ClinicalTrials.gov, First received Jan. 29, 2014, Last Updated Dec. 16, 2015, https://www.clinicaltrials.gov/ct2/show/NCT02050919, 5 pages.
NCT02122913, “Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Adult Solid Tumors,” ClinicalTrials.gov, First received Apr. 16, 2014, Last Updated Dec. 7, 2015, https://clinicaltrials.gov/ct2/show/NCT02122913.
Ni et al., “siRNA interference with a proliferation-inducing ligand gene in the Sgr-7901 gastric carcinoma cell line,” Asian Pacific Journal of Cancer Prevention, 2012, 13:1511-1514.
Ni et al., “Tyrosine receptor kinase B is a drug target in astrocytomas,” Neuro Oncol., Jan. 2017, 19(1):22-30.
Nollau et al., “Methods for detection of point mutations: performance and quality assessment. IFCC Scientific Division, Committee on Molecular Biology Techniques,” Clin Chem. Jul. 1997;43(7):1114-28.
Obianyo et al., “Novel small molecule activators of the Trk family of receptor tyrosine kinases. Biochim Biophys Acta, 1834:2214-2218,” Biochim Biophys Acta, Oct. 2013, 1834(10):2213-2218.
Ocgene.bioinfo-minzhao.org' [online]. “Ovarian Cancer Gene Database, Gene ID: 4914,” [retrieved on Jul. 17, 2017] Retrived from the Internet: URL<ocgene.bioinfominzhao.org/gene_mutation.cgi?gene=4914>, 13 pages.
Olivier, “The Invader assay for SNP genotyping,” Mutat Res, Jun. 3, 20015;573(1-2):103-10.
Orbach et al., “Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience,” Eur J Cancer, Apr. 2016, 57:1-9.
Orbach et al., “Infantile fibrosarcoma: management based on the European experience,” J Clin Oncol, Jan. 2010, 28(2):318-323.
O'Shea, “Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet?” Immunity, 1997, 7:1-11.
Ou et al., “Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib,” Lung Cancer, 2017, 108: 228-231.
Ou et al., “Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/R05424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib,” Journal of Thoracic Oncology, Apr. 2014, 9: 549-553.
Ovanan Cancer Gene Database, ocgene.bioinfo-minzhao org/gene_mutation.cgi?gene=4914, downloaded on May 31, 2016, 14 pages.
Ovarian Cancer Gene Database, ocgene.bioinfo-minzhao org/gene_mutation.cgi?gene=4916, downloaded on May 31, 2016, 21 pages.
Pao, W., et al. “Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain,” PLoS Med, Feb. 2005, 2(3), e73.
Papatsoris et al., “Manipulation of the nerve growth factor network in prostate cancer,” Exper Opin Invest Drugs, 2007, 16(3):303-309.
Park et al., “Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer,” Proc. Natl. Acad. Sci. U.S.A., Oct. 2015, 112(40):12492-12497.
Patani et al., “Bioisosterism: a rational approach in Drug Design,” Chem Rev., Dec. 1996, 96(8):3147-3176.
Patapoutian et al., “Trk receptors: mediators of neurotrophin action,” Current Opinion in Neurobiology, 2001, 11:272-280.
Pavlick et al., “Identification of NTRK fusions in pediatric mesenchymal tumors,” Pediatr Blood Cancer, Aug. 2017, 64(8). doi: 10.1002/pbc.26433. Epub Jan. 18, 2017.
Pediatric Cancer Gene Database, pedican.bioinfominzhao.org/gene_mutation.cgi?gene=4914, downloaded on May 31, 2016, 6 pages.
Pediatric Cancer Gene Database, pedican.bioinfominzhao.org/gene_mutation.cgi?gene=4915, downloaded on May 31, 2016, 5 pages.
Pediatric Cancer Gene Database, pedican.bioinfominzhao.org/gene_mutation.cgi?gene=4916, downloaded on May 31, 2016, 9 pages.
Perales et al., “Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies,” Biol Blood Marrow Transplant, Jan. 2016;22(1):17-22. doi: 10.1016/j.bbmt.2015.10.014. Epub Oct. 17, 2015.
Perez-Pinera et al., “The Trk tyrosine kinase inhibitor K252a regulates growth of lung adenocarcinomas,” Molecular and Cellular Biochemistry, 2007, 295(1&2):19-26.
Perrault et al., “The Synthesis of N-Aryl-5(S)-aminomethyl-2-oxazolidinone Antibacterials and Derivatives in One Step from Aryl Carbamates,” Org. Process Res. Dev., 2003, 7:533-546.
Philippines Office Action in Philippines Application No. PH 1/2012/500048, dated May 30, 2014, 2 pages.
Pierottia and Greco, “Oncogenic rearrangements of the NTRK1/NGF receptor,” Cancer Letters, 2006, 232:90-98.
Pinedo et al., “Translational Research: The Role of VEGF in Tumor Angiogenesis,” The Oncologist, 2000, 5(1): 1-2.
Pinski et al., “Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts,” Cancer Res, 2002, 62:986-989.
Ponsaerts et al., “Cancer immunotherapy using RNA-loaded dendritic cells,” Clin. Exp. Immunol., Dec. 2003, 134:378-384.
Prasad et al., “NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States,” Cancer, Apr. 2016, 122(7):1097-1107.
Pulciani et al., “Oncogenes in solid human tumours,” Nature, 1982, 300(5892):539-542.
Ramer and Bisby, “Adrenergic innervation of rat sensory ganglia following proximal or distal painful sciatic neuropathy: distinct mechanisms revealed by anti-NGF treatment,” Eur. J. Neurosci., 1999, 11:837-846.
Raychaudhuri et al., 'K252a, a high-affinity nerve growth factor receptor blocker, improves psoriasis: an in vivo study using the severe combined immunodeficient mouse-human skin model, J. Investigative Dermatology, 2004, 122(3):812-819.
Reungwetwattana et al., “Targeted therapies in development for non-small cell lung cancer,” J Carcinog, Dec. 2013, 12:22, doi: 10.4103/1477-3163.123972. eCollection 2013.
Reuther et al., “Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia,” Mol. Cell. Biol. 2000, 20:8655-8666.
Ricci et al., Neurotrophins and neurotrophin receptors in human lung cancer, Am. J. Respiratory Cell and Molecular Biology, Oct. 2001, 25(4): 439-446.
Richard et al., “Syngeneic stem cell transplant for spent-phase polycythaemia vera: eradication of myelofibrosis and restoration of normal haematopoiesis,” Br. J Haematol., Apr. 2002, 117(1):245-246.
Ro et al., “Effect of NGF and anti-NGF on neuropathic pain in rats following chronic constriction injury of the sciatic nerve,” Pain, 1999, 79:265-274.
Roberts et al., “Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia,” N Engl J Med, Sep. 2014, 371(11):1005-1015.
Roberts et al., Blood, vol. 128, No. 22. Abstract No. 278, 58th Annual Meeting of the American Society of Hematology, ASH 2016. San Diego, CA, United States. Dec. 3, 2016-Dec. 6, 2016, 2 pages.
Roblin et al., “Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis,” Acta Derm. Venereal., 2015, 95:542-548.
Roskoski, Jr. et al., “Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes,” Pharmacological Research, 2016, 103: 26-48.
Ross et al., “New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing,” Oncologist, 2014, 19:235-242.
Rubin et al., “Growth, survival and migration: the Trk to cancer,” Cancer Treat Res, 2003, 115:1-18.
Russo et al., “Acquired Resistance to the Trk Inhibitor Entrectinib in Colorectal Cancer,” Cancer Discovery, Jan. 1, 2016, 6(1):36-44.
Russo et al., “Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer,” Cancer Discov. Jan. 2016, 6(1):36-44.
Rutkowski et al., “Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection,” J. Eur. Acad. Dermatol. Venereol., 2011, 25:264-270.
Santoro et al., “Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Reasearh and Treatment of Cancer Soft Tissue and Bone Sarcoma Group,” J. Clin Oncol., 1995, 13(7):1537-1545.
Saragovi et al., “A TrkA-selective, fast internalizing nerve growth factor-antibody complex induces trophic but not neuritogenic signals,” J Biol Chem, Dec. 25, 1998;273(52):34933-34940.
Sassolas et al., “Oncogenic alterations in papillary thyroid cancers of young patients,” Thyroid Jan. 2012, 22(1):17-26.
Scaruffi et al., “Detection of DNA polymorphisms and point mutations of high-affinity nerve growth factor receptor (TrkA) in human neuroblastoma,” Int. J. Oneal., May 1999, 14:935-938.
Shah et al., “Cardiac metastasis and hypertrophic osteoarthropathy in recurrent infantile fibrosarcoma,” Pediatr. Blood Cancer, Jul. 2012, 59(1):179-181.
Shaw et al., “Ceritinib in ALK-rearranged non-small-cell lung cancer,” N Engl J Med, Mar. 27, 2014;370(13):1189-97. doi: 10.1056/NEJMoa1311107.
Shaw et al., “Crizotinib in ROS1-rearranged non-small-cell lung cancer,” N Engl J Med, Nov. 20, 2014;371(21):1963-71. doi: 10.1056/NEJMoa1406766. Epub Sep. 27, 2014.
Shaw et al., “Tyrosine kinase gene rearrangements in epithelial malignancies,” Nat Rev Cancer, Nov. 2013, 13(11):772-787.
Shelton et al., “Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis,” Pain, 2005, 116:8-16.
Sheng et al., “Congenital-infantile fibrosarcoma. A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffin-embedded tissues,” Am. J Clin. Pathol., Mar. 2001, 115:348-355.
Silverman, The Organic Chemistry of Drug Design and Drug Action, Second Edition, 2007, 20-21.
Sims et al., Journal of Immunotherapy of Cancer, vol. 4, Supp. Supplement 1; Abstract No. P280; 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer, SITC 2016. National Harbor, MD; Nov. 9-13, 2016.
Skalova et al., “Newly described salivary gland tumors,” Modern Pathology, Jan. 2017, 30, S27-S43.
Sleijfer et al., “Prognastic and predictive factors for outcome to firs-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas:an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group,” Eur J. Cancer, 2010, 46(1):72-83.
Sleijfer et al., “Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care,” Oncologist, 2005, 10(10):833-841.
Smith et al., “Annotation of human cancers with EGFR signaling-associated protein complexes using proximity ligation assays,” Sci Signal, 2015, 8(359):ra4, 12 pages.
Sohrabji et al., “Estrogen-BDNF interactions: implications for neurodegenerative diseases,” Frontiers in Neuroendocrinology, 2006, 27(4):404-414.
Stephens et al., “Trk receptors use redundant signal transduction pathways involving SHC and PLC-gamma 1 to mediate NGF responses,” Neuron, Mar. 1994, 12(3):691-705.
Stransky et al., “The landscape of kinase fusions in cancer,” Nature comm., 2014, 5:4846.
Tacconelli et al., “TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma,” Cancer Cell, 2004, 6:347-360.
Tafinlar, Highlights of Prescribing Information, GlaxoSmithKline, Jan. 2014, 41 pages.
Tahira et al., “dbQSNP. a database of SNPs in human promoter regions with allele frequency information determined by single-strand conformation polymorphism-based methods,” Hum Mutat, Aug. 2005;26(2):69-77.
Taipale et al., “Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specifities in living cells,” Nat Biotech, 2013, 31(7):630-637.
Taiwan Office Action in Taiwan Application No. 098135670, dated Jan. 20, 2014, 7 pages (with English Translation).
Taiwan Search Report in Taiwan Application No. 098132033, dated Dec. 13, 2013, 1 page (English translation only).
Taiwan Search Report in Taiwan Application No. 105143120, dated Aug. 10, 2017, 6 pages (with English translation).
Tanaka et al., “Brain-derived neurotrophic factor (BDNF)-induced tropomyosin-related kinase B (Trk B) signaling is a potential therapeutic target for peritoneal carcinomatosis arising from colorectal cancer,” PLoS One May 6, 2014, 9(5):e96410.
Tannenbaum-Dvir et al., “Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma,” Cold Spring Harb. Mol. Case Stud., Oct. 20015;1(1):a000471.
Tarate et al., “Oral Solid Self-Emulsifying Formulations: A Patent Review,” Recent Patents on Drug Delivery & Formulation, 2014, 8(2):126-143.
Theodosiou et al., “Hyperalgesia due to nerve damage: role of nerve growth factor,” Pain, 1999, 81:245-255.
Thiele, “On Trk—the TrkB signal transduction pathway is an increasingly important target in cancer biology,” Clinical Cancer Research, 2009, 105(19):5962-5967.
Thompson et al., “Brain-derived neurotrophic factor is an endogenous modulator of nociceptive responses in the spinal cord,” Proc.Natl. Acad. Sci. USA, 1999, 96:7714-7718.
Thress et al., “Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway,” Mol Cancer Ther, Jul. 2009;8(7):1818-27. doi: 10.1158/1535-7163.MCT-09-0036. Epub Jun. 9, 2009.
Tognon et al., “Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma,” Cancer Cell, Nov. 2002, 2(5):367-376.
Truzzi et al., “Neurotrophins and their receptors stimulate melanoma cell proliferation and migration,” J. Investigative Dermatology, 2008, 128(8):2031-2040.
Truzzi et al., “Neurotrophins in healthy and diseased skin ,” Dermato-Endrocrinology, 2008, 3(1):32-36.
Turtle et al., “Artificial antigen-presenting cells for use in adoptive immunotherapy,” Cancer J, Jul.-Aug, 2010;16(4):374-81. doi: 10.1097/PPO.0b013e3181eb33a6.
UniProtKB/Swiss-Prot: P04629.4, “RecName: Full=High affinity nerve growth factor receptor; AltName: Full=Neurotrophic tyrosine kinase receptor type 1; AltName: Full=TRK1-transforming tyrosine kinase protein; AltName: Full=Tropomyosin-related kinase A; AltName: Full=Tyrosine kinase receptor; AltName: Full=Tyrosine kinase receptor A; Short=Trk-A; AltName: Full= 140trk; AltName: Full=p140-TrkA; Flags: Precursor,” May 14, 2014, 28 pages, available at URL<https://www.ncbi.nlm.nih.gov/protein/94730402?sat=18&satkey=12407077>.
UniProtKB/Swiss-Prot: Q16288.2, “RecName: Full=NT-3 growth factor receptor; AltName: Full=GP145-TrkC; Short=Trk-C; AltName: Full=Neurotrophic tyrosine kinase receptor type 3; AltName: Full=TrkC tyrosine kinase; Flags: Precursor,” May 14, 2014, 13 pages, available at URL<www.ncbi.nlm.nih.gov/protein/134035335?report=genbank&log$=protalign&blast_rank=0&RID=0>.
UniProtKB/Swiss-Prot: Q16620.1, “RecName: Full=BDNF/NT-3 growth factors receptor; AltName: Full=GP145-TrkB; Short=Trk-B; AltName: Full=Neurotrophic tyrosine kinase receptor type 2; AltName: Full=TrkB tyrosine kinase; AltName: Full=Tropomyosin-related kinase B; Flags: Precursor,” May 14, 2014, 17 pages, available at URL<www.ncbi.nlm.nih.gov/protein/2497560?report=genbank&log$=protalign&blast_rank=0&RID=0>.
Vaishnavi et al., “TRKing Down an Old Oncogene in a New Era of Targeted Therapy,” Cancer Discovery, Jan. 2015, 5(1):25-34.
Vaishnavi et al., Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer, Nature Med., 2013, 19:1469-1472.
Van Gurp et al., “Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics,” Am. J. Transpl., 2008, 8:1711-1718.
Van Noesel et al., “Pediatric neuroblastomas: genetic and epigenetic ‘danse macabre’,” Gene, 2004, 325:1-15.
Wadhwa et al., “Expression of the neurotrophin receptors Trk A and Trk B in adult human astrocytoma and glioblastoma,” Journal of Biosciences, 2003, 28(2):181-188.
Walch et al., “Role of neurotrophins and neurotrophins receptors in the in vitro invasion and heparanase production of human prostate cancer cells,” Clin. Exp. Metastasis, 1999, 17:307-314.
Wang et al., “Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases,” J Med Chem, Aug. 14, 2008;51(15):4672-84. doi: 10.1021/jm800343j. Epub Jul. 23, 2008.
Wang et al., “T cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/neu tumors,” Breast Cancer Res Treat, Jul. 2012;134(1):61-70. doi: 10.1007/s10549-011-1912-5. Epub Dec. 16, 2011.
Wang et al., “Trk kinase inhibitors as new treatments for cancer and pain,” Expert Opin. Ther Patents, Mar. 2009, 19(3):305-319.
Wei et al., “Abstract #2136: Entrectinib is Effective Against the Gatekeeper and Other Emerging Resistance Mutations in NTRK-, ROS1- and ALK- Rearranged Cancers,” Poster, Presented at Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, New Orleans LA, Apr. 16-20, 2016; Cancer Res, Jul. 2016, 76(14): 1 page.
Weinstein,“Cancer. Addiction to oncogenes—the Achilles heal of cancer,” Science, Jul. 2002, 297(5578):63-64.
Wiesner et al., “Kinase fusions are frequent in Spitz tumours and spitzoid melanomas,” Nature Comm., 2014, 5:3116.
Winski et al., “LOXO-101, a pan-TRK inhibitor, for the treatment of TRK-driven cancers,” 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain, 2014, 175.
Wittwer et al., “High-resolution genotyping by amplicon melting analysis using LCGreen,” Clin Chem, Jun. 2003;49(6 Pt 1):853-60.
Wong et al., “Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib,” J Natl Cancer Inst, Nov. 2016, 108(1) pii: djv307.
Woodward, “Bi-allelic SNP genotyping using the TaqMan® assay,” Methods Mol Biol., 2014;1145:67-74. doi: 10.1007/978-1-4939-0446-4_6.
Woolf et al., “Letter to Neuroscience: Nerve Growth Factor Contributes to the Generation of Inflammatory Sensory Hypersensitivity,” Neuroscience, 1994, 62:327-331.
Wu et al., “The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma,” Nature Genetics, 2014, 444-450.
Wu et al., “The landscape of fusion transcripts in spitzoid melanoma and biologically indeterminate spitzoid tumors by RNA sequencing,” Modern Pathol., Apr. 2016, 29(4):359-369.
Xalkori, Highlights of Prescribing Information, Pfizer Labs, Initial approval 2011, revised Mar. 2016, 20 pages.
Yanai et al., “A rare case of bilateral stage IV adrenal neuroblastoma with multiple skin metastases in a neonate: diagnosis, management, and outcome,” J Pediatr. Surg., Dec. 2004, 39(12):1782-1783.
Yeh et al., “NTRK3 kinase fusions in Spitz tumours,” J Pathol., Nov. 2016, 240(3): 282-290.
Yilmaz et al., “Theraputic targeting of Trk supresses tumor proliferation and enhances cisplatin activity in HNSCC,” Cancer Biology and Therapy, 2010, 10(6):644-653.
Yu et al., “Denaturing high performance liquid chromatography: high throughput mutation screening in familial hypertrophic cardiomyopathy and SNP genotyping in motor neurone disease,” J Clin Pathol, May 2005;58(5):479-85.
Yuzugullu et al., “NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways,” Cell Discov., Sep. 2016, 2: 16030.
Zage et al., “The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic faxtor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan,” Cancer, Mar. 2011, 117(6): 1321-1391.
Zahn et al., “Effect of blockade of nerve growth factor and tumor necrosis factor on pain behaviors after plantar incision,” J. Pain, 2004, 5:157-163.
Zelboraf, Highlights of Prescribing Information, Genentech USA, Initial Approval 2011, revised Aug. 2015, 18 pages.
Zhang et al., “A novel multiplex tetra-primer ARMS-PCR for the simultaneous genotyping of six single nucleotide polymorphisms associated with female cancers,” PLoS One, Apr. 17, 2013;8(4):e62126. doi: 10.1371/journal.pone.0062126. Print 2013.
Zhang et al., “Expression of nerve growth factor receptors and their prognostic value in human pancreatic cancer,” Oncology Reports, 2005, 14:161-171.
Zhang et al., “Novel Phenotypic and Genetic Analysis of T-Cell Prolymphocytic Leukemia (T-PLL),” Blood, 2014, 124(21):1682.
Zheng et al., “Anchored multiplex PCR for targeted next-generation sequencing,” Nature Med., Dec. 2014, 20(12):1479-1486.
Sun et al., “P-loop conformation governed crizotinib resistance in G2032R-mutated ROS1 tyrosine kinase clues from free energy landscape,” PLoS computational biology, Jul. 17, 2014, 10(7): e1003729.
U.S. Appl. No. 14/321,246, filed Jul. 1, 2014, Shelley Allen.
U.S. Appl. No. 15/401,895, filed Jan. 9, 2017, Shelley Allen.
U.S. Appl. No. 15/401,913, filed Jan. 9, 2017, Shelley Allen.
U.S. Appl. No. 13/382,858, filed Jan. 6, 2012, Shelley Allen.
U.S. Appl. No. 13/614,968, filed Sep. 13, 2012, Steven W. Andrews.
U.S. Appl. No. 14/984,353, filed Dec. 30, 2015, Steven W. Andrews.
U.S. Appl. No. 15/401,792, filed Jan. 9, 2017, Steven W. Andrews.
U.S. Appl. No. 15/401,969, filed Jan. 9, 2017, Steven W. Andrews.
U.S. Appl. No. 13/063,894, filed Mar. 14, 2011, Steven W. Andrews.
U.S. Appl. No. 14/575,663, filed Dec. 18, 2014, Steven W. Andrews.
U.S. Appl. No. 15/350,888, filed Nov. 14, 2016, Steven W. Andrews.
U.S. Appl. No. 15/401,839, filed Jan. 9, 2017, Steven W. Andrews.
U.S. Appl. No. 15/401,952, filed Jan. 9, 2017, Steven W. Andrews.
U.S. Appl. No. 15/632,187, filed Jun. 23, 2017, Steven W. Andrews.
U.S. Appl. No. 13/698,922, filed Nov. 19, 2012, Steven W. Andrews.
U.S. Appl. No. 13/943,590, filed Jul. 16, 2013, Julia Haas.
U.S. Appl. No. 14/490,460, filed Sep. 18, 2014, Julia Haas.
U.S. Appl. No. 14/596,611, filed Jan. 14, 2015, Julia Haas.
U.S. Appl. No. 14/846,166, filed Sep. 4, 2015, Julia Haas.
U.S. Appl. No. 15/366,389, filed Jan. 5, 2017, Julia Haas.
U.S. Appl. No. 15/860,948, filed Jan. 3, 2018, Julia Haas.
U.S. Appl. No. 13/125,263, filed Apr. 20, 2011, Julia Haas.
U.S. Appl. No. 14/943,014, filed Nov. 16, 2015, Alisha B. Arrigo.
U.S. Appl. No. 15/399,207, filed Jan. 5, 2017, Alisha B. Arrigo.
U.S. Appl. No. 15/706,062, filed Sep. 15, 2017, Alisha B. Arrigo.
U.S. Appl. No. 15/335,378, filed Oct. 26, 2016, Nisha Nanda.
U.S. Appl. No. 15/785,174, filed Oct. 16, 2017, Nisha Nanda.
U.S. Appl. No. 15/785,228, filed Oct. 16, 2017, Nisha Nanda.
U.S. Appl. No. 15/785,218, filed Oct. 16, 2017, Nisha Nanda.
U.S. Appl. No. 15/860,789, filed Jan. 3, 2018, Nisha Nanda.
U.S. Appl. No. 15/579,007, filed Dec. 1, 2017, Tuch et al.
U.S. Appl. No. 15/622,388, filed Jun. 14, 2017, Michael Cox.
U.S. Appl. No. 15/861,017, filed Jan. 3, 2018, Michael Cox.
U.S. Appl. No. 15/622,544, filed Jun. 14, 2017, Mark Reynolds.
Calabresi and Chabner, Goodman & Gilnnan's “The Pharmacological Basis of Therapeutics,” 10th ed., 2001, p. 1388, para 2, lines 4-5.
Extended European Search Report in European Application No. 18151233.6, dated Jun. 26, 2018, 6 pages.
International Preliminary Report on Patentability in International Application No. PCT/US2016/058951, dated May 11, 2018, 11 pages.
Vogelstein and Kinzler, “The Genetic Basis of Human Cancer,” 2nd ed., 2002, p. 3, col. 1, para 2.
Related Publications (1)
Number Date Country
20180263984 A1 Sep 2018 US
Provisional Applications (2)
Number Date Country
61346767 May 2010 US
61224196 Jul 2009 US
Continuations (3)
Number Date Country
Parent 15401913 Jan 2017 US
Child 15724601 US
Parent 14321246 Jul 2014 US
Child 15401913 US
Parent 13382858 US
Child 14321246 US